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The platelet redox environment consists o f the blood plasma and within it the low 
molecular weight thiols glutathione and cysteine. Both glutathione and cysteine exist 
as independent redox couples comprising carefully controlled ratios o f the reduced 
(GSH, Cys) and oxidised (GSSG, CySS) form o f each thiol. These ratios yield a 
GSH/GSSG redox potential and a Cys/CySS redox potential in the plasma. Changes 
in the redox status o f the plasma are manifested by alterations in either the 
glutathione or cysteine redox potential and are associated with the progression of a 
large number o f  disease states including cancer, atherosclerosis and schizophrenia. In 
addition, oxidative changes in either o f the plasma redox potentials have been 
directly linked with risk factors for cardiovascular disease. The post-translational 
modification o f critical cysteine thiol groups on proteins is linked to such alterations 
in both the GSH/GSSG and Cys/CySS redox potentials and occurs extracellularly 
and intracellularly. Platelet integrins in particular are prime targets for redox 
modification due to their high cysteine content. Although the role o f thiol/ disulphide 
bond exchange in platelet activation is established the effects o f a changing redox 
environment on platelet reactivity are unclear. The aims o f this thesis therefore, are 
to explore the impact and consequences o f such changes on platelet function.
Platelet activation was significantly diminished in the presence o f either reducing 
GSH/GSSG or Cys/CySS redox potentials. Moreover, this response was most 
notable when platelets were activated with collagen only. The redox modulated 
effects were shown to be specific to the integrin 012P 1, through a mechanism 
involving disulphide bond reduction. An analysis o f the platelet integrin $ subunits 
revealed the presence o f the greatest number o f potentially reactive cysteine residues 
within the Pi subunit when compared to the other platelet integrin beta subunit P3.
Summary
Furthermore, platelet proteins were S-glutathionylated in a reducing extracellular 
redox environment. The findings o f this thesis reveal for the first time how 
exquisitely sensitive collagen-induced platelet activation is to alterations in the 
external redox environment. This, in fact, is potentially a novel demonstration o f 
reductive stress regulating platelet reactivity and provides a novel avenue for 
therapeutic intervention using physiological redox reagents or their precursors.
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Chapter 1 
Introduction
1.1 Platelets
1.1.1 Structure
Platelets are anucleate fragments o f large precursor cells known as megakaryocytes, 
which are located primarily in the bone marrow. Platelets are 2-5 |am in diameter and 
some 2 - 3 x 108 platelets are normally present per millilitre o f blood. They normally 
circulate in blood in a discoid resting state (Figure 1.1). However, following vascular 
injury and exposure o f  the underlying sub endothelial matrix proteins such as 
collagen and von Willebrand factor (VWF), platelets become rapidly activated and 
undergo a dramatic shape change with subsequent aggregation o f platelets leading to 
the formation o f a ‘platelet plug’ that seals the vessel wall thus maintaining normal 
haemostasis.
Figure 1.1 Scanning electron micrograph of a resting, discoid platelet. The micrograph shows the 
unactivated platelet. The small openings on the membrane surface are connected to the open 
canalicular system (OCS) below the platelet surface. This adds greatly to the surface area o f the 
platelet both for exchange o f  substances between the platelet and plasma, and for the process of 
platelet spreading (White 2007b). The image is taken from: 
http://www.denniskunkel.com/DK/Medical/20321A.html.
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The major structural features of the resting platelet are shown in the schematic in 
Figure 1.2.
Figure 1.2 Schematic representation of the internal structure o f the platelet. This schematic 
shows details o f  the ultrastructure o f the platelet. The following structures are illustrated: the exterior 
coat (EC), trilaminar unit membrane (CM), sub-membrane area, containing special filaments (SMF), 
the open canalicular system (OCS), mitochondria (M), dense tubular system (DTS), glycogen (Gly), 
dense bodies (DB), alpha-granules (G) and microtubules (MT). Adapted from White (White 2007a).
The surface connected open canalicular system (OCS) greatly increases the surface 
area for plasma borne substances to penetrate deep into the platelet, and is also 
critically involved in platelet spreading. The dense tubular system originates from 
rough endoplasmic reticulum in the parent megakaryocyte, and contains calcium- 
binding sites (White 2007b).
There are a small number of cell organelles, including mitochondria for energy 
production, lysosomes containing a variety o f degradative enzymes and peroxisomes
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containing catalase. The microtubule coil maintains the discoid shape o f the resting 
platelet.
Platelets contain two major storage granules, dense granules and a-granules. a- 
granules are the most abundant, containing many critical proteins including 
fibrinogen, VWF, P-selectin, integrin anbP3 and CD36. The dense granules contain 
haemostatically active substances released following platelet activation, including 
serotonin, adenosine diphosphate (ADP), adenosine triphosphate (ATP), calcium and 
cathecholamines (Rendu & Brohard-Bohn 2001).
1.1.2 Platelet Activation
When platelets are exposed to damaged vascular endothelium, they become 
activated. They rapidly change shape from discs to spheres with extended 
pseudopodia. The platelet can then adhere to the site o f injury, via an interaction 
between the plasma and endothelial adhesion molecule VWF and the platelet surface 
receptor complex GPIb-IX-V (Arya et al. 2003). Exposed collagen is bound by both 
the 012P1 integrin and the GPVI receptor on the platelet surface (Jarvis et al. 2004). 
Collagen alone is sufficient to activate platelets under static conditions in vitro, but 
under in vivo flow conditions, VWF is a necessary co-factor. VWF also binds to the 
fibrinogen receptor anbP3, strengthening the adhesion o f platelets to the underlying 
basement matrix. The sequence o f morphological changes seen in platelets following 
activation is shown in Figure 1.3.
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Figure 1.3 The process o f shape change in activated platelets. Scanning electron micrographs 
showing (A) A resting discoid platelet, magnification X  30,000. (B) The platelet with a more 
spherical shape and long extended pseudopodia magnification X  13,000. (C) The platelet beginning to 
spread onto the underlying matrix, magnification X 13, 000. (D) A  fully spread platelet, magnification 
X 9000. Adapted from J. White, Platelet Structure (White 2007b).
The formation o f pseudopodia is driven by the actin cytoskeleton within the platelet 
(Zucker & Nachmias 1985). Shape change is mediated by a rapid remodelling o f the 
resting platelet cytoskeleton and the assembly o f filamentous actin (F-actin) induced 
by receptor ligation (Hartwig 1992). For example, ligation o f thrombin or collagen 
receptors results in increases in platelet intracellular calcium levels, which activate 
gelsolin. Active gelsolin severs actin filaments, initially reorganizing the 
cytoskeleton o f the discoid platelet (Hartwig et al. 1999). Dissociation o f gelsolin 
from the fragmented filaments by newly generated membrane polyphosphoinositides 
supplies nucleation sites that are further amplified by the Arp2/3 complex leading to 
a burst o f actin assembly that drives the shape change reaction (Falet et al. 2005, Li 
et al. 2002). Once the initial wave o f platelets is securely adhered to the endothelial
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matrix, additional platelets are recruited in the second phase known as platelet 
aggregation. Under rapid flow conditions (shear rates > 1000 s '1) the initial tethering 
o f platelets to the surface o f immobilized platelets involves the specific VWF-GPIb 
interaction (Jackson 2007). This tethering is reversible at shear rates up to 10,000 s '1, 
and results in platelet movement or translocation across the thrombus surface. 
Platelet stimulation by one or more soluble agonists during translocation promotes 
the binding o f VWF and fibronectin to integrin anbP3, leading to sustained platelet- 
platelet adhesion. At elevated shear rates, the principal role o f the fibrinogen-integrin 
anbp3 interaction is to stabilize formed aggregates (Jackson 2007). Circulating 
platelets are engaged in reinforcing the growing platelet plug aided by increased 
local concentration o f  platelet agonists including thrombin which is generated at the 
platelet surface following conversion o f prothrombin to thrombin by factor Xa 
(Monroe et al. 2002), serotonin and ADP which are released from the platelet dense 
granules (Offermanns 2006) and thromboxane A2 (TxA2) which is the product o f the 
cyclooxygenase catalysed metabolism o f arachidonic (FitzGerald 1991).
1.1.3 Platelet Receptors
1.1.3.1 Glycoprotein VI (GPVI) Collagen Receptor
Collagen is an extracellular matrix protein and a potent platelet agonist. Following 
damage to the vascular sub-endothelium, collagen binds to the immunoglobulin-like 
receptor GPVI, and the integrin a 2Pi receptor on the platelet surface (Horii et al. 
2006, Jarvis et al. 2004). GPVI is a 60 -  65 kDa glycoprotein that has two 
extracellular immunoglobulin-like domains, a mucin like core, a transmembrane 
domain and a short cytoplasmic tail (Surin et al. 2008). The GPVI receptor 
associates with the 14 kDa Fc receptor (FcR) y subunit o f FcR via a salt bridge
6
within the platelet membrane (Tsuji et al. 1997). The GPVI ectodomain binds 
fibrillar collagen as its ligand, with low affinity (Miura et al. 2002). GPVI recognises 
the quaternary assembly o f the collagen fibre and cannot bind to acid solubilised 
collagen triple helices (Moroi & Jung 2004). The GPVI receptor forms a specific 
dimer conformation with resultant presentation o f the collagen binding domain on 
the platelet surface (Jung et al. 2009). The functional GPVI recognition m otif within 
collagen has been determined as -GPOGPO- where G = glycine, P = proline and O = 
hydroxyproline, representing the smallest m otif within the collagen structure that 
both recognises and activates platelets through GPVI. There are five such - 
GPOGPO- motifs within the a l  chains o f  both collagens I and III (Smethurst et al. 
2007). Platelet activation by collagen binding to GPVI results in phosphorylation of 
the FCRy immunoreceptor tyrosine-based activation m otif (ITAM), leading to the 
activation o f PI3-kinase, phospholipase C (PLCy2) and the formation o f IP3 and 
diacyl glycerol (DAG). IP3 releases calcium from the dense granules leading to 
increase in intracellular Ca2+ concentration, which activates PLA2 and TxA2 
generation, while DAG stimulates protein kinase C (PKC). The increase in 
intracellular Ca2+ concentration also leads to the activation o f myosin light chain 
kinase (MLCK) and cytoskeletal changes resulting in platelet shape change and 
activation (Surin et al. 2008). The GPVI receptor is able to bind other ligands 
including the snake venom glycoprotein convulxin (Cvx), a C-type lectin-like 
protein from the venom o f the South American rattlesnake Crotalus durissus 
terrificus which binds GPVI with a much higher affinity than collagen, forming a 
dimer structure in solution and binding with up to eight GPVI receptors 
simultaneously (Atkinson et al. 2001, Horii et al. 2009) and the triple helical 
collagen related peptide (CRP) comprising the sequence (GCO-(GPO)io-GCOG), a
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very potent GPVI specific agonist particularly when cross linked to introduce a 
quaternary structure (CRP-XL) (Smethurst et al. 2007).
1.1.3.2 The Integrin a2Pi
(X2P1 is a member o f the integrin family o f adhesion molecules consisting o f non- 
covalently linked a  and P subunits forming heterodimers that mediate cell-cell and 
cell-matrix interactions by binding distinct ligands (Shimaoka et al. 2002). There are 
eighteen different a-subunits and eight different P-subunits, which combine to make 
at least twenty-four known a /p  heterodimers (Bennett et al. 2009, Shimaoka & 
Springer 2003) (Figure 1.4). Platelets express five integrins, three members o f the pi 
subfamily ((X2P1, (X5P 1, ocePi) supporting platelet adhesion to collagen, fibronectin 
and laminin respectively (Nieswandt et al. 2009), and both members o f the P3 
subfamily (anbP3 and 0 ^ 3) (Bennett et al. 2009).
Platelet integrin 012P1 serves as an adhesion receptor primarily for collagen, showing 
an increased affinity for soluble collagen over fibrillar collagen (Savage et al. 1999). 
The typical integrin structure based on the crystal structure o f integrin a vP3 is shown 
in Figure 1.5 (Shimaoka & Springer 2003).
a,2pi is the second most abundant platelet integrin, with 2000 -  4000 copies per 
platelet (Cosemans et al. 2008). The integrin a-subunit contains an inserted I-domain 
that characteristically has a metal ion-dependent adhesion site (MIDAS), controlling 
the binding o f its ligand via co-ordination to a Mg2+ ion (Kamata et al. 1999). 
Cyanogen bromide (CB) cleaved fragments o f collagen a-chains can reassemble as 
triple helices, allowing the effects o f different collagen helical domains on platelet 
reactivity to be examined (Famdale et al. 2004). The collagen type I derived 
fragment ai(I)CB3 supports (X2P1 dependent platelet adhesion as well as the parent
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collagen, and using a set o f overlapping triple-helical peptides spanning the entire 
sequence o f ai(I)CB3, the sequence GFOGER was identified as the collagen binding 
m otif for a 2Pi (Knight et al. 1998). Triple helical peptide binding to the integrin ail- 
domain occurs at the MIDAS site, with the metal ion co-ordinated by three 
conserved residues S e ri53 and S eri55 which form direct bonds through their 
hydroxyl oxygens and Asp254 which makes a H2O mediated bond to the metal 
(Figure 1.6). The triple helical peptide is co-ordinated directly to the metal ion by 
one o f the carboxylate oxygens from the collagen peptide glutamate residue (Figure 
1.7) (Emsley et al. 1997). The Pi subunit o f (X2P1 has fifty-eight cysteine residues, 
thirty-one o f which are in the four I-EGF regions (Mor-Cohen et al. 2008, Xiong et 
al. 2001). A role for thiol/disulphide exchange between these cysteine residues 
mediated by protein disulphide isomerase (PDI) has been demonstrated in (X2P1 and 
is believed to be a general mechanism o f conformational change during activation 
common to all integrins (Lahav et al. 2003). (X2P1 can bind collagen and GFOGER 
even in the unactivated platelet (Morton et al. 1989). Several other structural features 
within the p subunit are fundamental to ligand binding and integrin activation. All P- 
subunits contain an I-like domain, containing a metal ion dependent adhesion 
(MIDAS) site located next to the ‘adjacent to M IDAS’ (ADMIDAS) site and the 
ligand associated metal binding site (LIMBS). The function o f the I-like domain is 
ligand binding, for which divalent cations are universally required, mediated through 
the I-like domain metal binding sites (Xiong et al. 2001).
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Figure 1.4 Integrili heterodimer combinations. The eighteen a  and eight p subunits form twenty- 
four heterodimers. The a-subunits containing I-domains are labelled with an asterisk. Adapted from 
Shimaoka and Springer, (Shimaoka & Springer 2003).
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Figure 1.5 Integrin structure, (a) Schematic diagram showing the organisation o f  the domains in the 
integral a  and p subunits. Some a  subunits contain an I-domain, located between blades 2 and 3 o f  
the p propeller as shown. Red and blue asterisks denote calcium and magnesium binding sites 
respectively. Black lines represent disulphide bonds between cysteine residues, (b) Representation o f  
the crystal structure o f the xvP3 integrin, in the latent, low-affinity bent conformation. Image adapted 
from Shimaoka and Springer, (Shimaoka & Springer 2003).
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Figure 1.6 The a 2-I domain MIDAS motif. The conserved metal ion co-ordinating residues are 
shown: Serl53, Serl55 and Asp254, with the Mg2+ ion (M) and co-ordinating water molecules (to). 
(Emsley et al. 1997).
Figure 1.7 Molecular surface of the a 2-I domain with a model of the 1-domain-collagen complex.
Two views o f  a collagen triple helix fitted into a groove on the MIDAS face o f the 012-I domain, with 
a glutamate side chain from the collagen co-ordinating the metal ion. (Blue = positive surface charge 
distribution, red = negative surface charge distribution, white = neutral) (Emsley et al. 1997).
1.1.3.3 The Integrin am^
anbP3 is another member o f the integrin family of adhesion molecules and one of two 
P3 integrins found on the platelet, 0,^3  being the other. The ligands o f anbP3 are
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fibrinogen, VWF, fibronectin, vitronectin and thrombospondin; the ligand(s) o f a vP3 
in vivo are uncertain but include osteopontin and vitronectin in vitro (Bennett et al. 
2009). anbPi receptors are expressed solely on platelets, numbering some 80,000 to 
100,000 copies per platelet (Wagner et al. 1996). Fibrinogen is the primary ligand of 
aubfo and is composed o f three different pairs o f identical subunits (a, P and y). 
Fibrinogen, along with several other am,P3 ligands contains two pairs of the Arg- 
Gly-Asp (RGD) sequence on the A a  chain that are recognised by am,P3 but it is the 
Lys-Gln-Ala-Gly-Asp-Val (KQAGDV) sequence located at the C-terminal o f the 
two y chains that are the primary binding sites for anbP3 necessary for platelet 
aggregation (Hawiger et al. 1989). Following ligand binding, outside-in signalling 
by a.]jbP3 occurs, whereby actin polymerisation and cytoskeletal rearrangement are 
promoted, in addition to stabilization o f platelet aggregates formed by adjacent 
platelets bridged by bound fibrinogen and secretion o f platelet granule contents.
The am, subunit is composed o f 1008 amino acids, and the P3 subunit contains 762 
amino acids, with the bulk o f each subunit located extracellularly. Each subunit also 
has a trans-membrane domain and a short cytoplasmic tail. Based on the crystal 
structure analysis o f am>P3 and a vP3 (Shimaoka & Springer 2003) as with integrin 
(X2P1 above, the individual domain structures o f  each subunit are shown in Figure 1.5. 
ctiibP3; unlike a 2pi, does not possess an inserted I-domain in its a  subunit (Bennett et 
al. 2009).
Both subunits o f the integrin anbp3 contain cysteine residues. The a-subunit has 
eighteen cysteines and the P-subunit has fifty-six cysteines, thirty-one o f which are 
located in an extracellular cysteine-rich domain in the four EGF-like domains and
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eight are located in the carboxyl-terminal P-tail domain, (Mor-Cohen et al. 2008, 
Xiong et al. 2001).
These highly conserved cysteine residues are believed to form intra-molecular 
disulphide bonds, but unpaired free thiols are known to be present in the P3 subunit, 
exhibiting the properties o f a redox site directly involved in am,P3 activation (Yan 
and Smith, 2000). Acquisition o f a ligand binding conformation (Figure 1.8) by 
anbP3 has been shown to be dependent on extracellular free thiols and enzymatically 
catalysed disulphide bond exchanges (Lahav et al. 2002).
Some o f the cysteine residues within aiibP3 form disulphide bonds with neighbouring 
cysteine residues that are believed to be critical to maintaining the structure o f the
r
inactive or ‘bent’ conformation seen in the non-ligand bound integrin while 
disulphide bond reduction and a reshuffling o f disulphide bond pattern with an 
increase in the number o f  free thiol groups (-SH) have been reported in the activated 
ligand binding conformation o f am,P3 (Mor-Cohen et al. 2008, Yan & Smith 2000, 
2001). The central role for thiol/disulphide exchange within ain,P3 during platelet 
activation was confirmed further by the discovery o f an endogenous thiol isomerase 
activity in otnbP3 which was predicted from the presence o f nine -CXXC- sequences 
in the P3 subunit (O'Neill et al. 2000). This m otif is found in the active site o f the 
several thiol oxidoreductase enzymes including PDI, thioredoxin and glutaredoxin 
(Atkinson & Babbitt 2009).
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Figure 1.8 Three different a vp3 integrin conformations as visualised by electron microscopy and 
crystal structures, (a) The low-affinity bent conformation, (b) an extended form with a closed 
headpiece, representing an intermediate affinity state and (c) the ligand-binding, high affinity, 
extended form with an open headpiece. Adapted from Xiao (Xiao et al. 2004).
1.1.3.4 PAR-1 and PAR-4 Thrombin Receptors
Thrombin is a serine protease and a potent platelet activator. Thrombin is generated 
from prothrombin following the release o f tissue factor, the activation o f factors VII 
and IX and the conversion o f factor X to factor Xa resulting in the formation of 
thrombin from prothrombin (Monroe et al. 2002). Platelet activation by thrombin is 
mediated by the PAR (protease activating receptor) receptors PAR-1 and PAR-4. 
Both are found on human platelets, and are activated by thrombin cleavage o f the N- 
terminus o f the receptor, exposing a new N-terminus that serves as a tethered ligand 
(Brass 2003). The PAR receptors are G protein coupled receptors (GPCRs), that 
once activated by thrombin, lead to activation o f phospholipase CP (PLCP) resulting 
in formation o f phosphatidylinositol 1,4,5-triphosphate (IP3) and diacylglygerol 
(DAG), inhibition o f cyclic adenosine r  onophosphate (cAMP) formation and an 
increase in intraplatelet calcium concentration. Platelet degranulation, shape change 
and platelet aggregation follow these events (Brass 2003, Ofosu 2003).
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1.1.3.5 ADP Receptors
Adenosine diphosphate (ADP) is a weak platelet agonist. ADP is released from the 
dense granules upon platelet activation. ADP binds to two GPCR (metabotropic) 
receptors on the platelet surface, P2Yi and P2Yi2. Adenosine triphosphate (ATP) 
interacts with the ligand-gated ion channel (ionotropic) P2Xi (Cattaneo & Gachet 
2001, Sun et al. 1998). Although a weak agonist itself, ADP once secreted, amplifies 
platelet responses induced by other agonists and stabilizes platelet aggregates 
(Cattaneo & Gachet 2001). ADP binds to the Gq-protein-linked P2Yi receptor on 
platelets, which causes a change in cell shape, mobilization o f calcium, and initiation 
o f reversible aggregation (Hechler et al. 1998). It also binds to the Gi-linked P2Yn 
receptor to amplify aggregation via decreased adenylyl cyclase-mediated cyclic 
AMP production (Communi et al. 2000, Raju et al. 2008). The P2Xi receptor is 
believed to be involved in platelet shape change and activation by collagen under 
shear conditions (Hechler et al. 2005).
1.1.3.6 Thromboxane A2, Epinephrine and Serotonin Receptors
Thromboxane A2 (TXA2) is the major metabolic product o f  arachidonic acid (AA) in 
the platelet. Arachidonic acid is released from membrane phospholipids by 
phospholipase A2, and converted by cyclooxygenase-1 (COX-1) to prostaglandin G2 
and then to prostaglandin H2, which is in turn metabolised by thromboxane synthase 
to TxA2 (FitzGerald 1991). TxA2 is a powerful platelet agonist, activating platelets 
via the G-protein coupled thromboxane prostanoid (TP) receptor (Dunlop et al. 
2000). Epinephrine is a weak platelet agonist, acting via the a,2-adrenergic receptors 
in platelets (Newman et al. 1978). Serotonin (5-HT) is also a weak platelet agonist, 
but shows vasoconstrictive and platelet aggregating properties. It is released from 
platelet dense granules following platelet activation and has the ability to enhance
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the aggregating ability o f other platelet agonists such as ADP. Platelets express the 
serotonin 5-HT2a receptors on their surface and the serotonin 5-HT transporter 
(SERT) for rapid re-uptake into the dense granules (Lopez-Vilchez et al. 2009).
1.2 Redox Modulation of Platelet Activation
As discussed in sections 1.1.3.2 and 1.1.3.3 above, free thiols and disulphide bonds 
primarily within the integrin P subunits, play a crucial role in determining the 
structural conformation of integrins. Reduction o f these disulphide bonds and 
subsequent thiol/disulphide exchange: the making and breaking o f disulphide bonds 
between vicinal cysteine thiols, is known to play a large part in the switching from 
an inactive conformation to the activated ligand-bound conformation (Manickam et 
al. 2011, Manickam et al. 2008, Mor-Cohen et al. 2008).
Several sulphydryl reagents are known to affect platelet aggregation and adhesion. 
Membrane impermeant reagents such as p-chloromercuribenzenesulfonate 
(PCMBS), and 5, 5’-dithiobis (2-nitrobenzoic acid) (DTNB) inhibit collagen- 
induced platelet aggregation (Essex et al. 2001). Platelet adhesion to collagen, 
fibrinogen and fibronectin is inhibited by the thiol (-SH) blocking agents N-ethyl- 
maleimide (NEM), PCMBS, and thiolyte monobromotrimethyl-ammoniobimane 
(qBBr). In addition, PCMBS completely abolishes adhesion o f platelets treated with 
the universal integrin activator manganese (Mn2+) (Essex et al. 2001, Lahav et al.
2000).
The role for vicinal thiols in anbp3 activation was demonstrated using the vicinal 
thiol blocking reagent phenylarsine oxide (PAO) that inhibited platelet aggregation 
and free thiol labelling in the integrin (Manickam et al. 2008). In our own laboratory 
it was shown that reduced glutathione (GSH) alone and in combination with nitric
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oxide (NO) reversed PAC-1 binding to Mn2+ and thrombin activated platelets, 
further indicating redox regulation o f integrin activation (Walsh et al. 2004).
Protein disulphide isomerase (PDI) activity in the form o f endoplasmic reticulum 
protein 5 (ERP5) is known to be secreted by activated platelets and has been 
localised to the platelet surface, playing a role in aiibP3 activation (Jordan et al. 
2005). Blocking o f free thiols with DTNB or pCMBS inhibited platelet adhesion to 
both GFOGER and monomeric collagen via a 2Pi (Lahav et al. 2003). In the same 
study, the PDI inhibitor bacitracin also inhibited platelet adhesion to these same 
substrates, but not to the GPVI specific peptide CRP (Lahav et al. 2003).
PDI catalyses several reactions which involve disulphide bonds and free thiol 
groups. These include thiol-disulphide exchange, isomérisation (intra-molecular 
switching o f two disulphide bonds) and disulphide bond reduction or disulphide 
bond formation (oxidation) (Figure 1.9).
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Figure 1.9 Reactions catalysed by PDI. (A) Intra-molecular thiol disulphide exchange giving 
rearrangement o f  a disulphide bond, whereby the catalytic thiol is in the protein itself. (B) Intra­
molecular switching o f  two disulphide bonds, here the nucleophilic thiolate anion can be external to 
the protein. (C) Reduction o f  a disulphide bond by a reducing agent RSH. (D) Formation o f  a 
disulphide bond by the oxidation o f two protein thiol groups by an oxidising species, RSSR. Adapted 
from Essex (Essex 2009).
Allosteric disulphide bonds are defined as disulphide bonds that control protein 
function by mediating conformational changes upon reduction. There are three 
disulphide bond configurations, hooks, spirals and staples, each o f which may be left 
handed (LH) or right handed (RH) (Chen & Hogg 2006). Disulphide bonds have 
been classified as follows:
1. Structural disulp1 ide bonds having a -L H  spiral configuration
2. Catalytic disulphides are +/-RH hook configuration
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3. All known allosteric disulphide bonds are -R H  staple configuration.
In ain,P3, the Cys 663-687 disulphide bond in the P-subunit has been identified as -  
RH staple. A feature o f allosteric disulphide bonds is the short C a -C a ’ distance 
between adjacent cysteine residues, 4.3 A  compared to 5.6 A for all disulphide 
bonds. They link adjacent strands in the same anti-parallel P-sheet, causing 
puckering o f the strands, deforming the sheet, imparting high torsional energy on the 
bond (Chen & Hogg 2006). Mutations disrupting the Cys 663-687 disulphide bond 
resulted in a constitutively active integrin (Butta et al. 2003). This bond is believed 
to be a potential site o f PDI regulation. Thiol-disulphide exchange mediated by PDI 
is likely to be occurring during integrin activation. Essex has proposed a model for 
PDI mediated aiibP3 activation whereby agonist stimulation o f platelets causes 
inside-out signalling, resulting in low-affinity binding o f fibrinogen to anbP3- A PDI 
catalysed event possibly a thiol-disulphide exchange or disulphide bond reduction 
occurs in the integrin. This leads to a high affinity, high avidity state. External 
glutathione, cysteine or other low-molecular weight thiols may also generate thiols in 
both PDI and anbP3- Cytoplasmic reducing equivalents m aybe supplied by a platelet 
membrane NAD(P)H system (Essex 2009).
The role o f thiols and disulphides in the activation o f platelet integrins in particular 
aubP3 are thus well established. This redox model o f integrin activation is believed to 
apply to all integrins. This thesis will examine the effects of varying the external 
redox environment o f  the platelet using endogenous redox reagents. Platelets exist 
with all o f the other blood components in the plasma environment. This environment 
contains within it a tightly regulated redox buffering system composed mainly o f the 
two low molecular weight thiol compounds glutathione and cysteine.
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GSH is present in all animal cells with a concentration range o f 0.5 -  10 mM 
(Kosower & Kosower 1978). Most cellular GSH is found in the cytosol (90%) with 
the remainder distributed between the various organelles including the nucleus and 
mitochondria (Wu et al. 2004). GSH is the reduced form o f glutathione, and its 
cysteine thiol may become oxidised losing an electron and hydrogen ion in the 
process (Figure 1.10A). Two o f these oxidised GSH molecules combine to form the 
disulphide linked GSSG, often referred to as oxidised glutathione (Figure 1.10B). 
Such oxidation o f GSH may occur enzymatically, as in the redox reaction with 
hydroperoxides catalysed by glutathione peroxidase (GPx), and GSSG may be 
converted back to GSH by glutathione reductase (GR) (Cohen & Hochstein 1963). 
GSH may also react non-enzymatically with a wide range o f substances to yield 
GSSG (Table 1.1). Plasma glutathione levels vary from 2 - 2 5  |aM or higher, mostly 
occurring in the reduced form (GSH) (Anderson & Meister 1980, Jones 2002, Jones 
et al. 2000). There is thus a very large GSH concentration gradient across the cell 
membrane. GSH is negatively charged, ionised to thiolate (GS'), at physiological pH 
and there is a large negative potential (-35 to -66  mV more negative relative to the 
extracellular redox potential) within the cell (Gukasyan et al. 2006). These large 
electro-chemical gradients drive GSH transport out o f the cell. In plasma, the most 
abundant thiol compound is cysteine, existing in both the reduced form cysteine 
(Cys) and the oxidised disulphide cystine (CySS) (Figure 1.10C). Total plasma 
cysteine is approximately 200(xM with the predominant form being CySS (Go & 
Jones 2005).
Within plasma, low molecular weight thiols have been reported to be disulphide 
linked to plasma proteins. The concentrations o f the protein bound forms are higher
1.3 Cellular and Plasma Thiols
2 0
than the free thiols. Cys is incorporated more rapidly into plasma proteins than GSH, 
possibly due its lower pKa value (8.3 vs. 8.8), and more readily oxidised at 
physiological pH. This process has been suggested to occur by non-enzymatic 
protein thiol/disulphide exchanges (Mansoor et al. 1992). Plasma protein-thiol 
binding is thought to be a thiol buffering system protecting against transient thiol- 
disulphide changes within the plasma (Lash & Jones 1985).
1.4 Extracellular redox environment
In living cells, energy is captured during oxidation o f glucose and other organic 
molecules to support and maintain the process o f building cellular structures. This 
energy comes from the movement o f electrons from these oxidised molecules to 
oxygen, the oxygen being reduced in the process. This results in an overall reducing 
environment within cells and tissues, that is maintained by several redox couples, 
that are responsive to electron flow and hence to changes in the reducing/oxidising 
(redox) environment. The redox environment may be thought o f  as a combination of 
the tendency o f such a redox couple to reduce another species (reduction potential), 
and the number o f electrons available for reduction (reducing capacity). Reducing 
capacity may be determined from the concentration o f the reduced species in a redox 
couple, and reduction potential can be determined from the Nemst equation (Schafer
& Buettner 2001). The major physiological redox couples include the glutathione 
system (GSH/GSSG), the cysteine system (Cys/CySS), the nicotinamide adenine 
dinucleotide phosphate system (NADPH/NADP+) and the thioredoxin system (Trx 
(SHVTrxSS), where the first species in each couple is the reduced species and the 
second is the oxidised form. As discussed in section 1.3, both the GSH/GSSG and 
Cys/CySS redox couples are present in blood plasma and may undergo reversible 
oxidation/reduction as shown in Figure 1.10A. Each o f these reactions forms an
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electrochemical cell comprising two half-cell reactions in equilibrium with each 
other, for example:
2GSH —> GSSG + 2H+ + 2e' and GSSG +2H+ + 2e —> 2GSH 
The electromotive force from each redox pair is AE = E2 -  Ej where E2 is the half­
cell reduction potential for the reduced species, and Ei is the half-cell reduction 
potential for the oxidised species. This electromotive force is a measure of the 
electrical potential energy driving the flow o f electrons in a particular direction.
If  AE = 0 there is no net electron flow but this is never the case in living organisms. 
In biological systems there is therefore always a net half-cell reducing potential (Eh) 
equal to AE for a given redox couple.
The Nemst equation is used to calculate the reducing (redox) potential o f any redox
j
couple once the absolute concentrations o f  both reduced and oxidised species are 
known. The Nemst equation is written as:
where R is the gas constant, 8.314 JK ^m ol'1, T is temperature in Kelvin, F is the 
Faraday constant, 9.6485 x 104 Cmol'1, n = number o f electrons, Q = [Reduced 
species]/[Oxidised species].
The value o f the redox potential calculated is expressed in millivolts (mV). The 
natural log (In) term may be replaced by logio using 2.303 as a conversion factor. 
As redox potential is pH dependent, it is necessary to modify the equation to allow 
for biological pH ranges. The term E° designates non-standard conditions, such as 
pH = 7.4 for plasma at 37°C (Schafer & Buettner 2001). Following these 
modifications, the Nemst equation becomes:
a e = a e°-■
nt
Eh = - 2 6 4 -
[GSSG]
or Eh -  —250 « -  [CySS]
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for the GSH/GSSG and Cys/CySS redox couples respectively.
Note from the equations in Figure 1.10A, that n = 2 for each o f these equations, 
representing two electrons available for reduction, and E° = -264 mV for GSH and -  
250 mV for Cys at pH = 7.4 and T = 37°C.
Recent work by Go and Jones (Go & Jones 2005) determined the redox potentials of 
both the GSH/GSSG and Cys/CySS redox couples in plasma samples from over 700 
randomly selected subjects. The mean ± SD plasma redox potentials (Eh) were -
130.9 ± 22.9 mV and -72.4 ± 12.8 mV for the GSH/GSSG and Cys/CySS redox 
couples respectively.
Figure 1.10 Chemical structures of the GSH/GSSG and Cys/CySS redox couples. Both GSH and 
Cys possess the thiol (-SH) functional group. (A) As reducing agents, GSH and Cys have the potential 
to readily lose an electron and a hydrogen atom, thus becoming oxidised. (B) Two oxidised GSH 
molecules combine together to form GSSG linked by a disulphide bond (S-S). (C) Two oxidised 
cysteine (Cys) molecules combine together to form cystine (CyaS) linked by a disulphide bond (S-S).
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Table 1.1 GSH mediated redox reactions. GSH reacts with a wide variety o f  reactive species, 
mostly through the thiolate (GS") anion and thiyl (GS-) radical. GS' is formed when GSH loses a 
proton (H*), whereas GS' formation occurs when GSH loses both H+ and an electron (e ) , which is 
then available for reduction reactions, leaving an unpaired electron behind. GPx = glutathione 
peroxidase; GR = glutathione reductase; DHR = dihydroascorbate reductase; OH' = hydroxyl radical; 
0 2" = superoxide radical; H20 2 = hydrogen peroxide; LOOH = lipid hydroperoxide; LOH = alcohol; 
NO = nitric oxide; GSNO = nitrosoglutathione; DNA' = DNA radical; GRx = glutaredoxin; PS" = 
protein thiyl, P-SS-G = protein mixed disulphide; P-SS-P = protein disulphide bond; NADPH = 
nicotinamide adenine dinucleotide phosphate. Adapted from (Franco et al. 2007, Hill & Bhatnagar 
2007).
Reactants Products
GSH + OH’ — ► GS1 + H20
g s h  + o 2'  + h 2 — GS’ + H20
g s h + n o  + o 2 — GSNO + 0 2'
GSH + DNA — GS* + DNA
2GSH + H20 2 GPx GSSG + 2H20
2GSH + LOOH GPx GSSG + LOH + H20
2GSH + Dihydroascorbate DHR GSSG + Ascorbic Acid
2GSH + P-SS-P GRx GSSG + P-SH2
GS + PS" + 0 2 — ► PSSG + 0 2"+ H+
GSH + Protein-SSG GR GSSG + Protein-SH
GSH + (Metal)" — (Metal)" '1 + GS’
GSSG + NADPH + H+ GR 2GSH + NADP+
GS' + GS’ — ► GSSG
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1.5 Glutathione and Cysteine Biochemistry
1.5.1 Cellular Synthesis of Glutathione
Glutathione (L-y-glutamyl-L-eysteinylglyeine) or GSH is the predominant low 
molecular weight thiol in mammalian cells (Meister 1988). It is a tripeptide, formed 
by the enzymatic amide-linkage o f L-glutamate to L-cysteine by the enzyme 
glutamate-cysteine ligase (GCL), and followed by addition o f the third amino acid 
glycine by glutathione synthase (GS) (Dickinson & Forman 2002, Meister & 
Anderson 1983). The reaction scheme is shown in Figure 1.11. Synthesis occurs in 
all cells, but the liver is the major producer and exporter o f  GSH (Wu et al. 2004). 
Bioavailability o f the amino acid cysteine is rate limiting for GSH synthesis, and 
GSH production itself serves to regulate the activity o f GCL via a negative feedback 
mechanism (Huang et al. 1988).
Cysteine is normally derived from the diet through protein breakdown, and also in 
the liver from methionine metabolism via the transsulphuration pathway (Lu 1999) 
(Figure 1.12).
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Figure 1.11 Glutathione synthesis. The ATP dependent, enzyme catalysed sequential amide linkage 
o f glutamate, cysteine and glycine to yield glutathione. GCL = glutamate-cysteine ligase; GS = 
glutathione synthase. GSH acts as an inhibitor o f  GCL by negative feedback (red line). Adapted from 
(Forman et al. 2009).
GSH is degraded into its constituent amino acids by the enzymes y-glutamyl- 
transpeptidase (y-GT) (Orlowski & Meister 1970) and cysteinyl-glycine dipeptidase 
(McIntyre & Curthoys 1982). Glutathione catabolism only occurs extracellularly, 
through the action o f y-GT, expressed mainly on the apical cell surface, which 
removes the y-glutamyl group from both GSH and GSH-conjugated compounds 
(Franco et al. 2007). The remaining amino acids cysteine and glycine are cleaved by 
ectoprotein dipeptidases and are transferred into the cell by specific transporters 
(Figure 1.13). The oxidised form o f cysteine, cystine (CySS), may be transported
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inwards across the membrane by the Na+ independent anionic amino acid transport 
system designated Xc", wherein it is reduced back to cysteine for GSH synthesis 
(Okuno et al. 2003). Cysteine itself may be imported by those cells possessing the 
alanine-serine-cysteine (ASC) neutral amino acid transporter system (Srivastava et 
al. 2010).
There are no transporters for GSH import currently described. There are several 
GSH transporter families implicated in GSH efflux across the membrane. These are 
the multidrug resistance-associated protein family (MRP), the cystic fibrosis 
transmembrane conductance regulator (CFTR), and the organic anion-transporting 
polypeptide OATP family (Ballatori & Rebbeor 1998).
The MRP family are co-transporters o f organic anions (OA') with GSH. ATP 
binding and hydrolysis provide the energy for transport o f substrates out o f the cell. 
The M RP’s are also transporters o f  GSH-conjugated xenobiotics, o f GSH- 
conjugated metabolites and also export the oxidised form o f glutathione (GSSG) 
from the cell (Cole & Deeley 2006). CFTR’s are chloride channels and have been 
suggested to mediate GSH transport directly or to modulate GSH transport by other 
proteins.
OATP mediated GSH transport has been demonstrated in the rat (OATP1 and 
OATP2), although the OATP proteins were initially believed to mediate bi­
directional GSH transport (Hagenbuch & Meier 2004), a more recent study has 
suggested this is not the case (Briz et al. 2006). The human OATP GSH transporters 
have yet to be identified (Li et al. 1998, Mahagita et al. 2007).
27
| Methionine |
ATP-------------► !
Figure 1.12 Transsulphuration pathways. This pathway is unique to the liver cell. Methionine is 
sequentially converted to cysteine in several enzyme-catalysed steps. The transsulphuration pathway 
(blue) follows the déméthylation o f  methionine to yield homocysteine, which is then condensed with 
serine to form cystathione. Cystathione is converted by cystathionase to free cysteine. The cysteine is 
then converted to GSH via the GSH synthetic pathway (lilac). Methionine may also be recycled from 
homocysteine via the remethylation pathways (green). 1: methionine adenosyltransferase; 2: 
transmethylation reaction; 3: S-adenosylhomocysteine hydrolase; 4: cystathione p-synthase; 5: y- 
cystathionase; 6: y-glutamylcysteine ligase; 7: glutathione synthase; 8: methionine synthase; 9: 
betaine-homocysteine methyltransferase. Adapted from Lu (Lu 1999).
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Figure 1.13 Glutathione recycling pathways. GSH, GSSG or GSH-conjugates are catabolised by y- 
glutamyl transpeptidase (y-GT) on the cell membrane surface. The cleaved y-glutamyl group may be 
then transferred to other acceptors such as amino acids (aa), and then transported back into the cell via 
specific transporters (shown in yellow). The cysteinyl-glycine moiety or its conjugates are 
enzymatically cleaved by membrane bound dipeptidases (DPT) into the individual amino acids 
glycine and cysteine, or cysteine-conjugates, all o f  which re-enter the cell via the specific amino acid 
transporters. Once inside the cell, the cysteine-conjugates are acetylated by N-acetyl transferase 
(NAT) to mercapturic acids and the y-glutamyl amino acids are converted to 5-oxoproline and the 
corresponding amino acid by y-glutamyl cyclotransferase (y-GCT). The 5-oxoproline is in turn 
converted into glutamate by 5-oxyprolinase (OXP). Glutamate, cysteine and glycine are then 
combined intracellularly to form GSH by glutamate-cysteine ligase (GCL) and glutathione synthase 
(GS) respectively. Adapted from Franco (Franco et al. 2007).
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Cysteine residues are the most conserved residues in functionally important sites
within proteins. Cysteine residues have been assigned the following functions
(Fomenko et al. 2008):
1. Catalytic redox-active cysteine residues are directly involved in catalytic 
reactions such as oxidation, reduction and isomérisation o f disulphide bonds. 
They are found in thiol-oxidoreductase enzymes including protein disulphide 
isomerase (PDI) (Noiva & Lennarz 1992) and thioredoxin (Schultz et al. 1999). 
The highly conserved CXXC m otif is commonly present (Chivers et al. 1996).
2. R egulatory cysteine residues regulate or modulate protein activity by changing 
their redox state, but are not catalytic themselves. Disulphide bond formation, S- 
glutathionylation and S-nitrosylation are the signalling mechanisms utilised by 
regulatory Cys residues (Adachi et al. 2004, Biswas et al. 2006). They are 
found in many proteins including kinases (Rhee et al. 2000), phosphatases 
(Salmeen et al. 2003) and transcription factors (Azevedo et al. 2003).
3. S truc tu ra l cysteine residues participate in protein structure through the 
formation o f stable intramolecular and intermolecular disulphide bonds 
(Thornton 1981).
2+4. M etal-coordinating cysteine residues coordinate metal ions such as Zn and 
are frequently in the form o f the highly conserved CXXC m otif (Gladyshev et 
al. 2004, Harding 2004) making distinction between catalytic redox cysteines 
and metal-binding cysteines difficult.
5. Catalytic non-redox cysteine residues participate in catalysis but do not 
change their redox state, are highly conserved and act as nucleophiles. Such
1.5.2 The Functions of Cysteine Thiols
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residues are found in glyceralderhyde-3-phosphate dehydrogenase (Zaffagnini et 
al. 2007).
GSH is involved in many reactions o f biological importance, all o f  which depend on 
the thiol (-SH) group o f cysteine, the GSH central amino acid (Sies 1999).
The thiol group o f GSH is long known to be important in cell functions such as 
antioxidant defence, xenobiotic and eicosanoid metabolism, regulation o f  cell cycle 
and gene expression (Dickinson & Forman 2002). GSH can protect cells from the 
toxic effects o f heavy metal ions such as mercury (Hg2+) and cadmium (Cd2+), and 
from the effects o f ionising radiation by neutralising the damaging effects of 
radiation-induced free radicals (Flora & Pachauri 2010, Meister 1988, Steel 2002). 
GSH is a strong nucleophile capable o f  reacting with electrophiles to form GSH 
conjugates (Ketterer 1982). Elimination of xenobiotic compounds is accomplished 
by formation o f such conjugates catalysed by GSH 5-transferases (GST), followed 
by secretion from the cell through membrane transporters (Forman et al. 2009, 
Meister 1988). GSH is also a powerful reducing agent for disulphides and peroxides 
(Thomas 1984). In addition, both GSH and cysteine itself play a role in the redox 
modification o f critical protein cysteine residues by the processes of 5- 
glutathionylation and 5-cysteinylation respectively. These are the formation o f inter- 
and intra-molecular disulphide bonds between glutathione or cysteine and low - pKa 
cysteinyl residues (Biswas et al. 2006, Dalle-Donne et al. 2007). Such protein 
cysteine residues are known ‘reactive cysteines’ and are frequently found adjacent to 
neighbouring basic amino acid residues (Snyder et al. 1981, Vukelic et al. 2012, 
Wakabayashi et al. 2004). Proteins can bind many thiol-containing molecules 
including GSH, cysteine, homocysteine and y-glutamyl-cysteine. The result is 
formation o f protein mixed disulphides denoted as PS-SX (proteins linked via a
31
disulphide bond to a thiol-containing species, X). GSH is the dominant ligand by 
virtue o f its greater abundance within the cell (Seres et al. 1996).
1.5.3 Thiols and Antioxidant Defence
The term “oxidative stress” may be used to describe an imbalance in the normal 
physiological levels o f pro- and anti-oxidant species either within or outside the cell. 
This may occur either through increased generation o f oxidants such as reactive 
oxygen/nitrogen species (ROS/RNS), or through depletion o f physiological anti­
oxidant molecules such as GSH, the radical scavenging vitamins E and C or the 
enzymatic ROS scavengers’ superoxide dismutase (SOD), catalase (CAT) and 
glutathione peroxidase (GPx) (Halliwell 1999, Hayes & McLellan 1999). Recently 
the redox phenomenon of “reductive stress” has become a major focus in redox 
biology. Reductive stress may be defined in terms o f the depletion o f the pro­
oxidants ROS and RNS and/or an over production or supply o f reducing redox 
species and anti-oxidants. Cardiomyocyte-specific over expression o f heat shock 
protein 27 (Hsp27) induces reductive stress in the mouse heart. Mice expressing high 
levels o f  Hsp27 displayed increased myocardial glutathione peroxidase expression 
and activity, increased GSH and GSH/GSSG ratio without altering GSSG levels and 
decreased reactive oxygen species levels, resulting in cardiac hypertrophy, 
dysfunction, and reduced lifespan (Zhang et al. 2010).
GSH is the major source o f reducing capacity within the cell. It contributes to anti­
oxidant metabolic pathways by acting as a strong reducing agent (electron donor) or 
as a cofactor o f electrophilic conjugates as described above (section 1.5.2). At pH 
7.4, GSH can readily dissociate to its thiolate form (GS‘ + H+) and it is this thiolate 
anion that mediates many o f the GSH mediated anti-oxidant reactions, by making its
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electron available for reduction reactions. Almost all physiological oxidants react 
with thiols (Winterboum & Hampton 2008) and several examples o f redox reactions 
involving GSH are illustrated in Table 1.1. Thiols may participate in either one or 
two-electron transfer reactions depending on the oxidant species involved. One- 
electron reactive species include superoxide (O2" ) and hydroxyl (OH') radical, which 
when reacting with thiols, yield the thiyl (S’) radical. Under aerobic conditions the 
most favoured subsequent reaction is with GSH or a protein thiol group to form a 
mixed disulphide (Winterboum & Metodiewa 1999). Two electron oxidants such as 
hydrogen peroxide (H2O2), hypochlorous acid (HOC1) or peroxynitrite (ONOO ) 
react with thiols to generate sulphenic acids (R-SOH) (Nagy & Ashby 2007). Figure
1.14 shows the products o f 1- and 2-electron oxidation o f protein cysteine residues. 
Sulphenic acids are unstable and highly reactive intermediates that may be further 
oxidised to higher oxidation states such as sulphinic and sulphonic acids (RSO2H 
and RSO3H). Sulphenic acids may be reduced by cellular reductants such as GSH or 
the enzyme thioredoxin (Trx) (Reddie & Carroll 2008). Sulphinylation o f protein 
cysteines may only be reversed by the action o f the recently discovered ATP- 
dependent enzymatic sulphinic acid reductase known as sulphiredoxin (Srx) (Biteau 
et al. 2003).
Oxidation o f protein cysteines to sulphonic acids is irreversible, leading to severe 
impairment o f protein structure and function. Protein sulphenic acid formation has an 
important role in the redox regulation o f transcription factors and enzymes such as 
protein tyrosine phosphatases (Denu & Tanner 1998, Poole et al. 2004). The 
formation o f cysteine-sulphinic acid by H2O2 inactivates the catalytic cysteine 
residue o f peroxiredoxin (Woo et al. 2003) and along with protein sulphonic acid, 
can also target a protein for ubiquitin-dependent degradation (Tasaki & Kwon 2007).
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1.5.4 Protection of Protein Cysteines by Æ-glutathionylation or S- 
cysteinylation
The reactive oxygen species referred to in section 1.5.3 above are produced 
continuously by the cell as a result o f the partial reduction o f oxygen by the 
mitochondrial electron transport chain, cytoplasmic lipoxygenases, and membrane 
associated multi-component nicotinamide adenenine dinucleotide phosphate 
(NADPH) oxidase enzymes (Nox) (Liu et al. 2002, Nardi et al. 2004, Seno et al.
2001).
Superoxide ( 0 2 ')> hydrogen peroxide (H2O2) and hydroxyl radical (OH') are 
generated by these enzymatic activities. These and other oxidant species are very 
reactive with thiol containing molecules. This applies not only to low molecular 
weight thiols such as GSH and Cys, but also to protein thiols (PSH), resulting in 
several oxidised products including protein sulphenic, sulphinic and sulphonic acids 
(Radi et al. 1991). All o f  these post translational modifications to cysteine residues 
lead to alteration o f protein function. Such changes in protein function include 
inhibition o f protein tyrosine phosphatase (PTP) enzyme catalytic function by 
hydrogen peroxide-induced oxidation o f the reactive cysteine to sulphenic acid 
(Denu & Tanner 1998), and hydrogen peroxide-induced oxidation o f two reactive 
cysteine residues in p/y-actin reduced its ability to polymerise (Lassing et al. 2007). 
Both o f these redox modifications however were reversible following reaction with 
the physiological redox buffers glutathione, cysteine (PTP) and thioredoxin (actin) 
respectively (Denu & Tanner 1998, Lassing et al. 2007).
The protective function o f both glutathione and cysteine is emerging as an important 
reversible post-translational modification with a critical role in thiol homeostasis and 
signal transduction (Gallogly & Mieyal 2007).
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Figure 1.14 Pathways for 1 and 2-electron oxidation of protein thiols. In the left-hand pathway, 2- 
electron oxidants (H2O2, ONOO', HOC1) initially oxidise protein thiols to sulphenic acid (Pr-SOH), 
which as an unstable intermediate may react with strong oxidants to form sulphinic or sulphonic acids 
(Pr-S02H, Pr-S03H), with GSH to form mixed protein disulphides (Pr-SS-G), or may react with 
vicinal thiols to yield inter or intra-molecular disulphide bonds within the protein. The right-hand 
pathway shows the effects o f  1-electron oxidants on protein thiols. 1-electron oxidants ( 0 2'- and OH) 
give rise to the thiyl radical (Pr-S-) that under aerobic conditions favours reaction with the thiolated 
anion as Pr-S' or GS~ to form Pr-SS-Pr or Pr-SS-G, the S-glutathionylated product. Reaction with 
oxygen also generates superoxide, thus amplifying the oxidant stress. In addition, the thiyl radical can 
react with oxygen to produce the sulphenyl radical (Pr-S02‘)- Adapted from Winterboum 
(Winterboum & Hampton 2008).
1.6 Aims
The aims of this thesis are to investigate how changes in the extracellular redox 
environment o f  the platelet impact on platelet function. The essential role o f thiol 
groups and disulphide bond reduction and reshuffling in platelet activation is well 
established. Not known, however, are the physiological mediators o f this
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thiol/disulphide regulation o f platelet function or the nature o f  the biochemical 
mechanisms involved. As the plasma redox environment is tightly controlled by both 
the glutathione and cysteine redox couples, the effects o f varying the redox 
potentials o f both these GSH/GSSG and Cys/CySS redox couples on platelet 
function will be examined on both resting and agonist stimulated platelets. The 
plasma redox state is intimately associated with cardiovascular disease progression 
(Ashfaq et al. 2006, Go & Jones 2005), during the course o f which platelets play a 
central role. Currently, the nature o f the influence o f the plasma redox state on 
platelet function remains to be explored. There are many examples o f the redox 
regulation o f protein function by both pro-oxidant reactive oxygen or nitrogen 
species and, o f more recent interest, by the low molecular weight thiol redox buffers 
glutathione and cysteine (Dalle-Donne et al. 2007, Hochgrafe et al. 2007). This 
redox regulation occurs primarily through redox reactions involving vital cysteine 
residues within the target proteins. Platelets integrals are prime targets for post- 
translational redox modification due to their unusually high number o f  cysteine 
residues particularly within their P-subunits. Identification o f potentially reactive 
cysteine residues on the platelet surface would point to possible targets o f redox 
modulation. Several key indices o f platelet function will be studied in response to 
varying redox conditions. The mechanism o f the redox-regulation o f platelet 
activation will be examined to better understand the basis o f the interaction between 
the platelet and its external redox environment and to try and put the thiol/disulphide 
mediated redox control o f platelet activation into a physiological context.
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Chapter 2 
Materials and Methods
2.1 Materials
2.1.1 General Reagents
a-tocopherol, bovine serum albumin (BSA), calcium chloride, citric acid anhydrous, 
cysteine (Cys), cystine (CySS), dextrose, dimethylsulfoxide (DMSO), dithiothreitol 
(DTT), ethylene diamine tetra acetic acid (EDTA), glycine, HEPES sodium salt, 
horseradish peroxidase (HRP) type I, Kodak (Biomax ML) film, L-ascorbic acid, 
luminol, D-mannitol, polyvinyldifluoride (PVDF), potassium chloride, magnesium 
chloride, phorbol 12-myristate 13-acetate (PMA), potassium phosphate, 
prostaglandin Ei (PGEi), sepharose 2B-300, sodium bicarbonate, sodium chloride, 
sodium citrate, sodium dodecyl sulphate (SDS), sodium fluoride, sodium 
pyrophosphate, sodium orthovanadate, tris (carboxyethyl) phosphine (TCEP), Triton 
X-100, trizma base, Tween-20, xanthine and xanthine oxidase (XO) were obtained 
from Sigma Aldrich Ltd, Tallaght, Dublin, Ireland.
5(6)-chloromethyl, 2 ’, 7’-dichlorodihydrofluorescein diacetate (DCFDA) was 
obtained from Molecular Probes, Oregon, USA.
Chrono-lume® Luciferin/luciferase reagent was obtained from Chrono-Log, 
Haverstown, PA, USA.
Disposable chromatography columns, mini-PROTEAN TGX™ gels and Bradford 
DC Assay kit were obtained from Bio-Rad Corporation, Bath, U.K.
5, 5'-Dithio-bis-(2-nitrobenzoic acid) (DTNB), N-acetyl-L-cysteine (NAC), catalase, 
superoxide dismutase (SOD), reduced glutathione (GSH) and oxidized glutathione 
(GSSG), were obtained from Merck Chemicals Ltd, Nottingham, UK.
L-012 was obtained from Wako, Neuss, Germany.
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96 well micro titre plates (Immulon 2HB) for platelet adhesion were obtained from 
Dynex Technologies, Sussex, UK.
White 96-well micro titre plates (Nunc) for chemiluminescence assays were obtained 
from Thermo Fisher Scientific, Dublin, Ireland.
Supersignal® West Pico chemiluminescent substrate, 4-20% Precise™ Protein gels 
and BupH Tris-HEPES-SDS running buffer were obtained from Pierce, Rockford, 
IL, USA.
Fluorescent mounting medium was obtained from Dako, CA, USA.
2.1.2 Antibodies
Anti-phosphotyrosine antibody.4G10 was obtained from Millipore, Cork, Ireland.
Anti-glutathione and anti-cysteine monoclonal antibodies were obtained from 
Virogen, MA. USA.
Horseradish peroxidase (HRP)-labelled secondary antibody (IgG), mouse 
monoclonal antibody anti-a2 integrin (P1E6) and goat anti-mouse IgGi-PE labelled 
secondary antibody, were obtained from Santa Cruz Biotechnology, Inc., CA, 
USA.
Monoclonal mouse PAC-1-FITC (fluorescein isothiocyanate) antibody, monoclonal 
mouse FITC-labelled antibody CD41a, monoclonal mouse anti-human CD49b 
(12F1) PE (phycoerythrin) labelled antibody, isotypic controls IgGi-PE and IgG2- 
PE, were obtained from Becton Dickinson, Oxford, England.
Mouse monoclonal arni-CD49b antibody (6F1) was a kind gift from Dr. Barry 
Coller, Rockefeller University, NY. USA.
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Soluble collagen bovine type I was obtained from BioData, Horsham, PA, USA.
Convulxin was obtained from Alexis Corporation, Lausen, Switzerland.
Soluble collagen type I from calf skin, FITC-labelled collagen bovine type I and 
bovine thrombin were obtained from Sigma Aldrich Ltd, Tallaght, Dublin, 
Ireland.
Collagen related peptide (CRP), and collagen related triple helical peptides 
(GFOGER, and GPPio) were a kind gift from Professor Richard Famdale, 
Department of Biochemistry, Cambridge University, UK.
2.1.3 Platelet agonists
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2.2 Methods
All blood donors were healthy volunteers, who were not taking any medication that 
would adversely affect platelet function in the previous two weeks. The use o f 
hum an blood was approved by the RCSI Research Ethics Committee. Whole blood 
(30 - 60ml) was drawn into a syringe using a 19-gauge butterfly needle from the 
antecubital vein into 15% (v/v) Acid-Citrate-Dextrose (ACD: 38mM citric acid, 
75mM  sodium citrate, 124mM dextrose) anticoagulant. Blood was divided into 5ml 
aliquots in 15ml plastic tubes and centrifuged at 160 x g  without brake for 15 
minutes at room temperature. The uppermost layer, corresponding to platelet rich 
plasm a (PRP), was carefully removed from each tube using a plastic transfer pipette 
to a 50ml plastic tube. 1ml o f  modified HEPES platelet buffer (6mM  dextrose, 
130mM NaCl, 9mM NaHCC>3, lOmM sodium citrate, lOmM HEPES sodium salt, 
3mM  KC1, 0.81mM KH2PO4, 0.9mM M gCh, pH 7.4), containing prostaglandin Ei 
(PGEi) at a final concentration o f  l^ M , was added to the remaining blood in each 
15ml tube (Vargas et al. 1982). The tubes were gently inverted and centrifuged at 
750 x g  for 3 minutes at room temperature. The top two-thirds o f PRP were removed 
to the first 50ml plastic tube. A further 10ml o f modified HEPES platelet/PGEi 
buffer was added to the PRP, which was gently inverted. The PRP was centrifuged at 
800 x g  for 15 minutes at room temperature, to pellet the platelets. The supernatant 
o f  the dilute platelet poor plasm a (PPP) was gently pipetted off. The platelet pellet 
was gently re-suspended in 1ml o f  platelet buffer per 30ml o f whole blood donated 
using a plastic transfer pipette.
2.2.1 Isolation of Platelets from Whole Blood
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2.2.2 Preparation of Gel-Filtered Platelets
The re-suspended platelets were filtered by passing them through a packed column 
o f sepharose 2B-300 beads. The plastic column used was 1.5cm in diameter, 
containing a 30 jam polyethylene bed support to retain fine particles that was pre­
rinsed with deionised water and then filled with 5 - 6ml o f  packed sepharose 2B-300 
for every 1ml o f platelet suspension to be filtered. The column was rinsed with at 
least 10 times its volume o f deionised water, and then equilibrated with 3 - 4  
volumes o f  modified HEPES platelet buffer. Buffer was allowed to pass through the 
column before platelets were layered onto it. Filtered platelets were collected into a 
15ml plastic tube. The gel-filtered platelets (GFP) were counted using a Sysmex K- 
21 counter (Kobe, Japan), and the count adjusted to 250 x 103/fj.1 with platelet buffer. 
Platelets were then allowed to ‘rest’ for 30 minutes at room temperature. CaCl2 was 
added to a final concentration o f  1.8mM to the platelets prior to use in experiments.
2.2.3 Preparation of Washed Platelets
W hole blood was collected as outlined in Section 2.2.1. W ashed platelets were 
prepared according to the method o f Dr. J. M. Howes, Department o f  Biochemistry, 
Cambridge University (personal communication from Dr. J.M  Howes). Briefly, the 
whole blood was centrifuged in 5ml aliquots at 150 x g  for 15 minutes at room 
temperature and the top two-thirds o f PRP were carefully removed to a 50ml plastic 
tube avoiding red cell contamination. PGEi (l^iM  final concentration) was added to 
the PRP which was then spun at 1200 x g  for 15 minutes. The supernatant was 
removed with a plastic transfer pipette, and the pellet was re-suspended in calcium- 
free Tyrodes platelet buffer (140mM NaCl, 5.6mM D-glucose, 2.1mM MgCl2, 
0.35mM NaH2P0 4 , 2.7mM  KC1, lOmM HEPES, pH 7.4) to a final concentration o f 
250 x 1 0 V .
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Stock solutions o f 200mM reduced glutathione (GSH), oxidised glutathione (GSSG), 
cysteine (Cys) and cystine (CySS) were prepared in 1M Hydrochloric acid (HC1). 
Aliquots were then serially diluted to the required working stock concentrations with 
platelet buffer. Vehicle control experiments determined that the HC1 vehicle, at the 
maximum concentration used in this study, had no effect on either the pH o f  the 
platelet buffer (Figure 2.1 A) or on platelet function as measured by using light 
transmission aggregometry (Figure 2 .IB). Redox reagents were prepared freshly 
every day and kept on ice prior to use.
2.2.4 Preparation of Redox Reagents
+ 500(JM 
HCI
Figure 2.1 Effects of HCI vehicle on buffer pH and platelet function. The maximal concentration 
of HCI (500|O.M) used in the preparation of the GSH and Cys redox reagents had no effect on either 
the pH o f the platelet buffer (A) or on the functionality o f platelets as measured by light transmission 
aggregometry (B). Data show mean ± SE of n = 4 separate experiments.
2.2.5 Redox Potentials (Eh)
The term “redox potential (Eh)” is a measure o f the tendency o f  a redox couple
(GSH/GSSG or Cys/CySS) to be m ore or less reducing. It is expressed in millivolts
(mV). A  m ore negative redox potential denotes a more reducing environment. In the
context o f human blood plasma: GSH/GSSG Eh = -264mV and Cys/CySS Eh = -
148mV. Conversely a less negative redox potential denotes a m ore oxidising redox
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environment such as GSH/GSSG Eh = -10mV or Cys/CySS Eh = +4mV. A  chemical 
species with a more reducing redox potential has a greater tendency to yield 
electrons that are then available to reduce another substance. The electron donor 
becomes oxidised in the process.
All redox potentials used in this study were calculated for the GSH/GSSG and 
Cys/CySS redox couples using the N em st equation in the following form:
Eh = E° -  RT/nF log [R ed]2/ [Ox]
where Eh represents the electromotive force (redox potential o f  the redox couple) 
relative to a standard hydrogen electrode; E° is the standard electrode potential with 
values o f -264mV and -250mV for GSH/GSSG and Cys/CySS redox couples at pH 
7.4, respectively; R is the gas constant: 8.314 JK ^m ol'1; T is the temperature in 
kelvin; F is the Faraday constant: 9.64 8 5 x 104 C m ol'1; n is the number o f  electrons 
transferred between species during the oxidation/reduction reaction; [Red] and [Ox] 
are the m olar concentrations o f the reduced and oxidised species o f  each redox 
couple respectively. Using the N em st equation, the redox potentials for the 
GSH/GSSG and Cys/CySS redox couples were generated to reflect the mean plasma 
values o f Eh = -130 m V  for GSH/GSSG and Eh = -82 mV for Cys/CySS as 
measured in over 700 randomly selected individuals (Go & Jones 2005). I also 
generated a range o f  redox potentials equivalent to the mean ±  6 standard deviations 
from the plasm a mean value. This range incorporated redox potentials that lay just 
beyond the normal redox potential range measured in human subjects (Jones et al. 
2002, M oriarty et al. 2003). This was done to simulate mean plasma redox potentials 
and quite oxidising and reducing redox potentials either side o f the mean in order to 
determine the effects i f  any on various indices o f  platelet function. All redox 
potentials were calculated mathematically using the Nem st equation. It was also
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ensured that total glutathione ([GSH] + [GSSG]) did not exceed 45|iM , or that total 
cysteine ([Cys] + [CySS]) did not exceed 200jxM, in line with established 
physiological limits (Go & Jones 2005). The molar concentrations o f  each redox 
couple used to generate each redox potential are shown in Table 2.1. These redox 
potentials were used for all assays, unless otherwise stated.
Table 2.1 The concentration of each glutathione or cysteine redox species required to generate the 
indicated redox potentials using the Nemst equation.
E h mV -264mV -130mV -10mV
[GSH] 45|j M 3|jM 250nM
[GSSG] 2nM 0.3jjM 25|iM
E h mV -148mV -82mV +4mV
[Cys] 60pM 14pM 0.5|jM
[CySS] 10|jM 93jjM 100|jM
2.2.6 Platelet Aggregation Studies
These studies were carried out using a Bio-Data PAP-4 or PAP-8 E platelet 
aggregometer (Horsham, PA, USA). The level o f  platelet aggregation is examined 
by measuring light transmission through stirred platelet suspensions. Stirring at 
11 00  rpm is required to reproduce the normal physiological shear stress environment 
o f  the blood and for the platelet-platelet contact that initiates the formation o f platelet 
aggregates. As these are formed, they fall out o f suspension to the bottom o f the 
tube and light transmission increases up to a maximum o f 100% compared to a 
buffer control. Thus, an increase in percentage light transmission is a direct measure 
o f  platelet aggregation. Aggregation is monitored in real-time as changes in light
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transmission following activation o f platelets with physiological agonists. The 100% 
light transmission base line was set using platelet buffer. 200^1 o f  gel-filtered 
platelets (25 0 x 103/jal) were pipetted into siliconised glass tubes. Platelets were 
activated with either bovine soluble type I collagen (38|xg/ml), convulxin (50ng/ml) 
or thrombin (0.1U/ml). These agonist concentrations were determined to induce 
comparable levels o f  platelet aggregation (Figure 2.2) and were used in all 
subsequent assays unless otherwise stated. Aggregations were carried out at 37°C 
with constant stirring at 1100 rpm and followed for at least 5 minutes.
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Figure 2.2 Platelet aggregation induced by collagen, convulxin and thrombin. Gel-filtered 
platelets were activated with (a) collagen (38|ig/ml), (b) convulxin (50ng/ml), (c) thrombin (0.1U/ml) 
or were left unactivated (d). These agonist concentrations were found to give comparable levels of 
platelet aggregation in all donors tested. Representative tracing from n = 50 separate experiments.
2.2.6.1 Platelet Aggregations with Varying Redox Potentials
200^1 o f  gel-filtered platelets (250 x 10 / ¡al) were pipetted into siliconised glass 
tubes. A  100% light transmission base line was set using buffer. Redox reagents
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(GSH/GSSG or Cys/CySS) were added to the platelets at the required redox 
potentials: GSH/GSSG Eh = -264mV, -130mV, -lOmV, representing plasm a mean Eh 
± 6  SD; Cys/CySS Eh = -148mV, -82mV, +4mV, representing plasm a mean Eh ± 6 
SD, for 3 minutes at 37°C under constant stirring at 1100 rpm prior to addition o f 
agonist in a final volume o f 250|xl. Aggregations were carried out at 37°C with 
stirring at 1100 rpm and were followed for at least 5 minutes.
2.2.6.2 Platelet Aggregations with Antioxidants and ROS Scavengers
Gel-filtered platelets prepared as in section 2.2.2 were activated with collagen 
(38|xg/ml), convulxin (50ng/ml) and throm bin (O.lU/ml), and allowed to aggregate 
for at least 5 minutes at 37°C with constant stirring at 1100 rpm. To some platelet 
samples, the antioxidants GSH, N-acetyl-cysteine, ascorbic acid or a-tocopherol (all 
50pM ) were added to platelets for 5 minutes at 37°C prior to addition o f agonist. 
50pM  was the antioxidant concentration chosen as it approximates the concentration 
o f  GSH and cysteine (45pM  and 60|xM respectively) used to generate the most 
reducing redox potentials with the N em st equation (Table 2.1). Aggregations were 
followed as before. Platelets were also activated in the absence o f antioxidants. In 
some aggregation studies, platelets were treated with the ROS scavengers catalase 
(lOOOU/ml), superoxide dismutase (300U/ml) or mannitol (3mM) as used previously 
in similar assays (Krotz et al. 2002, Pignatelli et al. 1998) for 5 minutes prior to 
activation with collagen (38pg/ml), convulxin (50ng/ml) or thrombin (O.lU/ml).
2.2.6.3 Platelet Aggregations with Reducing and Oxidising Agents
Gel-filtered platelets were treated with GSH, Cys or the disulphide bond reducing 
agents DTT and TCEP (all 45 pM  final concentration to match the concentrations o f 
GSH and Cys in the reducing redox potentials) for 5 minutes at 37°C prior to
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activation with collagen (38jxg/ml), convulxin (50ng/ml) or thrombin (O.lU/ml) in 
platelet aggregation studies and allowed to aggregate for at least 5 minutes at 37°C 
with stirring at 1100 rpm. Some platelet samples were activated in the absence o f 
any reducing agents. Platelets were also pre-treated with either oxidised glutathione 
(GSSG), oxidised cysteine (CySS) or the thiol-blocking agent DTNB (again all at 
45 )aM final concentration) for 5 minutes at 37°C. The platelets were then activated 
with collagen (38|ig/ml), convulxin (50ng/ml) or thrombin (O.lU/ml) and 
aggregations followed for at least 5 minutes under constant stirring at 1100 rpm at 
37°C. Platelets were also activated in the absence o f oxidising reagents and allowed 
to aggregate as before.
2.2.6.4 Determination of the Effects of Reducing and Oxidising 
Redox Potentials on Collagen Type I Functionality
Soluble type I collagen from bovine skin (1.9mg/ml) was divided into 5 x 25\A 
aliquots and these were either incubated with platelet buffer alone or with the 
GSH/GSSG (Eh = -264mV or -10mV) or Cys/CySS (Eh = -148mV or +4mV) redox 
potentials for 10 minutes at 37°C. These redox potentials represent the m ost reducing 
and most oxidising GSH/GSSG and Cys/CySS redox potentials used in all assays. 
Gel-filtered platelets were prepared as described in section 2.2.2. The ‘redox treated 
collagen’ at a final concentration o f 38|i,g/ml was used to activate 2 0 0 (il o f  gel- 
filtered platelets (250 x 103/(J.1) in a platelet aggregation study in a final volume o f 
250jj1 Aggregations were followed for 10 minutes with stirring at 1100 rpm at 37°C. 
Using the same donors platelets on the same day, gel-filtered platelets were divided 
into 5 x 200^.1 aliquots and were either left untreated or were incubated with 
GSH/GSSG (Eh = -264mV and -10mV) or Cys/CySS (Eh =  -148mV and +4mV) 
redox potentials and platelet buffer in a final volume o f 250^1 for 10 minutes at
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37°C. Platelet aggregations were carried out using fresh aliquots o f collagen 
(38|ig/ml final concentration) that had not been previously exposed to redox. 
Aggregations were allowed to proceed for at least 10 minutes.
2.2.6.5 The Effects of Increased Divalent Cation Concentration on 
Platelet Aggregation in the Presence of Varying Redox Potentials
The presence o f divalent cations are required for integrin function including 
stabilising integrin function and enhancing or suppressing its interaction with 
physiological ligands (Xiong et al. 2003). Platelet aggregation through anbf^ 
requires the presence o f  calcium ions (Ca2+) (Bennett & Vilaire 1979) and (X2P 1 
mediated adhesion to collagen is magnesium ion (Mg ) dependent (Staatz et al. 
1989). M y study was done to assess i f  the metal-chelating properties o f  either GSH 
or Cys could affect agonist induced platelet aggregation. Gel-filtered platelets were 
prepared as outlined in section 2.2.2. Platelets were activated with collagen 
(38|j,g/ml), convulxin (50ng/ml), throm bin (O.lU/ml) or remained unactivated in a 
platelet aggregometry assay as described in section 2.2.6. Platelets were treated with 
the following redox potentials: GSH/GSSG Eh = -264mV or Cys/CySS Eh = -148mV 
or with EDTA (50|jM  or 2mM) for three minutes at 37°C under stirring conditions at 
1100 rpm, before activation with the same platelet agonists as before. In this 
experiment, aliquots o f  redox treated and untreated platelets were supplemented with 
either C aC ^ (2mM) or MgCl2 (2mM) for a further three minutes at 37°C and 1100 
rpm stirring, and were left either unactivated or were activated with the platelet 
agonists: collagen (38jig/ml), convulxin (50ng/ml) and thrombin (O.lU/ml). 
Aggregations were followed for 1.C minutes with stirring at 1100 rpm.
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2.2.6.6 The Effects of Varying DTT Concentrations on Platelet 
Aggregation
Gel-filtered platelets were prepared as outlined in section 2.2.2 and were treated with 
platelet buffer or varying concentrations o f  the disulphide bond reducing agent 
dithiotreitol (DTT) (0|iM , 0.1 ljxM, lOjiM, 100(iM and IOOOjjM ) for 5 minutes 
at 37°C under stirring conditions at 1100 rpm in a platelet aggregometer. Platelets 
were either left unactivated or were activated with collagen (38|xg/ml), convulxin 
(50ng/ml) or thrombin (O.lU/ml) and aggregations were followed for 10 minutes at 
37°C with stirring at 1100 rpm.
2.2.7 Measurement of the Generation of Extracellular ROS from 
Platelets
Stock solutions o f  the luminol derivative L-012 were freshly prepared daily in 
deionised water to a final concentration o f  20mM. Gel-filtered platelets were
•aprepared as described in section 2.2.2. 85^ x1 o f  platelets (250 x 10 /jal) were added to 
each well in a white 96-well plate (Nunc, Thermo Fisher, Ireland). L-012 at 500|J.M 
final concentration (as per m anufacturers’ instructions for ROS detection) was added 
in a final volume o f  100jil/well. Platelets remained unactivated or were activated 
with the following agonists: collagen (38ng/ml), convulxin (50ng/ml), thrombin 
(O.lU/ml and lU /m l) and PM A (l|xM  and 10|iM). Chemiluminescence was read 
immediately upon the addition o f the agonists using a W allac 1420 Multi-label 
Counter (Perkin Elmer, MA, USA). Luminescence was read every 30 seconds for 12 
minutes at 37°C. Data were expressed as plots o f L-012 chemiluminescence over 
time, and as area under the curve (AU<^) to facilitate statistical analysis.
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The xanthine/xanthine oxidase system is used to generate superoxide radicals (Hille 
& M assey 1981). This experiment was carried out to verify the superoxide 
scavenging ability o f the enzyme superoxide dismutase (SOD). Using a slight 
modification o f  the method o f Krotz (Krotz et al. 2002), xanthine (3mM) was added 
to platelet buffer in the presence o f the chemiluminescent probe L-012 (500jiM) in a 
white 96-well micro-plate. Xanthine oxidase (2mU/ml) was then added and 
chemiluminescence was recorded immediately using a W allac 1420 Multi-label 
Counter (Perkin Elmer, MA, USA). In some assays, the superoxide scavenging 
enzyme superoxide dismutase (SOD, 300U/ml) was included. All assays were 
carried out in triplicate.
2.2.1.2 Hydrogen Peroxide/Catalase Reaction
In order to demonstrate the hydrogen peroxide scavenging ability o f  catalase, platelet 
buffer, hydrogen peroxide (H2O2) at required concentrations (0|iM , 1.25^M, 
12.5|J,M, 125jiM, 250|^M, 500jj,M, and Im M ) and luminol (50^iM) to a final volume 
o f 1 OOjo.1 were added to a white 96-well micro-plate. All assays were carried out in 
triplicate. Plates were kept in darkness throughout. Horseradish peroxidase (HRP) 
(lOU/ml) was added to each well and chemiluminescence was measured 
immediately using a W allac 1420 M ulti-label Counter (Perkin Elmer, MA, USA) at 
37°C. In some assays the H20 2  scavenging enzyme catalase (CAT, lOOOU/ml) was 
added to those wells containing the highest concentration o f hydrogen peroxide 
(Im M ).
22.1.X Superoxide Radical Generation Assay
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2.2.8 The Measurement of the Generation of Intraplatelet ROS by 
Flow Cytometry
Flow cytometry allows the analysis o f  surface expressed molecules on cells and 
platelets. Platelet suspensions are drawn upwards in a stream o f buffer and pass 
singly through the path o f a laser beam. Cell size, cell number and changes in cell 
internal structure m ay be determined based on the scattering characteristics o f the 
beam and on the intensity o f  cell bound fluorescently labelled compounds.
Gel-filtered platelets were prepared as described in section 2.2.2. A stock solution o f 
1.7mM DCFDA was m ade in absolute dimethylsulfoxide (DMSO). The platelet 
count was adjusted to 250 x 103/|il and platelets were incubated with DCFDA 
(8.5|xM) for 10 minutes at 37°C with DCFDA. This final concentration o f  DCFDA is 
an equivalent concentration to that used in a similar assay by Bakdash (Bakdash & 
W illiams 2008). The final DMSO concentration in assays was 0.5%. Vehicle control 
experiments showed no adverse effects o f this concentration o f  DMSO on platelet 
function (Figures 2.3). Incubation was carried out in darkness. Platelets remained 
unactivated or were activated with either collagen (38^g/ml), convulxin (50ng/ml) or 
thrombin (O.lU/ml and lU /m l) for 10 minutes at 37°C in a final volume o f  100fj.l. 
After 10 minutes the reactions were stopped by the addition o f 2ml o f platelet buffer. 
Samples were kept covered in darkness until analysed using a FACSCalibur flow 
cytometer. Data were expressed as mean fluorescence intensity, using CellQuest Pro 
software.
To examine the effects o f  external redox potentials on intraplatelet ROS generation, 
gel-filtered platelets were firstly incubated with the following GSH/GSSG or 
Cys/CySS redox potentials: GSH/GSSG Eh = -264mV, -130mV, -lOmV and 
Cys/CySS Eh = -148mV, -82mV, +4mV for 3 minutes at 37°C. Platelets were
activated in the presence o f  DCFDA (8.5|xM) with collagen (3 8 }ig/ml), convulxin 
(50ng/ml), throm bin (O.lU/ml) or were left unactivated, for 10 minutes at 37°C. 
Samples were kept covered in darkness until analysed using a FACSCalibur flow 
cytometer. D ata were expressed as m ean fluorescence intensity, using CellQuest Pro 
software.
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Figure 2.3 The effects of DMSO as a vehicle on platelet function. (A) Gel-filtered platelets were 
either left unactivated (A, B, C, D) or were activated with O.lU/ml thrombin (E, F, G, H) following 5 
minutes incubation at 37°C with dimethylsulfoxide (DMSO) at the following concentrations: 0%, 
0.5%, 1% or 10%. Platelet aggregations were followed for at least 10 minutes. This experiment is 
representative of n = 3 independent experiments. A: unactivated + 0% DMSO; B: unactivated + 0.5% 
DMSO; C: unactivated + 1% DMSO; D: unactivated + 10% DMSO; E: O.lU/ml thrombin + 0% 
DMSO; F: O.lU/ml thrombin + 0.5% DMSO; G: O.lU/ml thrombin + 1% DMSO; H: O.lU/ml + 10% 
DMSO. (B) Gel-filtered platelets were incubated with varying concentrations of DMSO (0, 0.5, 1.0 
and 10% v/v) for 5 minutes at 37°C prior to activation with O.lU/ml thrombin in a platelet aggregation 
study. There was no effect of platelet aggregation response in the presence of DMSO at the 
concentration (0.5% v / j v  used in these studies. Data are means ± SE of n = 3 separate experiments, 
*** p < 0.001, ** p < 0.01, n.s = not significant.
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2.2.9 The Measurement of the Binding of PAC-1 to the Integrin 
aiibP3 using Flow Cytometry
The PAC-1 antibody is conjugated with fluorescein isothiocyanate (FITC), and is 
specific only for the active conformation o f the anbp3 integrin on platelets (Shattil et 
al. 1987). Gel-filtered platelets were prepared as described in section 2.2.2. Platelets 
(250 x 103/(il) were activated with either collagen (38p,g/ml), convulxin (50ng/ml), 
thrombin (O.lU/ml), or left unactivated in the presence o f the mouse monoclonal 
antibody PAC-1 FITC (2.5|ig/ml) in a final volume o f lOOfil for 10 minutes at 37°C. 
The reaction was stopped after 10 minutes by the addition o f 2ml o f platelet buffer. 
Samples were read immediately by fluorescence activated cell sorter (FACS) 
analysis, on a FACSCalibur flow cytometer. In subsequent experiments, gel-filtered 
platelets (250 x 103/(xl) were pre-incubated for 5 minutes at 37°C with the following 
GSH/GSSG and Cys/CySS redox potentials: GSH/GSSG Eh = -264mV, -130mV, - 
lOmV and Cys/CySS Eh = -148mV, -82mV, +4mV. Platelets were then activated 
using the same agonists as before. The reaction was stopped after 10 minutes by the 
addition o f 2ml o f platelet buffer. Samples were read immediately by fluorescence 
activated cell sorter (FACS) analysis, on a FACSCalibur flow cytometer. The 
platelet populations were gated and data analysed using CellQuest Pro software. 
Data are represented as percentage o f gated population.
2.2.10 The Measurement of the Binding of the Monoclonal 
Antibodies P1E6 and 12F1 to the Integrin a2Pi using Flow 
Cytometry.
This assay was based on the method o f Cruz (Cruz et al. 2005). Gel-filtered platelets 
were prepared as outlined in section 2 .2.2 and treated with either platelet buffer or
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with Cys/CySS redox potentials (Eh = -148mV, -82mV and +4mV) in a final volume 
o f 150p,l for 5 minutes at room temperature. 10(0,1 aliquots o f each platelet sample 
was then incubated with 5(ig/ml o f the a 2Pi specific monoclonal antibodies P1E6, 
12F1 or their isotypic controls IgGi and IgG2, in a final volume o f 100(4,1 and 
incubated for 10 minutes in darkness at room temperature. After incubation, 1ml of 
platelet buffer was added to each sample, which were then analysed immediately on 
a FACS-Calibur flow cytometer (Becton Dickinson, USA). Data were expressed as 
percentage o f gated IgG control labelled population for each antibody.
2.2.11 The Binding of Collagen-FITC to Gel-filtered Platelets
Gel-filtered platelets were prepared as outlined in section 2.2.2. Platelets (250 x 
103/|xl) were treated with platelet buffer or with the reducing GSH/GSSG Eh = - 
264mV or Cys/CySS Eh = -148mV redox potentials or with EDTA (3mM) for 5 
minutes at room temperature. Type I collagen-FITC (100|j.g/ml) was then added for 
30 minutes at room temperature in darkness (Wang et al. 2003). Collagen-FITC 
(10|ig/ml) was added to some untreated platelets to illustrate concentration- 
dependent collagen binding to the platelets. To identify the platelet population and to 
gate on this population, the anti-am,P3 antibody CD41-FITC (1: 5 dilution) was 
added to some untreated platelets for 20 minutes at room temperature. Reactions 
were stopped by addition o f 1ml o f platelet buffer. Samples were read immediately 
on a FACS-Calibur flow cytometer (Becton Dickinson, USA). As stated the platelet 
population was identified using CD41 binding. All platelets within this labelled 
region were then analysed for collagen-FITC binding. The level o f collagen-FITC 
(100^g/ml) binding to the platelets in the presence or absence o f redox or EDTA was 
expressed as the geometric mean fluorescence o f the collagen-FITC labelled platelet 
population.
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Clear 96-well plates (Immulon 2HB, Dynex Technologies, Sussex, UK) were coated 
with 1 OOjj.1 o f type I collagen, collagen related peptide (CRP), or the triple helical 
collagen peptides GFOGER and GPPio (all at lO^g/ml in 0 .01M acetic acid) at room 
temperature for 1 hour. After incubation, excess solution was shaken off and 200(il 
o f blocking buffer (Tris-base 50mM, NaCl 140mM, 5% (w/v) BSA, pH 7.4) was 
added to each well for 1 hour at room temperature. After blocking for 1 hour the 
plates were washed three times with 200jj1 per well o f platelet adhesion buffer (Tris- 
base 50mM, NaCl 140mM, 0.1% (w/v) BSA, pH 7.4) that had been supplemented 
with either 2mM MgCl2 or 2mM EDTA. For some assays, washed platelets were 
used and were prepared as outlined in Section 2.2.3 above. For assays requiring gel- 
filtered platelets, the following modifications to the method used by Onley (Onley et 
al. 2000) were added. Platelet rich plasma (PRP) was prepared by centrifuging 30 - 
60ml o f whole blood in 15% (v/v) ACD for 15 minutes at 160 x g. Prostaglandin Ei 
(PGEi) was added to the decanted PRP at a final concentration o f 700nM, and the 
PRP was spun at 800 x g  for 15 minutes. The supernatant was removed and the 
platelet pellet was re-suspended in calcium-free platelet buffer and gel-filtered 
platelets were prepared as in Section 2.2.2. PGEi (300nM) final concentration was 
added to the gel-filtered platelets that were then centrifuged at 700 x g  for 6 minutes. 
The supernatant was discarded and the platelet pellet was re-suspended in platelet 
adhesion buffer. Platelet count was adjusted to 250 x 1 03/( l x 1 with platelet adhesion 
buffer. MgCl2 (2mM) or EDTA (2mM) final concentration were added to the 
platelets where required.
Platelets were allowed to rest for 30 minutes prior to use. Platelets were treated with 
GSH/GSSG: Eh = -264mV, -130mV, -lOmV or Cys/CySS: Eh = -148mV, -82mV,
2.2.12 Static Platelet Adhesion Assays
+4mV redox potentials for 5 minutes at room temperature. To show inhibition of 
(X2P ¡-dependent platelet adhesion to collagen, the function blocking anti-a,2 I domain 
antibody 6F1 (20|xg/ml) was added to platelets for 30 minutes at room temperature 
before addition o f platelets to substrate coated plates.
50(il o f platelets were added to each well and incubated for 1 hour at room 
temperature. Wells were then emptied and plates washed three times with 200|il per 
well o f platelet adhesion buffer. Adherent platelets were then solubilised by the 
addition o f 150|xl o f lysis buffer (sodium citrate 70mM, citric acid 30mM, 0.1% 
(v/v) Triton X-100) containing 5mM p-nitrophenyl phosphate (pnpp), to each well 
for 1 hour at room temperature. The reaction was stopped by the addition o f lOOpl of 
2M NaOH to each well. Adhesion was measured colorimetrically as the absorbance 
o f the p-nitrophenol product at 405nm in a Wallac multi-plate reader (Perkin-Elmer, 
MA, USA).
2.2.13 The Xcelligence Cell Adhesion Assay
Xcelligence 96-well micro titre plates (E-plate 96 Roche, Germany) were coated 
with 1 OOjj.1 o f collagen related peptide (CRP) or the triple helical collagen peptide 
GFOGER (10|ig/ml in 0.01M acetic acid) at room temperature for 1 hour. After 
incubation, excess solution was shaken off and 200|al o f  blocking buffer (50mM 
Tris, 140mM NaCl, 5% (w/v) BSA (fatty-acid free) pH 7.4) was added to each well 
for 1 hour at room temperature. After blocking, the E-plates were washed three times 
with 200|al per well o f  platelet adhesion buffer (50mM Tris-base, 140mM NaCl, 
0.1% (w/v) BSA, pH 7.4) that had been supplemented with MgCl2 (2mM). Washed 
platelets were prepared as outlined in Section 2.2.3. Platelets were treated with 
GSH/GSSG redox potentials: Eh = -264mV, -130mV, -lOmV as required or were left
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untreated for 5 minutes at room temperature. Prior to addition o f platelets, 50(il of 
adhesion buffer was added to each well and a baseline impedance reading was 
established for each well by placing the E-plate in the Xcelligence plate reader 
(Figure 2.4) and scanning the plate once at 37°C. Following measurement of the 
baseline impedance, 50(j,l o f treated platelets were added to each well and the E- 
plates were placed back into the Xcelligence plate reader where the change in 
impedance o f the electrodes covering the bottom of each well was measured 
electronically every minute for up to 3 hours. Platelet adhesion and spreading was 
recorded as the dimensionless quantity called cell index (Cl). Data are expressed 
graphically as the change in cell index over time.
Miaoeteclrode array 
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Figure 2.4 The Xcelligence system. The diagram shows the microelectrode array at the bottom of 
each well on the E-plate. The system measures the electrical impedance (Z) of the gold electrodes, 
which increases as cells adhere to and spread on the electrodes. This change in impedance may be 
plotted graphically as cell index (Cl) against time. From: http://www.roche-applied-
science.com/sis/xcelligence/index.
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2.2.14 Sodium Dodecyl Sulphate Poly-Acrylamide Gel 
Electrophoresis (SDS-PAGE)
SDS-PAGE is used to determine the molecular weight o f polypeptides based on their 
binding to SDS and subsequent separation within a poly-acrylamide gel, proteins 
having greater molecular weights migrate to a lesser extent under the influence o f the 
applied electric field, whereas proteins with smaller molecular weights migrate 
further through the gel (Laemmli 1970). Pierce Precise™ or mini-PROTEAN 
TGX™ (Bio-Rad) 12 or 15 lane pre-cast polyacrylamide mini gels were used in all 
assays unless otherwise stated and were run using a Mini-Protean III Gel 
Electrophoresis System (Bio-Rad).
2.2.14.1 Preparation of Platelet Lysates
Gel-filtered platelets were prepared as in section 2.2.2. Platelet aggregations were 
carried out as described in section 2.2.6, in the presence and absence o f GSH/SSSG 
and Cys/CySS redox potentials: GSH/GSSG Eh = -264mV, -130mV, -lOmV and 
Cys/CySS Eh = -148mV, -82mV, +4mV respectively, in unactivated platelets and in 
platelets activated with 38|ig/ml collagen, O.lU/ml thrombin or 50ng/ml convulxin. 
Platelets were allowed to aggregate for 10 minutes at 37°C before the addition of 
25 (il o f 10X radioimmunoprecipitation assay buffer (RIPA) platelet lysis buffer 
(0.5M NaCl, lOmM sodium orthovanadate (Na3V04), 200mM tetra sodium 
pyrophosphate (Na4P207.10H20 ), 500mM sodium fluoride (NaF), 10% (v/v) Triton 
X-100, and lOOmM Tris pH 7.4) containing 10X Pierce Halt protease inhibitor 
cocktail (100X protease inhibitor cocktail: lOOmM AEBSF.HC1, 80(jM Aprotinin, 
5mM Bestatin, 1.5mM E-^4, Im M  EDTA, 2mM Leupeptin, ImM  Pepstatin A all in 
95% DMSO). Platelets were vortexed and lysed platelets were allowed to stand on
ice for 1 hour with further occasional vortexing. Lysates were then frozen and stored 
in eppendorf tubes at -20°C.
2.2.14.2 Determination of Platelet Protein Concentration Using the 
Bradford Assay
The protein concentration o f platelet lysates was determined using the Bio-Rad DC 
Bradford Assay kit. The assay allows the determination o f the protein concentration 
within a platelet lysate sample based on a bovine serum albumin (BSA) standard 
curve. To generate the standard curve, 15mg o f BSA was dissolved in 1ml o f IX 
RIP A platelet lysis buffer. The 15mg/ml BSA solution was then serially diluted in 
RIPA buffer to the following concentrations: 0, 0.2, 0.4, 0.6, 0.8, 1.0, 1.5 mg/ml. 
Solution A' was prepared by adding -20^1 o f solution S to 1ml o f solution A. 5jj.1 of 
each BSA standard (0 -  1.5mg/ml) or platelet lysate sample were added to wells o f a 
clear 96 well plate in triplicate. 20jil o f  solution A' and 200(il o f solution B were 
added to each well. The plate was left for 15 minutes at room temperature and the 
absorbance was read at 690nm on a Wallac Multi-label counter. The concentration 
curve was constructed by plotting absorbance against protein concentration (Figure 
2.5) and the protein concentration o f the platelet lysate sample was calculated based 
on this standard curve. The volume o f platelets required per sample was then 
calculated to give 5 fig platelet protein per sample loaded.
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Figure 2.5 BSA concentration curve generated using the Bradford assay. BSA solutions (0 - 1.5 
mg/ml) in RIPA buffer were prepared and to each were added 20(0.1 solution A' (BioRad) and 200^1 
solution B (BioRad) in a 96-well plate assay. Absorbance was read at 690nm after 15 minutes. Data 
are means ± SE with each measurement carried out in triplicate, (r2 = 0.9807).
2.2.15 Sample Preparation and SDS-PAGE
The protein concentration o f each platelet lysate sample was determined using the
Bradford Assay as described in Section 2.2.14.2. Following determination of the
protein concentration o f the platelet lysates, the required volume o f lysate containing
this protein concentration was added to an equal volume o f 2X sample buffer
(125mM Tris pH 6 .8, 4% (w/v) SDS, 20% (v/v) glycerol, 0.2% (w/v) bromophenol
blue) with 50mM dithiotreitol (DTT) added for reduced samples. The protein
samples were then denatured by heating for 5 minutes at 95°C. The pre-poured
polyacrylamide gel was placed into the electrophoresis rig and immersed in 1L of
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running buffer (25mM Tris, 192mM glycine, 0.1% (w/v) SDS) if  using the Bio-Rad 
mini-gels or BupH™ Tris-HEPES-SDS running buffer (lOOmM Tris, lOOmM 
HEPES, 3mM SDS) if  using the Pierce Precise™ mini-gels. The required volume of 
protein sample corresponding to approximately 5p,g protein was loaded into each 
lane using gel-loading tips. A lane containing 12|xl o f pre-stained molecular weight 
markers (Page Ruler Plus™, Thermo Scientific) was included in all gels. A constant 
voltage o f 100V was applied across the gel until the proteins had separated to within 
0 .2cm of the bottom o f the gel.
2.2.16 Western Blotting
2.2.16.1 Blotting (Protein Transfer)
Proteins separated within a gel matrix by SDS-PAGE can be transferred to the 
surface o f an immobilising membrane such as polyvinyldifluoride (PVDF). A wet 
system is used in which the gel and membrane are clamped into a cassette between 
filter paper and sponges and immersed in buffer. The gel was removed from the 
plastic frame and placed onto three layers o f blotting paper on top o f the cassette 
sponge, all soaked in transfer buffer. A piece o f PVDF membrane cut to size was 
first soaked in methanol for 30 seconds to activate the membrane and then 
equilibrated in transfer buffer prior to placement onto the surface o f the gel. Three 
layers o f filter paper and a cassette sponge, all soaked in transfer buffer (25mM Tris, 
192mM glycine, 0.2% (w/v) SDS, 20% (v/v) Methanol) were placed on top o f the 
PVDF. All were clamped into the cassette and placed into the transfer rig (Bio-Rad). 
The cassette was immersed in transfer buffer with an ice pack to prevent overheating 
during the transfer, and the proteins v^ere transferred from the gel onto to the PVDF 
membrane for 1 hour at a constant voltage o f 100V.
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Following transfer, the membranes were checked for the presence o f coloured 
molecular weight markers to confirm protein transfer. The membranes were blocked 
with a blocking buffer (25ml/membrane) containing 5% (w/v) BSA in TBS-Igepal 
(170mM NaCl, 20mM Tris, 0.2% (v/v) Igepal CA-630, pH 7.4), with gentle rocking 
for 1 hour at room temperature. For experiments using anti-GSH as the primary 
antibody, the blocking buffer was supplemented with 5mM N-ethyl maleimide 
(NEM) to block any free thiols present. Membranes were then washed 4 times for 5 
minutes each in TBS-Igepal buffer on a rocking platform. The primary antibody was 
adjusted to the required dilution (anti-phosphotyrosine 4G10: 1: 1,000 and anti-GSH: 
1: 500) in TBS-Igepal containing 3% (w/v) BSA. Membranes were incubated with 
primary antibodies with gentle rocking at 4°C overnight or for 2 hours at room 
temperature. Following incubation, membranes were washed 4 times for 5 minutes 
with TBS-Igepal buffer. Secondary antibodies (goat anti-mouse IgG) conjugated 
with horseradish peroxidase (HRP) were diluted appropriately (1: 50,000) in TBS- 
Igepal containing 3% (w/v) BSA. Membranes were incubated with the secondary 
antibody for 1 hour at room temperature with gentle rocking. After incubation, 
membranes were washed 3 times for 10 minutes each with TBS-Igepal. The 
membranes were then treated with 4mls each o f enhanced Supersignal® W est Pico 
chemiluminescent substrate for 5 minutes, and developed using Kodak film or were 
visualised using the UVP imaging system. This provides a fast and sensitive system 
for the detection o f proteins by Western blot. The UVP system uses a high resolution 
camera and optics to achieve the high sensitivity detection.
2.2.16.2 Probing With Antibodies
64
2.2.17 The Platelet Dense Granule Secretion Assay
Gel-filtered platelets were prepared as described in section 2.2.2. Platelets were 
incubated at 37°C for 3 minutes with the following redox potentials: GSH/GSSG Eh 
= -264mV, -130mV, -lOmV and Cys/CySS Eh = -148mV, -82mV, +4mV or with 
platelet buffer. Meanwhile, the following agonist concentrations were added to wells 
in a white 96-well plate: collagen (38|ig/ml), thrombin (O.lU/ml) and convulxin 
(50ng/ml). 70|xl o f untreated or redox treated platelets (250 x 10 /¡il) were then 
added to each well. The plates were then incubated, with fast shaking for 3 minutes 
at 37°C in a Wallac multi-plate reader (Perkin Elmer, USA). Following incubation, 
Chrono-lume® (luciferin/luciferase) reagent (0.2jj,M) was added to each well. The 
plate was shaken for a further 10 seconds to ensure mixing o f reagents. 
Luminescence was then measured in the plate reader. ADP release is expressed as 
arbitrary luminescence units.
2.2.18 Preparation of Platelet Slides for Confocal Fluorescent 
Microscopy
Glass poly-L-lysine microscopy slides were cleaned with 100% ethanol and allowed 
to air dry. Each slide was divided into equal sized chambers with a liquid blocker 
Pap pen. Slides were coated with 200j_il o f  substrates: type I soluble collagen 
(10|xg/ml), GFOGER peptide (lOjag/ml) and cross-linked CRP (CRP-XL) (5ng/ml) 
for 1 hour at room temperature. Slides were washed twice with 200(il TBS (170mM 
NaCl, 20mM Tris, pH 7.4). Slides were then blocked with 200|xl o f 2% BSA in TBS 
for 1 hour at room temperature. After blocking, slides were washed twice with 200jal 
TBS and once in platelet buffer supplemented with 2mM MgC^. Washed platelets 
were prepared as outlined in Section 2.2.3, and the platelet count was adjusted to 30 
x 103/(il with platelet buffer and M gCh (2mM) was added to the platelets. Platelet
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were incubated with platelet buffer, or with GSH/GSSG Eh = -264mV, -130mV, - 
lOmV or with Cys/CySS Eh = -148mV, -82mV, +4mV for 5 minutes at room 
temperature. In some assays platelets were treated with the integrin a 2Pi specific 
anti-a,2 subunit antibody 6F1 (20|ig/ml) for 20 minutes at room temperature. 
Following incubations 200(xl o f  each platelet sample was applied to the slides and 
allowed to adhere for 1 hour at room temperature. Unbound platelets were removed 
by washing twice with 200|il o f platelet buffer. Platelets were then fixed for 10 
minutes at room temperature with 1% formaldehyde. After fixing, slides were 
washed twice with 200|xl platelet buffer and permeabilised with 1 OOjal o f 0.1% 
Triton X-100 in platelet buffer for 10 minutes at room temperature. Slides were 
again washed twice with 200(il platelet buffer. After washing, 100(il o f FITC- 
labelled phalloidin (diluted 1:100 in platelet buffer) was added to the slides for 20 
minutes at room temperature in the dark. Slides were washed three times with 200jxl 
platelet buffer, and excess buffer was carefully blotted with tissue. Cover slips were 
cleaned in ethanol and allowed to air dry before the addition o f 1 drop o f Dako 
mounting medium per chamber to the cover slips. Once cover slips were in place, 
slides were incubated in darkness for 1 hour at room temperature to dry. Slides were 
viewed using a Zeiss Axiovert 200M microscope. Images were produced with Zeiss 
LSM Imaging software and image analysis was performed using Image J (version 
1.4) software.
2.2.19 Statistical Analysis
For statistical analysis, all experiments were performed independently at least 4 
times. Significance levels were calculated using one-way ANOVA with the 
Bonferroni post-hoc test. Data are expressed as mean ± standard error o f the mean
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(SE). P-values were calculated using the GraphPad Prism 5 program and p-values of 
p < 0.05 were taken as statistically significant.
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The Effects of Varying External Redox 
Potentials on Platelet Function
Chapter 3
Platelets play a key role in maintenance o f normal haemostasis as part o f  a very 
precisely controlled microenvironment within the circulatory system. This control 
may be unbalanced by vascular injury and/or endothelial dysfunction, leading to 
platelet activation and thrombus formation. In the case o f vascular injury this is the 
normal course o f events leading to haemostasis and vessel repair. In the case o f 
oxidative-stress induced endothelial dysfunction, coupled with platelet activation, 
inappropriate thrombus formation may occur resulting in stroke or myocardial 
infarction (Higashi et al. 2009).
Oxidative stress is defined as an imbalance in the redox homeostasis between the 
body’s endogenous anti-oxidants and the pro-oxidant reactive oxygen or reactive 
nitrogen species (ROS/RNS). Collectively these species are referred to as reactive 
oxygen/nitrogen species (RONS) (Dalle-Donne et al. 2005). Such an imbalance may 
arise from depletion o f anti-oxidants or over-production o f RONS. ROS are freely 
generated by the turnover o f  molecular oxygen during aerobic respiration within the 
cell, resulting in the production o f superoxide, hydrogen peroxide and hydroxyl 
radicals (Gille & Sigler 1995). RNS are produced by the reaction o f endothelial 
derived nitric oxide (NO) with reactive oxygen species such as superoxide to form 
peroxynitrite (Beckman et al. 1990) and with molecular oxygen, transition metals 
and thiols yielding various RNS species such as N2O3, nitrosyl-metal complexes and 
S-nitrosothiols (Jourd'heuil et al. 1998, Wink & Mitchell 1998). RONS cause a wide 
variety o f  detrimental effects on cells and cellular components including extensive 
oxidative damage to membrane lipids (Goss et al. 1999, Gutteridge 1995), DNA 
(Beckman & Ames 1997, Burney et al. 1999) and proteins (Berlett & Stadtman 
1997, Tien et al. 1999). Such oxidative stress has been implicated in the progression
3.1 Introduction
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of many disease states including atherosclerosis (Harrison et al. 2003), diabetes 
mellitus (Pan et al. 2009) and cancer (Giles 2006) as well as being recorded in the 
aging population and among smokers (Go & Jones 2005). Within the cardiovascular 
system it has a role in increasing platelet activation (Olas & Wachowicz 2007), 
endothelial dysfunction (Mano et al. 1996) and hypertension (Griendling & 
FitzGerald 2003).
The redox control o f  platelet function has been established as a major research area 
over the last few years, with a growing acceptance o f the role o f variations in the 
redox state o f the local platelet environment playing a key role in platelet activation. 
Platelet function has been demonstrated to be sensitive to the presence o f other 
physiological redox reagents. The binding o f PAC-1 to Mn and thrombin activated 
platelets was reversed in the presence o f glutathione (GSH) and NO (Walsh et al.
2004), and platelet aggregation induced by a variety o f agonists was inhibited by 
millimolar concentrations o f GSH (Pacchiarini et al. 1996). Platelet function has 
long been known to be affected by a variety o f non-physiological exogenous redox 
species. These include dithiothreitol (DTT) induced platelet aggregation in the 
presence o f fibrinogen (MacIntyre 1974, Zucker & Masiello 1984) and the inhibition 
o f agonist-induced platelet aggregation by 5, 5 ’-dithionbis(2-nitrobenzoic acid) 
(DTNB) (2mM) and by p-chloro-mercuriphenylsulfonate (pCMPS) (125|xM - 
300jiM) (Lahav et al. 2002). It is interesting to note that almost all o f these redox 
species are believed to exert their effects on platelet function by direct interaction 
with platelet surface thiol (-SH) groups. DTT has been shown to reduce disulphide 
bonds in the cysteine-rich domain o f purified integrin aiibP3 leading to 
conformational changes in the receptor and resultant fibrinogen binding to the 
integrin (Yan & Smith 2001). The thiol blocking membrane impermeant agent
(pCMPS) (125(iM) inhibited platelet adhesion to both collagen and fibrinogen 
(Lahav et al. 2000). Increasing concentrations o f the membrane impermeable 
sulphydryl reagents p-chloro mercuribenzenesulfonate (pCMBS) and 3-(N- 
maleimidylpropionyl) biocytin (MPB) both inhibited ADP and collagen-induced 
platelet aggregation (Essex et al. 2001). Additionally, there is evidence o f a role for 
protein disulphide isomerase (PDI) in the regulation o f platelet function. Platelet PDI 
was found to mediate platelet aggregation, secretion and fibrinogen binding to 
integrin ain,P3 as well as having a role in platelet adhesion to fibrinogen and collagen 
by aiibP3 and a 2Pi respectively (Essex & Li 1999, Lahav et al. 2000, Lahav et al. 
2003).
Our laboratory has demonstrated an endogenous thiol isomerase activity: the ability 
to catalyse disulphide bond rearrangements, within the platelet integrins including 
ain,P3 and a vp3 (O'Neill et al. 2000). An S-nitrosylation-induced "shuffling" o f 
thiol/disulphide exchange that regulates the reversal o f the activated state o f the 
integrin anbP3 has also been demonstrated (Walsh et al. 2007). Thiol labelling 
studies with MPB in agonist-stimulated aggregating platelets showed increases in 
sulphydryl labelling in 11 platelet proteins (Burgess et al. 2000), further evidence of 
thiol/disulphide rearrangement playing an important role in platelet activation.
In light o f these observations, we are now turning our attention to examining the
effects o f changes in the redox state o f  the external platelet microenvironment on
platelet function, as brought about by alterations in the levels o f the endogenous
physiological redox buffers glutathione (GSH) and cysteine (Cys). All cells produce
a variety o f antioxidant molecules, chief among which are the low molecular weight
thiols GSH and Cys. Both o f these thiols exist in reduced (GSH, Cys) and oxidised
forms (GSSG, CySS). Each reduced/oxidised (redox) pair forms a discreet redox
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couple (GSH/GSSG and Cys/CySS), with the GSH/GSSG redox couple 
predominating within the cell, and Cys/CySS predominating in plasma (Go & Jones
2005). The plasma levels o f each redox couple are approximately 25(iM for 
GSH/GSSG and 200^M for Cys/CySS (Essex & Li 2003, Go & Jones 2005). The 
relative amounts o f reduced to oxidised thiol describe the redox state or redox 
potential (Eh) of the redox couple. This is calculated numerically using the Nemst 
equation (Schafer & Buettner 2001) as described in section 2.2.5. The redox state of 
each o f these redox couples has been shown to regulate a range o f biological 
processes such as enzyme catalysis (Claiborne et al. 1999), cell proliferation (Aw 
2003), apoptosis (Circu & Aw 2008), gene expression (Arrigo 1999) and 
atherosclerosis (Huang et al. 2009).
Changes in the cellular redox status due to variations in GSH/GSSG or Cys/CySS 
redox potentials or increased RONS generation, are believed to induce reversible 
formation o f mixed disulphides between protein thiol groups and 
glutathione/cysteine (S’-glutathionylation/S'-cysteinylation) on a range o f cellular 
proteins (Dalle-Donne et al. 2007). S-glutathionylation and S-cysteinylation may be 
viewed as modes o f redox regulation o f  protein function, serving both to maintain 
normal protein activity and also to protect critical protein cysteine thiols from 
oxidative damage. While the role o f  RONS and platelets has been the topic of much 
investigation over the past few years, there is relatively little known about the 
regulation o f platelet function in a varying external redox environment. We 
hypothesise that variation in the external redox environment o f the platelet results in 
modifications o f thiol/disulphide groups on platelet surface proteins that may impact 
on platelet function.
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The aim o f this chapter was to examine the effects o f varying redox potentials on 
platelet function using both the GSH/GSSG and Cys/CySS redox couples. It was 
hypothesised that platelet function could be modified by alterations o f the platelet 
external redox environment resulting from addition o f known amounts of reduced 
and oxidised glutathione or cysteine. The objective was to replicate a pro-oxidising 
or pro-reducing redox environment relative to established mean plasma redox values 
using these important physiological redox buffers. A gel-filtered platelet system was 
used to enable the redox potentials o f  the platelet environment to be precisely 
modified, and all redox potentials were calculated using the Nemst equation to 
correspond to established mean plasma values ± 6 standard deviations, thus 
representing a wide range o f redox potentials from reducing through to oxidising 
values, the effects o f which were examined on platelet activation using established 
platelet function assays.
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3.2 Results
3.2.1 The Effects of GSH/GSSG and Cys/CySS Redox Potentials on 
Platelet Aggregation
This study set out to examine the effects o f varying combinations o f reduced and 
oxidised glutathione (GSH/GSSG) and cysteine (Cys/CySS) on platelet aggregation 
using light transmission aggregometry. These redox buffers, like all redox couples, 
exist physiologically in a dynamic equilibrium between the reduced and oxidised 
forms, with each couple acting independently o f the other (Jones et al. 2004, Schafer 
& Buettner 2001). Gel-filtered platelets were used in these studies to remove any 
autologous redox species. The effects o f varying redox potentials on platelet 
aggregation responses to three platelet agonists: soluble type I collagen acting 
preferentially on the platelet collagen receptor integrin (X2P1, thrombin, the potent 
physiological platelet activator, acting on the G-protein coupled receptors PAR-1 
and PAR-4 and convulxin, a snake venom toxin, targeting the glycoprotein VI 
(GPVI) collagen receptor were examined, as well as their effects on unactivated 
platelets.
3.2.1.1 The Effect of a Varying GSH/GSSG or Cys/CySS Redox 
Potential on Aggregation Response in Unactivated Platelets
None o f the GSH/GSSG redox potentials used (Eh = -264mV, -130mV or -10mV) 
had any effect on the aggregation response o f unactivated platelets (Figure 3.1 A and 
C). Platelets were also treated with varying Cys/CySS redox potentials (Eh = - 
148mV, -82mV or +4mV). No effect on aggregation response was seen with any of 
the Cys/CySS redox potentials used (Figure 3 .IB and C).
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3.2.1.2 Reducing Redox Potentials Inhibit Collagen-Induced Platelet 
Aggregation
Treatment o f platelets with the most reducing GSH/GSSG redox potential (Eh = - 
264mV) resulted in almost complete abolition o f aggregation response to collagen 
only, compared to agonist induced aggregation in the absence o f redox (n = 6, P <  
0.001) (Figure 3.2A and C). As the redox environment approached the mean plasma 
redox potential o f Eh = -130mV a small but statistically insignificant decrease in 
platelet aggregation to collagen was noted. No apparent effect was observed in a 
redox environment o f Eh = -10mV (Figure 3.2A). Neither convulxin nor thrombin 
induced platelet aggregations were affected by any o f the GSH/GSSG redox 
potentials used (Figure 3.2A and Figure 3.2D and E). Similarly, when gel-filtered 
platelets were pre-incubated with Cys/CySS redox potentials, the most reducing 
redox potential (Eh = -148mV) again resulted in ablation o f the aggregation response 
to collagen only, compared to aggregation response in the absence o f redox (n = 6 , p 
< 0.001) (Figure 3.2B and C). Interestingly, there was also significant reduction of 
aggregation response to collagen at the mean plasma redox potential (Eh = -82mV), 
(n = 6, p < 0 .001) when compared to the aggregation response in absence o f redox. 
At the most oxidising redox potential (Eh = +4mV), aggregation response to collagen 
showed a slight decrease that was not statistically significant. None o f the Cys/CySS 
redox potentials had any effect on convulxin or thrombin-induced platelet 
aggregation (Figures 3.2B and 3.2D and E). It was noted that the shape o f the 
collagen aggregation response graphs in figures 3.2A and 3.2B for each redox couple 
is quite distinctive. There is a very small decrease in aggregation response following 
collagen activation as the GSH/GSSG redox potential changes from Eh = -10mV 
through Eh = -130mV. Beyond this value there is a very steep decline in platelet
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aggregation response, with almost full inhibition at Eh = -264mV. This is in contrast 
to the more linear shape o f the Cys/CySS graph, where there is a graded inhibitory 
response as the redox potentials become more reducing (Figure 3.2A and 3.2B).
3.2.2 FACS Analysis of PAC-1 Binding to Integrin anbP3, in Gel- 
filtered Platelets with Varying Redox Potentials
To examine the effects o f a varying external redox environment on the activation 
state o f the platelet integrin otnbP3, the fluorescein-isothiocyanate-(FITC)-conjugated 
antibody PAC-1 was used. PAC-1 is a monoclonal antibody selected for its ability to 
bind only to an activated but not resting conformation o f the platelet integrin 0 ,^ 3  
(Shattil et al. 1987). PAC-1 is a mimetic o f the integrins’ natural ligand fibrinogen, 
and binds to the RGD binding region at the apex o f the extended integrin in its active 
conformation.
To study the effects o f varying GSH/GSSG and Cys/CySS redox potentials on PAC- 
1 binding to both unactivated and activated platelets, gel-filtered platelets were 
treated with GSH/GSSG Eh = -264mV, -130mV or -lOmV or Cys/CySS Eh = - 
148mV, -82mV or +4mV or with platelet buffer (no redox) in the presence o f PAC-1 
antibody (2.5fj.g/ml) as described in section 2.2.9. None o f the GSH/GSSG or 
Cys/CySS redox potentials resulted in PAC-1 antibody binding to unactivated 
platelets (Figure 3.3). PAC-1 binding to activated platelets was confirmed following 
activation with lU/m l thrombin in the absence o f any redox, (n = 4, p < 0.001) when 
compared to PAC-1 binding to unactivated platelets (Figure 3.3G).
In redox treated activated platelets the most reducing redox potential o f  either redox 
couple (GSH/GSSG Eh = -264mV; Cys/CySS Eh = -148mV) resulted in a significant 
reduction in PAC-1 binding to collagen activated platelets, (n = 4, p < 0.001) when
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compared to PAC-1 binding in the absence o f redox (Figure 3.4A, D, G, H). There 
was also significant reduction in PAC-1 binding to collagen activated platelets at 
mean plasma redox potentials that was more pronounced with the Cys/CySS redox 
couple, (n = 4, p < 0.001) for Cys/CySS Eh = -82mV and (n = 4, p < 0.05) for 
GSH/GSSG Eh = -130mV compared to PAC-1 binding in the absence of redox 
(Figure 3.4G and H). At the most oxidising GSH/GSSG redox potential (Eh = - 
lOmV) there was an increase, although not statistically significant, in PAC-1 binding 
to collagen activated platelets (Figure 3.4G). At the most oxidising Cys/CySS redox 
potential Eh = +4mV there was a slight decrease in PAC-1 binding to collagen 
activated platelets although this did not reach statistical significance (Figure 3.4H).
In the absence o f redox, the level o f binding o f PAC-1 antibody to collagen and 
convulxin activated platelets was similar and there was significantly less PAC-1 
antibody binding to platelets activated with thrombin, (n = 4, p < 0.05) when 
compared to either collagen or convulxin activated platelets (Figure 3.4G and H).
PAC-1 binding to convulxin activated platelets was also decreased in the presence of 
Cys/CySS Eh = -148mV, (n = 4, p < 0.05) compared to PAC-1 binding in the 
absence o f redox. None o f the redox potentials used had any effect on PAC-1 
binding to thrombin activated platelets (Figure 3.4G and H).
As convulxin is a glycoprotein VI (GPVI) specific agonist, and my data showed a 
decrease in PAC-1 binding to convulxin activated platelets in the presence of 
Cys/CySS Eh = -148mV, I decided to perform this assay with another GPVI agonist 
namely collagen related peptide (CRP). This was a kind gift from Prof. Richard 
Famdale, Cambridge University. Platelets were treated with GSH/GSSG and 
Cys/CySS redox potentials in the presence o f PAC-1 (2.5(ig/ml) as above, and were
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either activated with CRP (ljig/m l) or remained unactivated. Although there was a 
slight decrease in PAC-1 binding as the GSH/GSSG redox potentials became more 
reducing, this was not statistically significant (Figure 3.5A). Similarly there was no 
significant effect o f Cys/CySS redox potentials on CRP induced PAC-1 binding 
(Figure 3.5B).
3.2.3 The Effects of Varying External Redox Potentials on Platelet 
Dense Granule Secretion
Platelet dense granules contain high concentrations o f the adenine nucleotides 
adenosine triphosphate (ATP) and adenosine diphosphate (ADP), serotonin and 
bivalent cations such as Ca2+ and Mg2+ (Rendu & Brohard-Bohn 2001). Agonist- 
induced dense granule secretion results in recruitment o f other nearby platelets to the 
growing thrombus, exerting pro-aggregating effects via secondary activation o f these 
platelets by the secreted contents including serotonin via the 5-HT2A receptor and 
adenine nucleotides, in particular ADP acting on the P2Yi and P2Y i2 receptors 
(Hollopeter et al. 2001, Leon et al. 1997).
Using a 96-well plate ADP detection assay as a metric o f  platelet dense granule 
secretion (Sun et al. 2001), and as described in section 2 .2 .17 ,1 examined the effects 
o f collagen, convulxin and thrombin-induced platelet dense granule secretion both in 
the presence and absence o f GSH/GSSG and Cys/CySS redox potentials.
Activation o f gel-filtered platelets with collagen (38|Ag/ml), convulxin (50ng/ml) or 
thrombin (O.lU/ml) all resulted in ADP secretion above that seen in unactivated 
platelets (Figure 3.6). Collagen induced activation resulted in the greatest level of 
ADP secretion, (n = 4, p < 0 .01) compared to unactivated platelets followed by
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convulxin, (n = 4, p < 0 .05), with the level o f ADP secretion following thrombin 
activation not reaching statistical significance.
None o f the GSH/GSSG or Cys/CySS redox potentials used had any effect on ADP 
secretion from unactivated platelets or those activated with convulxin (50ng/ml) or 
thrombin (O.lU/ml) (Figure 3.7A, C, D respectively). There was a significant 
decrease in ADP secretion from collagen activated platelets treated with either 
reducing GSH/GSSG Eh = -264mV (n = 4, p < 0.05) or reducing Cys/CySS Eh = - 
148mV (n = 4, p < 0.05) when compared to collagen activated platelets in the 
absence o f redox (Figure 3.7B). Following collagen activation there was no 
significant difference between levels o f  ADP secretion in the presence o f the most 
oxidising redox potentials for either redox couple (GSH/GSSG Eh = -lOmV and 
Cys/CySS Eh = +4mV) compared to collagen activated platelets in the absence of 
redox. In collagen activated platelets, although levels o f ADP secretion in the 
presence o f all three Cys/CySS redox potentials were decreased compared to levels 
seen in the absence o f  redox, only the decrease seen at the most reducing redox 
potential (Eh = -148mV) reached statistical significance, (n = 4, p < 0.05) (Figure 
3.7B).
The indices o f platelet function I had studied thus far, i.e. platelet aggregation, PAC- 
1 binding and dense granule secretion, all involved quantification o f platelet 
activation status by measurement o f  those activation responses occurring to the 
platelet exterior. These next two studies were carried out to examine if  changing the 
external redox environment would reflect in corresponding changes within the 
platelet itself. Detection o f tyrosine phosphorylated platelet proteins and detection of 
intraplatelet reactive oxygen species (ROS) were chosen as the two internal indices 
o f platelet activation to be examined.
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3.2.4 Comparison of Tyrosine Phosphorylated Proteins in 
Unactivated and Activated Platelets in the Presence of Varying 
GSH/GSSG Redox Potentials
This study was carried out using only GSH/GSSG redox potentials due to the limited 
supply o f anti-phosphotyrosine antibody 4G10. Gel-filtered platelets were treated 
with platelet buffer or with GSH/GSSG redox potentials (Eh = -264mV and -lOmV) 
for 3 minutes at 37°C and then activated with collagen (38|ig/ml), convulxin 
(50ng/ml), thrombin (0.1U/ml) or were left unactivated in a platelet aggregation 
assay for 10 minutes at 37°C. Platelet lysates were generated and samples were 
separated on 4 -  20% gradient gel and transferred to PVDF membrane as described 
in section 2.2.14. The membrane was probed with the anti-tyrosine phosphorylation 
antibody 4G10 (Figure 3.8).
In unactivated platelets in the absence o f redox there was a basal level o f tyrosine
phosphorylation between approximately 55 and 70 kDa, most likely the
constitutively tyrosine phosphorylated tyrosine kinase p60src (Varshney et al. 1986)
and also at approximately 40-45kDa (Figure 3.8, lane 1). A similar profile is seen
with unactivated platelets treated with the reducing GSH/GSSG Eh = -264mV or the
oxidising Eh = -lOmV redox potentials (Figure 3.8, lanes 2 and 3 respectively).
Activation o f platelets by collagen (3 8 jig/ml) in the absence o f redox resulted in a
large increase in the number o f  tyrosine phosphorylated proteins at approximately
35kDa, 47kDa, 68kDa, 76kDa, 88kDa, 112kDa and 124kDa (Figure 3.8, lane 4).
These bands are absent in collagen activated platelets in the presence of the reducing
Eh = -264mV (Figure 3.8, lane; />). The tyrosine phosphorylation profile following
collagen activation in the presence o f the oxidising Eh = -lOmV (Figure 3.8, lane 6)
was the same as that seen with collagen in the absence o f redox (Figure 3.8, lane 4).
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The phosphorylation profiles o f eonvulxin activated platelets without redox (Figure
3.8, lane 7) and in the presence o f the reducing GSH/GSSG Eh = -264mV (Figure
3.8, lane 8) were very similar to each other, but showed a different profile compared 
to collagen activation under the same conditions (Figure 3.8, lanes 4 and 5). 
Similarly, thrombin activation in the absence o f redox (Figure 3.8, lane 10) and 
thrombin activation in the presence o f the reducing GSH/GSSG Eh = -264mV 
(Figure 3.8, lane 11) displayed very similar phosphorylation profiles to each other, 
but yet again, these were different to either collagen or eonvulxin under these same 
conditions. Interestingly, in both eonvulxin and thrombin activated platelets in the 
presence o f the most oxidising redox potential GSH/GSSG Eh = -lOmV, there 
appeared to be an overall increase in the intensity o f the tyrosine phosphorylation 
profiles at approximately 50kDa, 85kDa, 117kDa, and 125kDa (Figure 3.8, lane 9) 
and 35kDa, 45kDa, 70kDa and 90kDa (Figure 3.8, lane 12).
3.2.5 Measurement of Intra-platelet Reactive Oxygen Species
The reagent 5(6)-chloromethyl, 2 ’, 7’-dichlorodihydro fluorescein diacetate
(DCFDA) is readily cell-permeable. Once inside the cell it is de-acetylated by 
intracellular esterases to form the non-fluorescent reduced dye dichlorofluorescein 
DCFH, which then is rapidly oxidized to form the highly fluorescent DCF in a 
reaction with the oxidizing species hydrogen peroxide (H2O2), superoxide (O2' ) and 
hydroxyl (OH) (Myhre et al. 2003). Thus by determining the level o f DCF 
fluorescence within the platelet using flow cytometry, the generation o f intra-platelet 
reactive oxygen species (ROS) may be measured.
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3.2.5.1 Measurement of Intra-platelet Reactive Oxygen Species in 
Activated Platelets
Gel-filtered platelets were treated as described in section 2.2.8. Briefly, platelets 
were incubated in the dark in the presence o f DCFDA (8.5|aM) either with platelet 
buffer or with the following concentrations o f agonist: collagen: 0, 10, 19, 38, 76, 
152jig/ml; convulxin: 0, 5, 10, 50, 250ng/ml or thrombin: 0, 0.05, 0.1, 0.5, l.OU/ml 
for 10 minutes at 37°C. Following addition o f 2ml platelet buffer to stop the reaction, 
samples were analysed immediately by flow cytometry. Data are expressed as mean 
DCF fluorescence.
Each o f the agonists showed a concentration dependent increase in intraplatelet ROS 
generation compared to unactivated platelets (Figure 3.9). Collagen activation 
resulted in significant generation o f ROS at concentrations o f 10(j.g/ml and 19|ig/ml 
(n = 4, p < 0.001) and 38^g/ml (n = 4 - 6, p < 0.01), with no significant increase in 
ROS generation at the higher concentrations o f  76^g/ml and 152^g/ml (Figure 
3.9A). Activation with convulxin also resulted in a significant increase in 
intraplatelet ROS generation at the two highest concentrations tested, 50ng/ml and 
250ng/ml (n = 4 - 6 , p < 0.05 and p < 0.01 respectively) when compared to 
unactivated platelets (Figure 3.9B). Activation with thrombin also showed a 
concentration dependent increase in ROS generation, with significant increases at 
O.lU/ml (n = 4 - 6 , p < 0.05), 0.5U/ml and lU/m l (n = 4 - 6 , p < 0.001) although the 
generation o f ROS with thrombin activation was far lower overall than that seen with 
either collagen or convulxin (Figure 3.9C).
The concentrations o f the agonists used previously in my platelet aggregation, PAC- 
1 binding and dense granule secretion studies were collagen (38|jg/ml), convulxin
(50ng/ml) and thrombin (O.lU/ml). A comparison o f the internal ROS generated
82
following platelet activation by each agonist at these concentrations is shown in 
Figure 3.10. There was a difference in the level o f ROS generated within the platelet 
by each agonist at these concentrations. Both collagen and convulxin activated 
platelets generated significantly greater levels o f ROS (n = 4, p < 0 .01) when 
compared to unactivated platelets or thrombin activated platelets (O.lU/ml or 
lU/ml). The mean fluorescence levels o f  collagen (38|o.g/ml) induced intra-platelet 
ROS were consistently higher than those generated by either convulxin (50ng/ml) or 
thrombin (O.lU/ml) activated platelets (Figure 3.10).
3.2.5.2 Effects of GSH/GSSG and Cys/CySS Redox Potentials on 
Intra-Platelet ROS Generation
Gel-filtered platelets were incubated with the GSH/GSSG or Cys/CySS redox 
potentials indicated for 3 minutes at 37°C and then remained unactivated or were 
activated with collagen (38|ig/ml), convulxin (50ng/ml) or thrombin (OrlU/ml) in the 
presence o f DCFDA (8.5|iM) as outlined in section 3.2.5.1. There was no significant 
effect o f  any o f the redox potentials on intra-platelet ROS generation in unactivated 
platelets (Figure 3.11 A). There was a large decrease in ROS generation in collagen 
activated platelets pre-treated with the most reducing GSH/GSSG Eh = -264mV or 
Cys/CySS Eh = -148mV (57% and 62% respectively) though this did not reach 
statistical significance (Figure 3.1 IB, Figure 3.12A and D). At the mean plasma 
redox potential GSH/GSSG Eh = -130mV internal ROS generation was 
approximately 78% of the level seen in collagen-activated platelets in the absence of 
redox (Figure 3.1 IB and Figure 3.12B) and at the most oxidising GSH/GSSG Eh = - 
lOmV the level o f  internal ROS was the same as that generated in the absence of 
redox (Figures 3.1 IB and 3.12C). Internal ROS generation in collagen-activated 
platelets pre-treated with the mean plasma Cys/CySS Eh = -82mV was 49% of that
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generated in the absence o f redox and was comparable to the level generated in 
platelets treated with the most reducing Cys/CySS Ej, = -148mV (Figure 3.1 IB and 
Figure 3.12D and E), ROS generation in platelets treated with the most oxidising 
Cys/CySS Eh = +4mV was the same as that generated in the absence o f redox 
(Figure 3.11B and Figure 3.12F).
There was no effect on ROS generation in convulxin or thrombin activated platelets 
at any o f the GSH/GSSG or Cys/CySS redox potentials used in this study (Figure 
3.11C and D).
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Figure 3.1 Varying GSH/GSSG and Cys/CySS redox potentials have no effect on aggregation 
response in unactivated platelets. A. Gel-filtered platelets were treated with the indicated 
GSH/GSSG redox potentials or with platelet buffer (no redox) for 3 minutes at 37°C. Platelet 
aggregation responses were followed for up to 10 minutes at 37°C with constant stirring at 1100 rpm. 
B. Platelets treated with Cys/CySS redox potentials or with platelet buffer for 3 minutes at 37°C. 
Platelet aggregation responses were followed for up to 10 minutes at 37°C with constant stirring at 
1100 rpm. Data are means ± SE of n = 6 separate experiments (n.s: not significant). C. A 
representative platelet aggregation tracing from a single experiment, 1 = no redox, 2, 3 and 4 = 
GSH/GSSG Eh = -264mV, -130mV and -lOmV respectively; 5, 6, J1 = Cys/CySS Eh = -148mV, - 
82mV and +4mV respectively.
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Figure 3.2 Reducing external redox potentials inhibit collagen induced platelet aggregation. A.
Gel-filtered platelets were treated with the indicated GSH/GSSG redox potentials or with platelet 
buffer (no redox) for 3 minutes at 37°C. Platelets were activated with 38^g/ml collagen (blue), 
n ITT/m l thrombin (red) or 50ng/ml convulxin (green). Platelet aggregations were followed for 10 
minutes at 37°C with constant stirring at 1100 rpm. B. Gel-filtered platelets were treated with the 
indicated Cys/CySS redox potentials or with platelet buffer (no redox) for 3 minutes at 37°C. Platelets 
were activated with 38|Jg/ml collagen (blue), O.lU/ml thrombin (red) or 50ng/ml convulxin (green) as 
before. Data are means ± SE of n = 6 separate experiments, *** p < 0.001 compared to agonist 
induced aggregation in the absence of redox. C. A representative platelet aggregation tracing of 
collagen activated platelets from a single experiment. D. A representative platelet aggregation tracing 
of convulxin activated platelets from a single experiment. E. A representative platelet aggregation 
tracing of thrombin activated platelets from a single experiment. In C, D and E: 1 = no redox, 2, 3 and 
4 = GSH/GSSG Eh = -264mV, -130mV and -lOmV respectively: 5, 6 and 7 = Cys/CySS Eh = - 
148mV, -82mV and +4mV respectively.
86
0  80 
70 
60
« 50
1 <0 
y  30
20
tO
O
-148mV
105 10' 10-' 10' 10* 
Mem Fluor wc«oc« 
PAC-I Brndng
G
100 -i
I 80 -\ 
ffi
3 ^
á  ,0 
í
$ 20 
0
F «0
70 I 
60 
« 50
+4mV
M **n FkXKHCMKI
PAC-1 Binding
i& J  
105 10’ 10-' 10’ 10* 
Mmo Fluor*»c«ne* 
PAC-1 BM ng
No -264 -130 -10 -148 -62 +4 1U/ml
Redox _________  _________  thrombin
E), GSH/GSSG E*, Cys/CySS
Figure 3.3 GSH/GSSG or Cys/CySS redox potentials do not cause PAC-1 binding to integrin 
a iibP3 011 unactivated platelets. Gel-filtered platelets were treated with platelet buffer (black lines) or 
with GSH/GSSG Eh = -264mV, -130mV and -lOmV (green lines in A, B and C respectively) or 
Cys/CySS Eh = -148mV, -82mV and +4mV (red lines in D, E and F respectively) for 3 minutes at 
37°C. PAC-1 antibody (2.5(-ig/ml) was added to the platelets for 10 minutes at 37°C. 2 ml of platelet 
buffer was then added to the platelets. Samples were read immediately by fluorescence activated cell 
sorter (FACS) analysis. Data are representative histograms from one of n = 4 separate experiments. G. 
Graph showing levels of PAC-1 binding to untreated and redox treated unactivated gel-filtered 
platelets, and to platelets activated with lU/ml thrombin in the absence of ndox, *** p < 0.001 
compared to unactivated platelets. Data are means ± SE of n = 4 separate experiments.
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Figure 3.4 Reducing redox potentials decrease PAC-1 binding to integrin am,P3 on collagen 
activated platelets. A -  F: Gel-filtered platelets were treated with platelet buffer (black lines) or with 
the GSH/GSSG redox potentials indicated (green lines in A, B and C respectively) or Cys/CySS 
redox potentials indicated (red lines in D, E and F respectively) for 3 minutes at 37°C. Platelets were 
then activated with 38(a.g/ml collagen in the presence of PAC-1 antibody (2.5p.g/ml) for 10 minutes at 
37°C. 2 ml of platelet buffer was then added to the platelets. Blue lines show PAC-1 binding 
following collagen activation in the absence of redox. Samples were read immediately by FACS 
analysis. Data represent histograms from one of n = 4 separate experiments. G and H: PAC-1 binding 
to collagen (blue), convulxin (green) and thrombin (red) activated platelets in the presence and 
absence of GSH/GSSG and Cys/CySS redox potentials, *** p < 0.001, * p < 0.05. Data shown are 
means ± S.E. of n = 4 separate experiments.
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Figure 3.5 GSH/GSSG and Cys/CySS redox potentials do not affect the binding of PAC-1 to 
integrin anbp3 in unactivated and CRP activated platelets. A. Gel-filtered platelets were treated 
with platelet buffer (no redox) or the GSH/GSSG redox potentials indicated for 3 minutes at 37°C in 
the presence of PAC-1 FITC antibody (2.5|xg/ml). Platelets were then either left unactivated or were 
activated with lug/ml CRP for 10 minutes at 37°C. B. Platelets were treated with platelet buffer (no 
redox) or the Cys/CySS redox potentials indicated and were left unactivated or were activated with 
1 ng/ml CRP for 10 minutes at 37°C. Data shown are means ± SE of n = 4 separate experiments.
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Figure 3.6 Greater dense granule secretion in collagen activated platelets. Gel-filtered platelets 
were either left unactivated or were activated with collagen (38|ig/ml), convulxin (50ng/ml) or 
thrombin (O.lU/ml) for 6 minutes at 37°C. Dense granule secretion was measured as the level of 
chemiluminescence of the luciferin-luciferase reaction following platelet ADP release using a Wallac 
multi-plate reader. Each measurement was carried out in triplicate. Data shown are mean ± SE of n = 
4 separate experiments, ** p < 0.01, *** p < 0.05 compared to unactivated platelets.
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Figure 3.7 The Effects of varying GSH/GSSG and Cys/CySS redox potentials on platelet dense 
granule secretion. A. Gel-filtered platelets were treated with platelet buffer (no redox) or 
GSH/GSSG redox potentials or Cys/CySS redox potentials for 3 minutes at 37°C. Dense granule 
secretion was quantified by measuring the chemiluminescence of the luciferin-luciferase reaction 
following platelet ADP release, using a Wallac multi-plate reader. B. Gel-filtered platelets were 
treated as in A, activated with 38|ig/ml collagen for 10 minutes at 37°C and ADP release was 
measured. C. Gel-filtered platelets treated as in A, activated with 50ng/ml convulxin and ADP release 
was measured. D. Gel-filtered platelets were treated as in A, activated with 0.1U/ml thrombin and 
ADP release was measured. Each measurement was carried out in triplicate. Data are means ± SE of n 
= 4 separate experiments, * p < 0.05 compared to platelets activated in the absence of redox.
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Figure 3.8 Tyrosine phosphorylated proteins in unactivated and agonist activated platelets in 
the presence and absence of GSH/GSSG redox potentials. Gel-filtered platelets were treated with 
platelet buffer or with the GSH/GSSG redox potentials indicated below in a PAP-8E platelet 
aggregometer for 3 minutes at 37°C with stirring at llOOrpm. Platelets were then either left 
unactivated or were activated with 38(.ig/ml collagen, 50ng/ml convulxin or O.lU/ml thrombin, and 
aggregations were followed for 10 minutes. Platelets were lysed using RIP A lysis buffer and proteins 
were separated by SDS-PAGE, transferred to PVDF membrane and then probed with anti- 
phosphotyrosine antibody 4G10. Lanes 1, 2, 3: unactivated platelets treated with platelet buffer, Eh = - 
264mV and Eh = -lOmV respectively. Lanes 4, 5, 6: platelets activated with 38(xg/ml collagen treated 
with platelet buffer, Eh = -264mV and Eh = -lOmV respectively. Lanes 7, 8, 9: platelets activated with 
50ng/ml convulxin treated with platelet buffer, Eh = -264mV and Eh = -lOmV respectively. Lanes 10, 
11, 12: platelets activated with O.lU/ml thrombin treated with platelet buffer, Eh = -264mV and Eh = - 
lOmV respectively. Molecular weight markers are indicated on the left of the figure. This is 
representative of one of n = 4 separate experiments.
92
0 10 19 38 76 152 0 5 10 50 250 0 005 0.1 0,5 1,0
Collagen ConvuWn ng/ml Thrombin ll/ml
Figure 3.9 Intra-platelet ROS generation varies with agonist concentration. . A. Gel-filtered 
platelets were activated with soluble type I collagen (0 -  152|ig/ml) for 10 minutes at 37°C in the 
presence of the ROS detection reagent DCFDA (8.5|iM). The reaction was stopped by addition of 2ml 
platelet buffer, and samples were analysed immediately by flow cytometry. B. Gel-filtered platelets 
were activated with convulxin (0 -  250ng/ml) for 10 minutes at 37°C in the presence of the ROS 
detection reagent DCFDA (8.5|aM) as in (A) above. C. Gel-filtered platelets were activated with 
thrombin (0 -  l.OU/ml) for 10 minutes at 37°C in the presence of the ROS detection reagent DCFDA 
(8.5^M) as in (A) above. Data are means ± SE of n = 4 -  6 separate experiments, *** p < 0.001, ** p 
< 0.01, * p < 0.05 when compared to unactivated platelets.
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Figure 3.10 Collagen activation of platelets generates greater intra-platelet ROS than thrombin 
or convulxin activation. Gel-filtered platelets were activated with collagen (38(.ig/ml), convulxin 
(50ng/ml) or thrombin (lU/ml and O.lU/ml) for 10 minutes at 37°C in the presence of DCFDA 
(8.5|uM). The reaction was stopped by addition of 2ml of platelet buffer. Samples were analysed by 
flow cytometry and data expressed as mean DCF fluorescence. Data shown are means ± SE of n = 4 -  
6 separate experiments, * p < 0.05, ** p < 0.01 compared to unactivated platelets.
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Figure 3.11 The effects of varying GSH/GSSG or Cys/CySS redox potentials on intraplatelet 
ROS generation. A. Gel-filtered platelets were incubated with platelet buffer (no redox) or with 
GSH/GSSG redox potentials or Cys/CySS redox potentials as indicated for 3 minutes at 37°C in the 
presence of DCFDA (8.5(j.M). Platelets were left unactivated for a further 10 minutes at 37°C before 
addition of 2ml of platelet buffer to stop the reaction. Samples were analysed by flow cytometry. Data 
are expressed as mean DCF fluorescence. B. Platelets were treated with and without GSH/GSSG or 
Cys/CySS redox potentials as in (A) and were then activated by collagen (38|ig/ml) for 10 minutes at 
37°C. C. Platelets were treated with and without GSH/GSSG or Cys/CySS redox potentials as in (A) 
and were activated by convulxin (50ng/ml) for 10 minutes at 37°C. D. Platelets were treated with and 
without GSH/GSSG or Cys/CySS redox potentials as in (A) and were activated by thrombin 
(O.lU/ml). Data shown are means ± SE of n = 4 separate experiments.
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Figure 3.12 A reducing GSH/GSSG redox potential decreases collagen-induced intra-platelet 
ROS generation. Gel-filtered platelets were either treated with platelet buffer or the indicated 
GSH/GSSG redox potentials for 3 minutes at 37°C before activation with 38(ig/ml collagen, in the 
presence of the reactive oxygen species detecting agent DCFDA (8.5(.iM). Unactivated platelets 
without redox were used as controls (black lines). Intra-platelet ROS generation was measured by 
flow cytometry after 10 minutes activation. A. Collagen-induced ROS generation in the absence of 
redox (red line) and collagen-induced ROS generation in the presence of GSH/GSSG Eh = -264mV 
(green line). B. Collagen-induced ROS generation in the absence of redox (red line) and collagen- 
induced ROS generation in the presence of GSH/GSSG Eh = -130mV (green line). C. Collagen- 
induced ROS generation in the absence of redox (red line) and collagen-induced ROS generation in 
the presence of GSH/GSSG Eh = -lOmV (green line). Histograms are representative of one of n = 4 
separate experiments.
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Platelets exist within the environment o f the blood plasma and spend the majority o f 
their life span in a quiescent, non-activated state. Platelets are maintained in this 
quiescent mode by endothelial cell generation o f nitric oxide and prostacyclin via 
activation o f adenylate cyclase and elevation o f cyclic GMP levels (de Graaf et al. 
1992, Radomski et al. 1987b). This unactivated state depends largely on the physical 
and biochemical integrity o f the vascular endothelium (Rex 2007). Vascular injury or 
rupture o f atherosclerotic plaques result in exposure o f the underlying matrix 
proteins collagen and von Willebrand factor (VWF) to platelets, and is the initiating 
step in the complex process o f platelet activation leading to thrombus formation and 
vascular repair. Fundamental to this process is the adhesion o f platelets directly to 
collagen, or indirectly via VWF binding to the glycoprotein (GP) Ib/IX/V receptor 
complex (Savage et al. 1996). Collagen-induced activation o f platelets stimulates 
further thrombus formation through release o f secondary platelet agonists such as 
adenosine diphosphate (ADP), thromboxane A2 and serotonin, and by the cell 
surface formation o f thrombin (Freedman 2008).
In addition to exposure o f sub-endothelial matrix proteins, variations in the redox 
status o f the blood plasma are also believed to be involved in platelet activation and 
thrombotic events. An altered plasma redox state may be brought about by increased 
local RONS generation during thrombus formation (Krotz et al. 2002), variations in 
the levels o f physiological redox buffers such as GSH/GSSG and Cys/CySS (Ashfaq 
et al. 2006) or by addition o f exogenous antioxidants such as a-tocopherol, which 
has been shown to dose-dependently inhibit platelet aggregation response to ADP, 
collagen and epinephrine (Steiner 1983).
3.3 Discussion
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The GSH/GSSG and Cys/CySS redox couples, both o f which are normally present in 
the plasma, tightly control the plasma redox state. The redox state or redox potential 
(Eh) of each redox couple varies among individuals, ranging from Eh = -200mV to - 
50mV for GSH/GSSG and from Eh = -130mV to -20mV for Cys/CySS, with a 
plasma mean value o f approximately Eh = -130mV and Eh = -80mV for each redox 
couple respectively (Go & Jones 2005). There is much evidence to show that the 
redox status o f the plasma becomes more oxidised in normal ageing, smokers, type 2 
diabetics and in patients with cardiovascular disease (Harrison et al. 2003, Jones et 
al. 2000, Pan et al. 2009). Recent work has established that the redox potentials of 
both the GSH/GSSG and Cys/CySS redox couples also become measurably more 
oxidising with increasing age, with GSH/GSSG Eh changing by +0.7mV/year and 
Cys/CySS Eh by +0.16mV/year (Jones et al. 2002). Among smokers the mean 
plasma GSH/GSSG and Cys/CySS redox potentials were over 6% and 15% more 
oxidising than those o f non-smokers respectively (Moriarty et al. 2003). Despite this 
body o f research, there has been very little, i f  any, investigation into the direct 
effects o f  varying plasma redox potentials on platelet function. In this study, I set out 
to examine platelet reactivity to a variety o f external redox potentials. As each redox 
couple acts independently (Jones et al. 2004), the effects o f  each on platelet function 
were assessed separately.
Inhibitory platelet aggregation responses to varying GSH/GSSG and Cys/CySS 
redox potentials showed that the collagen activation pathway was more sensitive 
than either convulxin or thrombin to a reducing redox environment for both redox 
couples. At the most oxidising redox potentials for both redox couples, collagen- 
induced platelet aggregation proceeded as it had in the absence o f redox. Inhibition 
o f platelet aggregation in redox treated platelets was not seen when thrombin or
convulxin were used as platelet activators. These three agonists were chosen to 
activate specific rcceptors on the platelet surface; soluble type I collagen acting 
preferentially on integrin (X2P 1 (Savage et al. 1999), convulxin acting on GPVI 
(Vargaftig et al. 1980) and thrombin acting on the PAR-1 and PAR- 4 receptors 
(Kahn et al. 1998). This approach was thus undertaken to examine any effects of 
varying redox potentials on platelet function under different activating conditions or 
in scenarios that may arise in the local environment o f a traumatised or damaged 
blood vessel.
To underscore the independent nature o f  both redox couples, note should be made of 
the shapes o f the platelet aggregation line graphs (Figures 3.2A and B) for each 
couple, with an almost linear aggregation response to varying Cys/CySS redox 
potentials, compared to a gradual inhibition o f aggregation up to GSH/GSSG Eh = - 
130mV followed by an abrupt, large inhibition response at the most reducing 
GSH/GSSG Eh = -264mV. This is suggestive o f differing reactivity between the 
thiol groups o f each redox couple, with Cys/CySS appearing the more reactive, 
probably due to the differing pKa ionisation constants for the thiol groups o f GSH 
and Cys (8.3 and 8.8 respectively) (Winterboum & Metodiewa 1999).
That none o f the redox potentials o f either redox couple had any effect on thrombin
or convulxin-induced aggregation points to an anbfo independent process. As
mentioned earlier, work in our laboratory had previously shown a reversal of
thrombin-induced anbPi activation by GSH (3mM) as measured by decreased PAC-1
binding to this integrin in intact platelets (Walsh et al. 2004). However, as reported
here, the c . ncentration o f GSH used to generate the most reducing redox potential
never exceeded 45jiM, or in the case o f  Cys, 60|iM, representing at least a 50-fold
decrease in reducing potential. As activation o f anbP3 and fibrinogen binding are the
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‘final common’ events culminating in platelet aggregation in response to all o f the 
agonists used in this study, the fact that only collagen-induced aggregation was 
inhibited by reducing redox potentials precludes any direct interaction between 
GSH/GSSG or Cys/CySS redox potentials and integrin anbP3 mediated aggregation 
under these conditions.
To further explore this, the effects o f varying external redox potentials on PAC-1 
binding to anbP3 were examined. Consistent with the aggregation data, PAC-1 
binding to collagen-activated platelets was significantly reduced by the most 
reducing redox potentials o f  either redox couple. A lack o f any effect on PAC-1 
binding with thrombin activation again appears to rule out aubP3 as a redox target 
here. These data however, yield an interesting observation regarding PAC-1 binding 
to convulxin activated platelets. The significant decrease in convulxin-induced PAC-
1 binding in the presence o f the reducing Cys/CySS redox potential suggests that 
GPVI may itself be a target for redox or that more than one receptor is involved in 
convulxin activation o f platelets. When collagen related peptide (CRP) was used as 
the GPVI specific agonist, the data showed no significant change in PAC-1 binding 
at any o f  the redox potentials used suggesting that redox modification o f ligand 
binding to GPVI is unlikely. The specificity o f convulxin for GPVI has been 
questioned previously, with Kanaji et al demonstrating that convulxin binds strongly 
to human GPIba on platelets from human GPIb transgenic mice (Kanaji et al. 2003). 
This raises the possibility o f  convulxin having a redox sensitive binding component 
involving GPIb, and a redox insensitive component associated with GPVI. Both 
GPVI and the GPIb-IX-V receptor complex have been demonstrated to be 
functionally and spatially linked (Arthur et al. 2005), and both have recently been 
shown to have functional interactions with TNF receptor associated factor (TRAF)-
4, Hic-5, Pyk2 and p47phox in activated washed platelets (Arthur et al. 2011). 
Thrombin-induced activation and aggregation o f  washed platelets resulted in an 
increase in free thiol expression in both PDI and GPIba, believed to be due to 
disulphide bond reduction within the receptors or presentation on activation of 
previously cryptic protein thiols (Burgess et al. 2000). These data point to a potential 
redox modification o f GPIb, that could, in part explain the decrease in PAC-1 
binding seen here in convulxin activated platelets. That GPVI plays the major 
signalling role in convulxin-induced platelet aggregation is suggested from the full 
extent o f platelet aggregation seen in redox treated, convulxin-activated platelets 
even though PAC-1 binding is significantly decreased in these platelets at the most 
reducing Cys/CySS redox potential. The thrombin and CRP data point to a 
receptor(s) other than GPVI or am,P3 as targets o f reducing redox potentials.
Platelet dense granule secretion as measured by ADP release, again showed a 
significant decrease in collagen-activated platelets only, in the presence o f 
GSH/GSSG and Cys/CySS reducing redox potentials. The lack o f any effect o f 
redox on thrombin or convulxin-activated platelets again points to a targeting o f the 
collagen-platelet interaction, with the data implying that collagen binding is 
‘prevented’ under these redox conditions, or that once bound, the “outside-in” 
signalling following collagen binding is disrupted or attenuated. Measurement of 
both internal ROS generation and tyrosine phosphorylation o f platelet proteins show 
a clear attenuation o f internal signalling events with collagen-activation o f platelets 
in reducing redox environments. These indices o f internal signalling return towards 
levels seen in platelets activated in the absence o f redox as the redox environment 
becomes more oxidising. The influence o f reducing redox potentials on the 012P1 
collagen receptor is implied once again by the lack o f any effects o f  these reducing
redox potentials on intra-platelet ROS generation or tyrosine phosphorylation 
following thrombin or convulxin activation. Interestingly, there is an increase in 
tyrosine phosphorylation seen at the most oxidising GSH/GSSG redox potentials in 
both thrombin and convulxin activated platelets. In the case o f convulxin this may be 
due to a redox modulation o f GPIb in the oxidising environment giving rise to 
increased outside-in signalling over and above that seen in the absence o f this 
oxidant redox state. It is still unclear why a similar effect is seen in thrombin 
activated platelets.
An interesting feature o f the assays carried out in this study so far is the pre­
dominance o f the magnitude o f the platelet response, particularly intra-platelet ROS 
generation and dense granule secretion, to collagen, over and above that o f the other 
platelet agonists used. Collagen-induced intra-platelet ROS generation increased 
concentration-dependently but decreased at higher concentrations. I believe this to be 
due to formation o f an insoluble collagen agglutinate at higher concentrations due to 
the static nature o f the assay and the assay temperature o f 37°C, preventing proper 
ligand-receptor interaction. Although comparable levels o f platelet aggregation were 
observed with the concentrations o f each agonist used in these assays, the levels of 
PAC-1 binding, ROS generation and dense granule secretion varied dramatically 
with each agonist. Both dense granule secretion and ROS generation within the 
platelet were much greater with collagen-induced platelet activation, than with 
convulxin or thrombin. This is in agreement with a previous study by Sun et al who 
demonstrated that collagen induced platelet activation results in greater dense 
granule secretion than thrombin in washed platelets (Sun et al. 2001). In my study, 
the response to thrombin was the lowest o f the three agonists, with convulxin 
showing an intermediate response. Thrombin is a strong platelet agonist, yet there
appears to be only a small requirement for intraplatelet ROS generation in thrombin- 
induced platelet activation relative to the levels generated with collagen activation of 
the platelets. My results are in agreement with those o f Bakdash and Williams in that 
they also showed a significant intraplatelet ROS generation with convulxin 
compared to thrombin, with ROS levels generated comparable to those seen in my 
assays. No data for collagen-induced ROS generation were shown (Bakdash & 
Williams 2008).
The origins o f ROS are believed to be by-products o f enzymatic reactions both 
within the cell and on the cellular membrane. The nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidases, nitric oxide synthases (NOS), xanthine oxidase (XO), 
cyclooxygenase (COX) and 12-lipoxygenase (LOX) have all been implicated in ROS 
generation within the platelet (Olas & Wachowicz 2007). ROS products in platelets 
include superoxide radical (O2" ), hydrogen peroxide (H2O2), hydroxyl radical ( OH), 
and the RNS, nitric oxide (NO ) (Krotz et al. 2002, Muruganandam & Mutus 1994, 
Pignatelli et al. 1998). Activation o f platelets by collagen (and convulxin) via GPVI 
is believed to result in a cascade o f tyrosine phosphorylation leading to activation of 
phospholipase Cy (PLCy) and subsequent activation o f protein kinase C (PKC) 
(Siess 1989). PKC activates NAD(P)H oxidase resulting in ROS generation 
(Wachowicz et al. 2002). ROS are increasingly implicated as second messengers 
within the platelet, with NAD(P)H oxidase generated ROS reported to be involved in 
activation o f integrin ain>P3 (Begonja et al. 2005) and superoxide radicals from 
NAD(P)H oxidase believed to be involved in platelet recruitment (Krotz et al. 2002).
My data strongly suggests tv at intra-platelet ROS plays an important role in collagen 
and convulxin-induced platelet activation, while playing a lesser role in thrombin- 
induced activation. This ROS is possibly NAD(P)H derived, but the underlying
103
signalling events leading to its formation are still not clear. The effects o f the varying 
external redox potentials may point to the source o f the initiation o f both collagen 
and convulxin-induced ROS within the platelet. The decrease in collagen but not 
convulxin-induced ROS noted at the most reducing redox potentials is again 
suggestive o f integrin o^Pi activation and not GPVI as the source o f soluble type I 
collagen-induced ROS. Several groups have demonstrated a role for integrins and 
012P1 in cellular ROS generation. Type I collagen induced an increase in COX-2 
expression and COX-2 ROS generation mediated by o^Pi on human intestinal 
epithelial cells (Broom et al. 2006), binding o f type IV collagen to human colon 
adenocarcinoma cells induced an increase in NAD(P)H oxidase ROS production 
compared to cells adhered to plastic or laminin (Honoré et al. 2003) and internal 
ROS were shown to play a major role in the signalling cascade triggered by the 
interaction o f human fibroblast integrin receptors and the extracellular matrix protein 
fibronectin (Chiarugi et al. 2003). NAD(P)H oxidase ROS generation requires 
assembly o f an array o f  protein complexes at the plasma membrane, including Nox 
itself, p22phox, p67phox, p47phox, p,40phox and the small GTPase Rac (Bedard & Krause 
2007). Rac proteins were found to be activated upon platelet adhesion through (X2P1 
(Guidetti et al. 2009) in addition, the activation o f integrin asPi on rabbit synovial 
fibroblasts with an anti-a .5 activating antibody demonstrated activation o f Rac and 
subsequent ROS generation (Werner & Werb 2002). M y data show that both GPVI 
and 012P1 ligand binding result in generation o f intra-platelet ROS. However, only the 
ROS derived from the type I collagen-o^Pi interaction is redox sensitive. From the 
data presented thus far, the interaction o f reducing GSH/GSSG and Cys/CySS redox 
potentials with gel-filtered platelets appears to be targeting the collagen activation
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pathway independently o f GPVI. It is the nature o f this redox sensitivity o f the 
collagen-integrin interaction that forms the basis o f the rest o f this thesis.
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Characterisation of the Redox Modulation
of Platelet Function
C h a p t e r  4
The relationship between platelet activation and the redox environment has been 
highlighted by several studies showing DTT induced platelet aggregation (MacIntyre 
et al. 1977, Zucker & Masiello 1984) and by Yan and Smith who demonstrated a 
redox-dependent alteration o f the activation state of purified integrin anbp3 by the 
combination o f GSH and nitric oxide (NO) (Yan & Smith 2000) and a DTT induced 
disulphide bond reduction within the receptor resulting in am,P3 activation (Yan & 
Smith 2001). Studies from this laboratory have demonstrated endogenous thiol 
isomerase activity in anbP3 thought to regulate the conformation o f the integrin by 
thiol/disulphide isomérisation between cysteine residues within the receptor (O'Neill 
et al. 2000) and more recently a redox modulation o f am,P3 by S-nitrosylation 
following exposure o f  platelets to the nitric oxide donor S-nitrosoglutathione 
(GSNO) (Walsh et al. 2007). The role o f platelet-surface cysteine free thiols and/or 
cysteine-cysteine disulphide bonds in aiibP3-mediated platelet activation is thus 
firmly established (Manickam et al. 2011, Mor-Cohen et al. 2008). All integrin 
receptors are assumed to activate in a similar manner (Springer & Wang 2004), as 
they all possess a group o f highly conserved cysteine residues particularly in the 
EGF-region o f the P-subunits (Brower et al. 1997, O'Neill et al. 2000).
The cysteine thiol (-SH) group itself is highly reactive (Marino & Gladyshev 2011). 
The thiol group o f both cysteine and glutathione is responsible for a large range of 
physiological functions including ROS scavenging and antioxidant defence 
(Winterboum & Metodiewa 1999), chelation o f potentially toxic metal cations and 
conjugation o f xenobiotics for secretion and /.r excretion (Meister 1988), disulphide 
bond reduction and thiol oxidation (Thomas 1984) and a more recently ascribed role
4.1 Introduction
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in protecting critical protein cysteine residues from irreversible thiol oxidation by 
pro-oxidant species (Biswas et al. 2006, Dalle-Donne et al. 2007).
The studies referred to above emphasise the inter-relationship between the platelet 
redox environment and its activated state. These studies have used redox reagents 
such as DTT, GSH and NO as useful tools to understand the mechanisms o f the 
redox-platelet interaction in particular highlighting the role o f integrin am,ß3 (Walsh 
et al. 2007, Yan & Smith 2000, 2001). In contrast, my work set out to examine this 
redox-platelet relationship in a physiological context using the endogenous redox 
buffers glutathione and cysteine.
Using GSH/GSSG and Cys/CySS redox couples to generate redox potentials gives a 
truer approximation of the in vivo redox system, as these redox species always occur 
as redox couples, never in isolation (Schafer & Buettner 2001) and constitute the 
major plasma redox buffering system (Jones et al. 2000). The redox mediated effects 
on platelet function from previous studies used millimolar concentrations of 
individual redox reagents, not as part o f a redox couple. However, I used 
concentrations o f these redox reagents that approximated known physiological limits 
(total glutathione = 45p.M and total cysteine = 200|xM) (Anderson & Meister 1980, 
Go & Jones 2005) as discussed previously in chapters two and three. The global 
effects (via anbßs) o f the larger concentrations o f  redox reagents on platelet function 
in other previous studies may have masked other more redox-sensitive activation 
pathways which would only become apparent in the presence o f much lower levels 
o f  redox. Using a gel-filtered platelet system removed all existing endogenous redox 
from the platelet surroundings but allowed subse uent accurate manipulation o f the 
external redox environment by addition o f precisely calculated quantities o f redox to 
generate the required redox state.
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Results obtained in chapter three showed that platelets are sensitive to reducing 
redox potentials but only when activated by collagen. These results differ from the 
findings o f the studies mentioned above in that the redox-mediated effects on platelet 
function described in this thesis are not mediated via integrin cxnbP3. As discussed, 
the effects o f reducing GSH/GSSG or Cys/CySS redox potentials on platelet 
function were confined almost exclusively to collagen-activated platelets. Neither 
thrombin nor convulxin activated platelets showed redox dependent effects under the 
same experimental conditions, thus making a direct interaction between reducing 
redox potentials and anbP3 unlikely.
This represents a novel redox regulatory mechanism o f platelet function acting on 
the activation pathway o f a specific agonist, namely collagen. The effects o f  redox 
dependent inhibition o f  collagen-induced platelet activation are also seen in events 
preceding platelet aggregation, such as inhibition o f agonist-induced tyrosine 
phosphorylation o f platelet proteins and inhibition o f dense granule secretion 
suggesting that the effects o f  reducing redox potentials are extracellular in nature and 
are acting at the level o f  the collagen/collagen receptor interaction.
The mechanism o f this redox-platelet interaction could possibly be described in 
terms o f the physiological functions carried out by the GSH/GSSG and Cys/CySS 
redox couples. A detailed description o f the effects o f  the GSH/GSSG or Cys/CySS 
redox couples on platelet function has yet to be elucidated. Any one or a 
combination o f the functions o f  GSH and Cys may be responsible for the redox 
dependent inhibition o f  collagen-induced platelet activation.
Having demonstrated the effects o f reducing redox potentials on collagen-induced 
platelet activation in chapter three, my aim in this chapter is to look more closely at
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the interaction o f the GSH/GSSG and Cys/CySS redox potentials with platelets. I 
will set out to explain the basis o f  the redox-mediated inhibition o f collagen-induced 
platelet activation in terms o f the physiological functionality o f  the glutathione and 
cysteine redox couples.
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4.2 Results
Previously, washed platelets have been reported to generate extracellular ROS 
following activation by thrombin (Bakdash & Williams 2008). This ROS has been 
implicated in playing a role in platelet activation, aggregation and recruitment of 
other platelets during thrombus formation (Krotz et al. 2002). To determine if  such 
ROS was produced in our gel-filtered platelet system, and if  the inhibitory effects of 
reducing GSH/GSSG and Cys/CySS redox potentials on collagen-induced platelet 
activation were due to their ROS scavenging and/or antioxidant capacity, an 
investigation o f extracellular ROS generation in gel-filtered platelets was carried out.
L-012 is a luminol derivative that reacts with various extracellular reactive oxygen 
species, with a large chemiluminescence, under physiological conditions (Daiber et 
al. 2004, Nishinaka et al. 1993). I used the xanthine/xanthine-oxidase ROS 
generating system similar to that used previously (Krotz et al. 2002) to demonstrate 
the ROS detecting ability o f L-012 and in addition, the superoxide scavenging 
capability of the enzyme superoxide dismutase (SOD). Superoxide radicals (O2'") are 
generated by the action o f the enzyme xanthine oxidase (XO) on its substrate 
xanthine (X). In this reaction, xanthine is converted to uric acid, producing O2'' as 
follows (Cos et al. 1998):
Xanthine + 2O2 + H2O —► Uric acid + 2O2'’ + 2H+
The superoxide generated then oxidises the chemiluminescent probe L-012, which 
emits photons o f light in the process. These photons are iien  detected by a 
photomultiplier with no filter in a 96-well plate luminometry assay. L-012 showed 
significant chemiluminescence (n = 4, p < 0 .001), in the presence of the
4.2.1 Detection and Measurement of Platelet Extracellular ROS
111
xanthine/xanthine oxidase superoxide generating system in a cell free assay (Figure 
4.1). This chemiluminescence was totally abolished in the presence of the superoxide 
scavenging enzyme superoxide dismutase (SOD, 300U/ml).
4.2.2 No Increase in Extracellular ROS is Detected in Activated 
Platelets
Unactivated gel-filtered platelets showed a basal level o f  extracellular ROS as 
detected by L-012 chemiluminescence, measured over a 12 minute period that was 
reduced in the presence o f the cell-impermeable enzyme SOD (Figure 4.2A). No 
increase in extracellular ROS generation above this basal level was observed after 
activation o f platelets by collagen (38|xg/ml), thrombin (0 .1U/ml) or convulxin 
(50ng/ml) (Figure 4.2B, C and D). However, activation o f platelets by thrombin 
(0.1U/ml and lU/ml) resulted in a significant decrease in basal extracellular ROS 
generation, (n = 4, p < 0.01) (Figure 4.4). The only increase in ROS generation 
occurred following platelet activation with phorbol 12-myristate 13-acetate (PMA 
lO^M), (n = 4, p < 0.01) (Figures 4.3 and 4.4), which was also ablated in the 
presence o f SOD (300U/ml).
4.2.3 Hydrogen Peroxide is Scavenged by Catalase
Hydrogen peroxide (H2O2) reacts with luminol (3-aminophtalhydrazide) in the 
presence o f horseradish peroxidase (HRP) to produce chemiluminescence by photon 
emission (E = hv), and the by-products water and oxygen. The chemiluminescence 
reaction is shown below (Forghani et al. 1998):
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Horse radish peroxidase
Luminol ------------------------------------------------------------------->• Light
Hydrogen peroxide
This assay was used to demonstrate the scavenging capacity o f catalase on H2O2. 
Hydrogen peroxide caused a concentration dependent increase in luminol/HRP 
chemiluminescence in a cell .free assay. The luminescence resulting from the highest 
concentration o f H2O2 (ImM ) was abolished in the presence o f the ROS scavenging 
enzyme catalase (lOOOU/ml) (Figure 4.5).
4.2.4 No Effect of ROS Scavengers on Platelet Aggregation Response
To determine if  any undetected platelet derived extracellular ROS were produced 
during platelet aggregation, the three ROS scavengers SOD (300U/ml) (Krotz et al.
2002) which enzymatically converts superoxide free radicals to hydrogen peroxide, 
catalase (CAT) (lOOOU/ml) (Pignatelli et al. 1998) an enzyme which converts 
hydrogen peroxide to water and molecular oxygen, and mannitol (3mM), that 
scavenges the most reactive o f all ROS, the hydroxyl radical ( OH) (Begonja et al. 
2005) were used. Gel-filtered platelets were activated with collagen (38|j.g/ml), 
thrombin (O.lU/ml) or convulxin (50ng/ml) in the presence o f the ROS scavengers 
for 10 minutes and aggregations were followed for a further 8 minutes at 37°C with 
constant stirring at llOOrpm. None o f ROS scavengers had any effect on the rate or 
extent o f platelet aggregation in response to any of the agonists used (Figure 4.t>A-
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4.2.5 Differing Effects of Antioxidants on Platelet Aggregation
GSH and Cys are two o f  the most important physiological antioxidants (Franco et al. 
2007, Iyer et al. 2009) along with vitamin C (ascorbic acid) (Padayatty et al. 2003) 
and vitamin E (a-tocopherol) (Burton & Traber 1990). In order to elucidate if  the 
effects o f the reducing GSH/GSSG and Cys/CySS redox potentials on platelet 
function outlined in the previous chapter were due to the antioxidant properties of 
these redox couples, gel-filtered platelets were either left untreated or were treated 
with equi-molar concentrations (50|aM) o f ascorbic acid, a-tocopherol or the 
commonly prescribed drug and dietary supplement, N-acetyl cysteine (NAC) for 5 
minutes at 37°C prior to activation with collagen (38pg/ml), convulxin (50ng/ml) or 
thrombin (O.lU/ml) and were allowed to aggregate for 10 minutes at 37°C with 
stirring at llOOrpm. Untreated platelets aggregated to expected levels with each 
agonist. NAC (50jxM) significantly inhibited platelet aggregation in collagen 
activated platelets only (n = 4, p < 0.001) (96% reduction). Ascorbic acid and a- 
tocopherol had no effect on collagen induced platelet aggregation (Figures 4.7A and 
D). None o f  the antioxidants had any effect on platelet aggregation induced by 
convulxin or thrombin (Figures 4.7B, C and D).
4.2.6 Examining the Effects of Reducing and Oxidising Agents on 
Platelet Aggregation
The thiol-blocking, disulphide bond containing agent 5, 5’-Dithio-bis-(2-
nitrobenzoic acid (DTNB) can act as an oxidising agent when it reacts with thiol (-
SH) groups forming disulphide linkages with the target thiol (Ellman 1959). A
comparison o f the effects o f DTNB and the two other di'sulphide bond containing
reagents, oxidised glutathione (GSSG) and oxidised cysteine (CySS), was carried out
using platelet aggregation as the measure o f platelet function. Concentrations of
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DTNB, GSSG and CySS were set at 45pM  for the assay as the maximal 
concentrations o f redox reagents used previously in this study to generate reducing 
redox potentials approximated this value (45joM GSH and 60(iM Cys). Gel-filtered 
platelets were treated with DTNB, GSSG or CySS for 5 minutes at 37°C, or were left 
untreated and were then activated with collagen (38|ig/ml), convulxin (50ng/ml) or 
thrombin (O.lU/ml) and aggregations were followed for 10 minutes at 37°C with 
stirring at 1 lOOrpm. There was no significant effect on platelet aggregation with any 
o f the oxidising agents used (Figure 4.8A), although DTNB treatment did result in a 
slight increase in collagen induced aggregation (9.5%), which was not statistically 
significant.
The reducing agents dithiotreitol (DTT) a di-thiol containing compound and tris (2- 
carboxyethyl) phosphine (TCEP) a non-thiol reductant are well established in 
platelet biology as useful tools in studying disulphide bond reduction in platelet 
proteins (Bums et al. 1991, Yan & Smith 2001). As GSH and Cys are also reducing 
agents, the effects o f DTT and TCEP on platelet function were explored in platelet 
aggregation studies to investigate if  the effects o f reducing GSH/GSSG and 
Cys/CySS redox potentials on platelet function seen in chapter three were due to the 
disulphide bond reducing ability o f GSH and Cys. As the concentrations o f GSH and 
Cys used previously in this study to generate reducing redox potentials were similar 
(45 (iM GSH and 60 (iM Cys), it was decided to compare the effects o f  45 (aM GSH, 
DTT and TCEP on platelet aggregation using collagen (38|ig/ml), convulxin 
(50ng/ml) and thrombin (O.lU/ml) as platelet agonists as before. Gel-filtered 
platelets were activated directly with agonists or were treated with DTT, TCEP or 
GSH for 5 minutes at 37°C, prior to addition o f agonists. Platelet aggregations were 
followed for 10 minutes at 37°C with constant stirring at 1 lOOrpm. Each o f the
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reducing agents significantly inhibited collagen induced platelet aggregation only (n 
= 4, p < 0.001) (Figure 4.8B). None o f the reducing agents had any effect on 
convulxin or thrombin induced platelet aggregations.
4.2.7 Sensitivity of Collagen Activation Pathway to Disulphide Bond 
Reduction
Having determined that the platelet-collagen interaction was sensitive to disulphide 
bond reducing agents, I looked at the effects o f varying concentrations o f DTT on 
agonist-induced platelet aggregation. DTT caused a marked concentration- 
dependent inhibition o f platelet aggregation in gel-filtered platelets activated with 
collagen (IC50 = 13jaM) (Figures 4.9A and 4.10). DTT also caused a concentration 
' dependent inhibition o f platelet aggregation when platelets were activated with 
convulxin and thrombin, but to a lesser extent. Thrombin (O.lU/ml) activated 
platelets showed the least sensitivity to DTT (IC50 = 858|iM), with the value for 
convulxin (50ng/ml) activated platelets lying between that o f collagen and thrombin 
(IC50 = 50|iM) (Figures 4.9B, 4.9C and 4.10). Unactivated platelets were unaffected 
by concentrations o f DTT less than IOOOjxM. At this concentration the slow partial 
aggregation response was noted (Figure 4.9D).
4.2.8 Determination of the Effects of Reducing and Oxidising Redox 
Potentials on Collagen Type I Functionality
In order to determine if  the inhibitory effects o f reducing redox potentials on 
collagen induced indices o f platelet function were due to some modification o f the 
functionality o f the collagen itself, fresh aliquots of soluble type I collagen were 
treated with the most reducing and most oxidising redox potentials (GSH/GSSG Eh = 
-264mV or -lOmV and Cys/CySS Eh = -148mV or +4mV). The aliquots o f collagen
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(1.9mg/ml) were incubated with redox for 10 minutes at 37°C and were each then 
used to activate gel-filtered platelets in aggregation experiments as before at a final 
concentration o f 3 8 (ig/ml.
At the same time, gel-filtered platelets were pre-incubated with the same redox 
potentials for 10 minutes at 37°C before being activated in the aggregometer with 
aliquots o f collagen that had not been exposed to redox. Gel-filtered platelets with no 
added redox were activated with collagen (38|j.g/ml) as a positive control.
Collagen (38jo,g/ml) pre-incubated with either GSH/GSSG Eh = -264mV or Eh = - 
lOmV induced the same level o f platelet aggregation in gel-filtered platelets as 
untreated collagen (Figures 4.11A and 4.1 IB (Redox 1)). Neither redox potential had 
any effect on the ability o f  collagen to induce platelet aggregation.
W hen untreated collagen was used to activate platelets that were pre-exposed to 
varying GSH/GSSG redox potentials, there was significant inhibition o f platelet 
aggregation in platelets treated with GSH/GSSG Eh = -264mV only (n = 3, p < 
0.001) (Figure 4.11 A (Redox 2)). Platelets treated with GSH/GSSG Eh = -lOmV 
aggregated to the same extent as untreated collagen activated platelets (fig 4.4.11 B 
(Redox 2)).
Similarly, collagen pre-treated with Cys/CySS Eh = -148mV or +4mV, induced 
platelet aggregation to the same extent as untreated collagen (Figure 4.11C and D 
(Redox 1)). Pre-incubation o f collagen with either Cys/CySS redox potential had no 
effect on agonist function. However, gel-filtered platelets pre-treated with the 
reducing Cys/CySS redox potential (Eh = -148mV) failed to aggregate when 
activated by untreated collagen (38jxg/ml). Platelets treated with the more oxidising
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Cys/CySS Eh = +4mV aggregated to the same extent as untreated collagen activated 
platelets (Figure 4.11C and 4.1 ID (Redox 2)).
4.2.9 Effects of Increased Divalent Cation Concentration on Redox 
Treated Platelet Function
As discussed in section 1.5.2, both GSH and Cys are known to possess metal
chelating properties (Flora & Pachauri 2010). Platelet aggregation is critically
• , 2~i” * * * * dependent on the presence o f the divalent cation Ca for integrin am,P3 activation
and fibrinogen binding (Bennett & Vilaire 1979, Bom & Cross 1964). In addition,
Mg2+ is necessary for platelet activation by and adhesion to collagen via integrin
(X2P1 (Staatz et al. 1990). In light o f these observations, it was necessary to determine
if  the inhibitory effects o f the reducing GSH/GSSG and Cys/CySS redox potentials
on collagen-induced platelet activation seen in this study were due to divalent cation
chelation by either GSH or Cys. Such chelation could be responsible for depleting
the extracellular divalent cation concentrations to levels insufficient to allow normal
integrin activation. Ethylene diamine tetra acetic acid (EDTA) is well established as
a chelator o f divalent cations including Ca2+ and Mg2+ and is known to inhibit
agonist induced platelet aggregation at low millimolar concentrations (Peerschke et
al. 1980). EDTA was used at 50)iM to approximate the concentrations o f GSH and
Cys (GSH = 45p,M, Cys = 60^M) used to generate the most reducing redox
potentials to determine i f  either GSH or Cys were acting as divalent cation chelators.
This could possibly account for the inhibition o f collagen induced platelet
aggregation seen in reducing GSH/GSSG and Cys/CySS redox environments in the
previous chapter. EDTA at 2mM was used to totally inhibit platelet aggregation
responses.
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Addition o f EDTA (2mM) to gel-filtered platelets resulted in complete inhibition of 
platelet aggregation in thrombin (O.lU/ml) activated platelets, (n = 5, p < 0.001) 
(Figure 4.12A and B). A lower concentration o f EDTA (50jaM) comparable to the 
concentrations o f GSH and Cys used in generating the most reducing redox 
potentials had no effect on thrombin (O.lU/ml) induced platelet aggregation (Figure 
4.12A and B). Similarly, addition o f EDTA (2mM) to collagen (38|xg/ml) activated 
platelets also resulted in complete inhibition o f platelet aggregation response (n = 6, 
p < 0.001) (Figure 4.13A and B). EDTA (50p,M) had no effect on collagen induced 
platelet aggregation. Neither 2mM nor 50(xM EDTA had any effect on unactivated 
platelets (Figures 4.12 and 4.13).
Platelets incubated with the reducing redox potentials (Eh GSH/GSSG = -264mV or 
Eh Cys/CySS = -148mV) displayed the expected significant inhibition o f collagen 
induced platelet aggregation seen previously, when compared to collagen induced 
aggregation in the absence o f redox (n = 6 , p < 0.001), (Figure 4.14A, B and C). 
When platelets were supplemented with excess M gC^ (2mM) over and above that 
present in our HEPES platelet buffer (0.9mM), collagen induced platelet aggregation 
was still inhibited in the presence o f reducing GSH/GSSG or Cys/CySS redox 
potentials. In the absence o f redox, addition o f M gC^ (2mM) had no effect on the 
aggregation response o f  either unactivated or collagen (38|ig/ml) activated platelets 
(Figure 4.14A, B and C).
Following incubation with the same reducing redox potentials (Eh GSH/GSSG = - 
264mV or Eh Cys/CySS = -148mV), collagen-induced platelet aggregation was still 
inhibited, even when the platelets were supplemented with excess (2mM) CaCl2 <n = 
6 , p < 0.001), (Figure 4.15A, B and C). Moreover, addition o f this excess o f CaCl2 
(2mM) to collagen activated platelets resulted in a significant increase, (n = 6, p <
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0.05), in platelet aggregation compared to collagen induced aggregation in the 
absence o f  excess CaC^. Addition o f excess CaCl2 had no effect on unactivated 
platelets (Figure 4.15A and B).
4.2.10 Binding of Collagen-FITC to Gel-filtered Platelets in the 
Presence of Varying Redox Potentials
To investigate i f  the reducing redox potentials used in this study were affecting the 
binding o f soluble type I collagen to its primary receptor 012P1, gel-filtered platelets 
were incubated with FITC-labelled bovine type I collagen according to the method 
of Wang (Wang et al. 2003) and the level o f  collagen binding was determined both 
in the absence and the presence o f reducing GSH/GSSG and Cys/CySS redox 
potentials. To ensure that only platelet-specific collagen-binding was observed, the 
platelet population was first identified by using the integrin ain,P3 specific antibody 
CD41-FITC and subsequent collagen-binding events were measured in this gated 
platelet population (Figures 4.16A-D). Levels o f  collagen-FITC binding were 
expressed as mean fluorescence units.
Platelets treated with 100|xg/ml collagen-FITC showed a large, significant increase 
in collagen binding when compared to 1 0|Ag/ml collagen (n = 4, p < 0.01) (Figure 
4.17). The levels o f collagen binding at 100jj,g/ml collagen-FITC were decreased by 
pre-treatment o f  the platelets with the most reducing GSH/GSSG or Cys/CySS redox 
potentials (Eh GSH/GSSG = -264mV or Eh Cys/CySS = -148mV), with a significant 
decrease at Eh Cys/CySS = -148mV (n = 4, p < 0.05) (Figure 4.17). EDTA (3mM) 
significantly decreased collagen-FITC (100(ig/ml) binding to gel-filtered platelets 
reducing the binding to a level comparable to that achieved with 10(j.g/ml collagen (n 
= 4, p < 0.01) (Figure 4.17).
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Gel-filtered Platelets in the Presence of Varying Redox Potentials
In order to determine if  a varying redox environment was modifying or blocking the 
a 2-subunit collagen binding site thus preventing the collagen-receptor interaction 
necessary for platelet activation, the effects o f the reducing, plasma mean and 
oxidising Cys/CySS redox potentials (Eh = -148mV, -82mV and +4mV) on the 
binding o f PE-labelled anti-a.2 integrin subunit antibodies 12F1, a non-function 
blocking antibody (Savage et al. 1999) and the function blocking antibody P1E6 
(Keely & Parise 1996) to gel-filtered platelets were examined in this experiment. I 
set out to examine if  varying Cys/CySS redox potentials were causing some redox 
modification o f the collagen binding site located at the a,2-I domain (Emsley et al. 
2000). It was hoped to measure this indirectly by comparing the level o f binding of 
two different anti-a,2 subunit antibodies to the collagen binding site under varying 
redox conditions. Only the Cys/CySS redox couple was used in this experiment due 
to limited availability o f antibodies. The method used was based on the method of 
Cruz (Cruz et al. 2005).
Significant binding o f P1E6 to on gel-filtered platelets was observed when 
compared to an IgGi isotype control antibody, (n = 4, p < 0.001). The binding o f 
both P1E6 and IgGi antibody was unaffected by pre-treatment o f platelets with 
varying Cys/CySS redox potentials: Eh = -148mV, -82mV and +4mV (Figures 
4.19A-D and Figure 4.21A). Similarly, antibody 12F1 binding to (X2P1 was 
significantly greater than that o f  its isotype control IgG2 antibody, (n = 4, p < 0.001). 
Pre-treatment o f platelets with varying Cys/CySS redox potentials: Eh = -148mV, -
4.2.11 The Binding of a2pi Specific Antibodies 12F1 and P1E6 to
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82mV and +4mV, had no effect on 12F1 binding to (X2P1 or o f the isotype control 
antibody IgG2 binding to 012P1 (Figure 4.20A-D and Figure 4.21B).
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Figure 4.1 Superoxide dismutase abolishes superoxide radical generated by the 
xanthine/xanthine oxidase (X/XO) system. In a cell-free assay, 2mU/ml xanthine oxidase was 
added to 3mM xanthine solution in the presence o f the chemiluminescence detecting probe L-012 
(500fiM). Chemiluminescence was measured immediately at 37°C in a Wallac 1420 Multi-label 
counter without any filter and was recorded as arbitrary units. The assay was also carried out in the 
presence o f 300U/ml o f  the superoxide scavenging enzyme superoxide dismutase (SOD). Data shown 
are expressed as mean ± SE o f n = 4 separate experiments carried out in triplicate, *** p < 0.001 
compared to chemiluminescence in the absence o f  SOD.
123
100 n
3 80 •CO
8  60
o
0
S 40c
§ 20
+300U/mlSOD
Unactivated
------ 1---------1---------1---------1
0 3 6 9 12
Time minutes
100 n
0.1 U/ml Thrombin 
+ 300U/mlSOD
3 6 9
Time minutes
B
100
3  80 -I 
ro,
u  60 ■cID
in 40 c ™ c
I  20
’ 38pg/ml Collagen 
■ +300U/mlSOD
3 6 9
Time minutes
12
100 -i
3 80*1 (D ©
8  60-1oo
40
20
■ 50ng/ml Convutxin
■ + 300U/ml SOD
- 1
I -------- 1-------- 1-------- 1
3 6 9 12
Time minutes
Figure 4.2 No increase in extracellular ROS is detected in activated platelets. Gel-filtered 
platelets were either (A) left unactivated or were activated with (B) 38^g/ml collagen, (C) 0.1U/ml 
thrombin or (D) 50ng/ml convulxin, in the presence o f the ROS detection reagent L-012 (500|iM) for 
12 minutes at 37°C in a 96-well plate Wallac Multi-label counter. The assay was also carried out with 
the same conditions in the presence o f  300U/ml superoxide dismutase (SOD). Extracellular ROS 
generation was recorded every 30 seconds and is expressed as arbitrary chemiluminescence units 
(a.u.). Data shown are expressed as mean ± SE o f n = 4 separate experiments each carried out in 
triplicate.
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Figure 4.3 PM A induces large extracellular ROS generation in gel-filtered platelets. In a 96-well 
plate assay, platelets were activated with phorbol 12-myristate 13-acetate (PMA) (lO^M) in the 
presence o f  L-012 (500|iM) at 37°C for 12 minutes in the presence or absence o f  superoxide 
dismutase (SOD) (300U/ml). Extracellular ROS generation was recorded every 30 seconds in a 
Wallac Multi-label counter and is expressed as arbitrary luminescence units (a.u.). Data shown are 
expressed as mean ± SE o f  n = 4 separate experiments each carried out in triplicate.
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Figure 4.4 No external ROS are generated by gel-filtered platelets activated by collagen, 
thrombin or convulxin. Gel-filtered platelets were activated with the agonists indicated for 12 
minutes in the presence o f  L-012 chemiluminescence detection probe (500pM) in a 96-well plate. 
Extracellular ROS generation was recorded every 30 seconds in a Wallac Multi-label counter and 
expressed as arbitrary luminescence units. Histograms show area under curve (AUC) calculated over 
the 12 minute period for each agonist. Data shown are expressed as mean ± SE o f  n = 4 independent 
experiments carried out in triplicate, ** p < 0.01 compared to unactivated platelets.
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Figure 4.5 Catalase scavenges hydrogen peroxide. Varying concentrations (0-lmM ) o f hydrogen 
peroxide (H20 2) were added to luminol (50|xM) and horseradish peroxidase (HRP) (lOU/ml) in a cell- 
free assay and chemilummescence expressed as arbitrary units (a.u.) was measured immediately at 
37°C using a Wallac 1420 Multi-label Counter. In some assays the H2C>2 scavenging enzyme catalase 
(CAT, lOOOU/ml) was added to those wells containing the highest concentration o f hydrogen 
peroxide (lmM ). Data shown are expressed as mean ± SE o f  n = 4 separate experiments carried out in 
triplicate, *** p < 0.001 compared to H2C>2 chemiluminescence in the absence o f  catalase.
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Figure 4.6 ROS scavengers have no effect on agonist-induced platelet aggregations. Gel-filtered 
platelets were activated with (A) collagen (38jig/ml), (B) convulxin (50ng/ml) or (C) thrombin 
(0.1U/ml), with and without the ROS scavengers superoxide dismutase (SOD, 300U/ml), catalase 
(CAT, 1000U/ml) and mannitol (Man, 3mM). Aggregations were followed for at least 8 minutes at 
37°C with constant stirring at llOOrpm. The tracings show platelet aggregation responses from a 
single representative experiment. (D) Graph showing the data as mean ± SE o f  n = 3 separate 
experiments.
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Figure 4.7 Effects of antioxidants on platelet aggregation responses in gel-filtered platelets. Gel- 
filtered platelets were activated with (A) collagen (38|ag/ml), (B) convulxin (50ng/ml) or (C) 
thrombin (O.lU/ml) alone, or were activated following 5 minutes incubation at 37°C with the 
antioxidants N-acetyl-cysteine (NAC), a-tocopherol or ascorbic acid. All antioxidants were used at 
50pM final concentration. Aggregations were followed for 10 minutes with continuous stirring at 
1100 rpm. The tracings show platelet aggregation responses from a single representative experiment. 
(D) Graph showing the data as mean ±  SE o f  n = 4 separate experiments, *** p < 0.001 compared to 
aggregation response to agonist alone.
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Figure 4.8 Effects of oxidising and reducing agents on platelet aggregation. Gel-filtered platelets 
were activated with collagen (38pg/ml), thrombin (O.lU/ml) or convulxin (50ng/ml) (agonist alone) 
and platelet aggregations were followed for 10 minutes at 37°C with constant stirring at 1100 rpm. 
(A) Unactivated platelets were treated with oxidised glutathione (GSSG, 45pM), oxidised cysteine 
(CySS, 45(xM), or the thiol-blocking agent DTNB ((5 -5 ’-Dithio-Z»/s (2-nitrobenzoic acid), 45|aM) for 
5 minutes at 37°C. Agonists were added to the platelets and aggregations were followed for 10 
minutes at 37°C with stirring at llOOrpm. (B) Unactivated platelets were treated with reduced 
glutathione (GSH, 45^M) or the disulphide bond reducing agents dithiotreitol (DTT, 45^M) or tris (2- 
carboxyethyl) phosphine (TCEP, 45pM) for 5 minutes at 37°C. Agonists were added to the platelets 
and aggregations were followed for 10 minutes at 37°C with stirring at llOOrpm. Data shown are 
expressed as mean ± SE o f  n = 4 separate experiments, *** p < 0.001 compared to platelets activated 
with agonist alone.
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Figure 4.9 Effect of varying DTT concentration on agonist-induced platelet aggregation. (A)
Gel-filtered platelets were incubated with varying concentrations o f  DTT (0 — ImM) for 5 minutes at 
37°C before activation with (A) collagen (38|ag/ml), (B) thrombin (O.lU/ml), (C) convulxin (50ng/ml) 
or (D) left unactivated, where a = 0|xM DTT, b = 0.1 (iM DTT, c = ljiM  DTT, d = lOpM DTT, e = 
50^M DTT, f  =  lOOuM DTT and g = ImM DTT. Aggregations were allowed to proceed for 10 
minutes at 37°C under constant stirring at 1 lOOrpm. Shown are representative tracings o f one o f  n = 4 
separate experiments.
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Figure 4.10 Collagen activated gel-filtered platelets are more sensitive to disulphide bond 
reduction than those activated with convulxin or thrombin. Gel-filtered platelets were activated 
with collagen (38|ig/ml), convulxin (50ng/ml) or with thrombin (O.lU/ml) or were left unactivated, in 
the presence o f  a range o f  concentrations (0 -  ImM) o f  the disulphide bond reducing agent 
dithiothreitol (DTT). Aggregations were followed for 10 minutes at 37°C with constant stirring at 
1100 rpm. Data shown are expressed as the mean ± SE o f  n = 4 separate experiments.
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Figure 4.11 GSH/GSSG and Cys/CySS redox potentials have no effect on the functionality of 
soluble type I collagen. Gel-filtered platelets were activated with soluble type I collagen (38|xg/ml) 
and platelet aggregations were followed for 10 minutes at 37°C with constant stirring at 1100 rpm. 
Aliquots o f  the same collagen stock solution (1.9mg/ml) were incubated with the following redox 
potentials (A) GSH/GSSG Eh = -264 mV; (B) GSH/GSSG Eh= -10 mV (C) Cys/CySS Eh = -148 mV 
or (D) Cys/CySS Eh = +4 mV for 10 minutes at 37°C (Redox 1). This collagen was then used to 
activate gel-filtered platelets in a platelet aggregation assay at the same concentration (38|ig/ml) and 
the aggregations were followed as above. Gel-filtered platelets were incubated at 37°C for 10 minutes 
with the same GSH/GSSG and Cys/CySS redox potentials (Redox 2). Soluble type I collagen 
(38^g/ml) that had no prior exposure to redox was then used to activate these platelets. Data shown 
are expressed as mean ± SE o f  n = 3 separate experiments, *** p < 0.001 compared to platelets 
activated by collagen in the absence o f redox.
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Figure 4.12 Chelation o f divalent cations inhibits thrombin induced platelet aggregation. Gel- 
filtered platelets were either left untreated or were incubated with EDTA (50^M or 2mM) for 5 
minutes at 37°C before activation with thrombin (O.lU/ml) in a platelet aggregation assay. 
Aggregations were followed for 10 minutes at 37°C with constant stirring at llOOrpm. (A) A  
representative platelet aggregation tracing from a single experiment. (B) Graph showing data 
expressed as mean ± SE o f  n = 5 separate experiments, *** p < 0.001 compared to thrombin-induced 
platelet aggregation in the absence o f  EDTA.
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Figure 4.13 Chelation of divalent cations inhibits collagen induced platelet aggregation. Gel- 
filtered platelets were either left untreated or were incubated with EDTA (50|iM or 2mM) for 5 
minutes at 37°C before activation with collagen (38|ig/ml) in a platelet aggregation assay. 
Aggregations were followed for 10 minutes at 37°C with constant stirring at llOOrpm. (A) A 
representative platelet aggregation tracing from a single experiment. (B) Graph showing data 
expressed as mean ± SE o f n = 6 separate experiments, *** p < 0.001 compared to collagen-induced 
platelet aggregation in the absence o f EDTA.
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Figure 4.14 Reducing GSH/GSSH or Cys/CySS redox potentials do not chelate M g2+ cations. 
Gel-filtered platelets were either left untreated or were incubated with MgCl2 (2mM) for 3 minutes at 
37°C before being activated with collagen (38fxg/ml). Platelet aggregations were followed for up to 12 
minutes at 37°C with constant stirring at 1100 rpm. In addition, platelets were also incubated for 3 
minutes at 37°C with A: reducing GSH/GSSG (Eh = -264mV) where: 1 = unactivated + MgCl2 
(2mM), 2 = collagen + Eh -264mV, 3 = collagen + Eh -264mV + MgCl2, 4 =  collagen alone, 5 = 
collagen + MgCl2 (2mM), or B: reducing Cys/CySS (Eh = -148mV) redox potentials where: 1 = 
unactivated + MgCl2 (2mM), 2 = collagen + Eh -148mV, 3 = collagen + Eh -148mV + MgCl2, 4 =  
collagen alone, 5 = collagen + MgCl2 (2mM). Platelet aggregations were followed for up to 12 
minutes at 37°C under stirring at 1100 rpm. Shown are representative tracings o f one o f  n = 6 
separate experiments. C: Bar-graphs showing data expressed as mean ± SE o f  n = 6 separate 
experiments. *** p < 0.001 compared to collagen induced platelet aggregation in the absence o f redox 
or MgCl2 treatment.
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Figure 4.15 Reducing GSH/GSSG or Cys/CySS redox potentials do not chelate Ca2+ ions. Gel- 
filtered platelets were either left untreated or were incubated with excess CaCl2 (2mM) before being 
activated with collagen (38fig/ml) and platelet aggregations were followed for up to 12 minutes at 
37°C with constant stirring at 1100 rpm. In addition, platelets were also incubated for 3 minutes at 
37°C with A: GSH/GSSG (Eh = -264mV) where: 1 = unactivated + CaCl2 (2mM), 2 = collagen + Eh - 
264mV, 3 = collagen + Eh -264mV + CaCl2, 4 = collagen alone, or B: Cys/CySS (Eh = -148mV) 
redox potentials where: 1 = unactivated + CaCl2 (2mM), 2 = collagen + Eh -148mV, 3 = collagen + Eh 
-148mV + CaCl2, 4 = collagen alone, 5 = collagen + CaCl2 (2mM). Platelet aggregations were 
followed for up to 12 minutes at 37°C under stirring at 1100 rpm. Shown are representative tracings o f 
one o f  6 separate experiments. C: Bar-graphs showing data expressed as mean ± SE o f n = 6 separate 
experiments. *** p < 0.001, * p < 0.05, compared to collagen induced platelet aggregation in the 
absence o f  redox or CaCl2 treatment.
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Figure 4.16 Binding o f FITC-collagen to platelets labelled with anti-anbPa antibody CD41a. (A)
Gel-filtered platelets were incubated with the FITC-labelled monoclonal anti-anbp3 antibody CD41a 
(a IIb-subunit specific) in a 1: 5 dilution for 20 minutes at room temperature. Following addition o f 
lm l o f  platelet buffer, the samples were analysed immediately on a FACS-Calibur flow cytometer. 
The CD4la-labelled platelet population was identified and gated (R l) as shown. All subsequent 
FACS analyses for the collagen-binding assay were performed using platelets within this gated 
region. (B) Histogram showing platelet population positively labelled with CD41a. (C) Histograms 
showing the same Rl gated platelet population labelled with FITC-collagen (lOjig/ml and lOOjig/ml). 
Data are from a single experiment repre ;ntative o f one o f  n = 4 separate experiments.
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Figure 4.17 Reducing redox potentials decrease FITC-collagen binding to gel-filtered platelets.
Platelet were either left untreated or were incubated with GSH/GSSG Eh = -264mV or Cys/CySS Eh = 
-148mV or EDTA (3mM) for 5 minutes before the addition o f FITC-collagen (lO^g/ml or 100(ig/ml 
as indicated) for 30 minutes at room temperature. Collagen binding was expressed as mean 
fluorescence, by comparing the level o f  collagen binding at a collagen concentration o f 100ng/ml 
with that at 10jig/ml. Samples were analysed on a FACS-Calibur flow cytometer and data was 
expressed as mean fluorescence. ** p < 0.01 compared to collagen binding at collagen 10|ig/ml, # p < 
0.05 and ## p < 0.01 compared to collagen binding at collagen 100ng/ml. Data shown are expressed 
as mean ± SE o f  n = 4 separate experiments.
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Figure 4.18 Binding of the integrin o^Pi-specific antibody P1E6 to gel-filtered platelets is not 
altered in the presence o f Cys/CySS redox potentials.
Gel-filtered platelets were left untreated or were incubated with Cys/CySS redox potentials (Eh = - 
148mV, -82mV or +4mV) for 5 minutes at room temperature, and then for a further 10 minutes in the 
presence o f 5|xg/m1 o f the integrin a 2-subunit specific antibody PE-labelled P1E6 or its isotype 
control (IgGi). (A) Density plot o f  resting platelet population labelled with IgGi in the absence of  
redox with gating on region R l. (B) Histogram showing P1E6 labelling o f  platelets with no redox 
(blue line) and after treatment with Eh = -148mV (red line). (C) P1E6 labelling with no redox (blue) 
and after treatment with Eh = -82mV (red). (D) P1E6 labelling with no redox (blue line) and after 
treatment with Eh = +4mV (red line). Black histograms show gated region (Ri) o f IgGi labelled 
population in the absence o f  redox treatment. Data shown are representative o f one o f n = 4 separate 
experiments.
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Figure 4.19 Binding of the integrin o^Pi-specific antibody 12F1 to gel-filtered platelets is not 
altered in the presence of Cys/CySS redox potentials.
Gel-filtered platelets were left untreated or were incubated with Cys/CySS redox potentials (Eh = - 
148mV, -82mV or +4mV) for 5 minutes at room temperature and then for a further 10 minutes in the 
presence o f  5^g/ml o f the integrin a 2-subunit specific antibody PE-labelled 12F1 or its isotype control 
(IgG2). (A) Density plot o f  resting platelet population labelled with IgG2 in the absence o f  redox. (B) 
Histogram showing 12F1 labelling o f platelets with no redox (blue line) and after treatment with Eh = 
-148mV (red line). (C) 12F1 labelling with no redox (blue) and after treatment with Eh = -82mV (red). 
(D) 12F1 labelling with no redox (blue line) and after treatment with Eh = +4mV (red line). Black 
histograms show gated region (R2) o f IgG2 labelled control population in the absence o f  redox 
treatment. Data shown are representative o f  one o f  n = 4 separate experiments.
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Figure 4.20 Binding of the (X2|3rspecific antibodies P1E6 or 12F1 to gel-filtered platelets is not 
altered in the presence o f Cys/CySS redox potentials. (A) Gel-filtered platelets were left untreated
(no redox) or were incubated with the Cys/CySS redox potentials (Eh = -148mV, -82mV or +4mV) 
for 5 minutes at room temperature, and then for a further 10 minutes in the presence o f 5|ig/ml o f  the 
integrin a 2-subunit specific antibody PE-labelled P1E6 or its isotype control (IgGO and were analysed 
by flow cytometry. (B) Platelets were treated with the same Cys/CySS redox conditions as above for 
5 minutes and then for a further 10 minutes in the presence o f  5^g/ml o f  the integrin <X2-subunit 
specific antibody PE-labelled 12F1 or its isotype control (IgG2). Data are expressed as percentage o f 
gated IgG-labelled population and as mean ± SE o f n =  4 separate experiments. *** p < 0.001 
compared to binding o f  IgG control antibody to platelets.
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The luminol derivative L-012 is used specifically to detect extracellular ROS (Daiber 
et al. 2004). The ROS levels I detected from unactivated or agonist activated 
platelets were comparable to background even when measured over a twelve minute 
time period, and only PM A (IOjiM) stimulation resulted in an appreciable ROS 
generation from platelets. I could find no evidence o f ROS generation in the 
extracellular environment o f platelets activated by collagen, convulxin or thrombin 
at the concentrations used. This is in close agreement with the study o f Bakdash and 
Williams who could detect no extracellular ROS generation in response to convulxin 
activation (50ng/ml or 250ng/ml) (Bakdash & Williams 2008).
The L-012 assay used also detected ROS generation by the xanthine/xanthine 
oxidase system in cell-free control experiments, and showed the effectiveness o f the 
ROS scavenging cell-impermeable enzyme SOD in quenching ROS ^  The quenching 
o f hydrogen peroxide by catalase was also demonstrated in control experiments. The 
lack o f any effect o f the ROS scavengers SOD, catalase or mannitol on the platelet 
aggregation response to collagen, thrombin or convulxin in conjunction with the 
absence o f L-012 ROS detection from these activated platelets, suggests that external 
ROS is not playing a role in agonist induced platelet aggregation under these 
conditions. These results differ from those o f Pignatelli (Pignatelli et al. 1998) who 
showed that catalase inhibited collagen but not thrombin or ADP induced platelet 
aggregation, and that catalase also inhibited intraplatelet ROS generation in response 
to collagen activation. This second result is surprising as catalase itself is cell 
impermeable, and can only exert its hydrogen peroxide scavenging effects 
extracellularly (Jin et al. 2001).
4.3 Discussion
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Similarly, when ascorbic acid or a-tocopherol were added to platelets neither of 
these antioxidants had any effect on agonist-induced platelet aggregation. However, 
the antioxidant N-acetyl cysteine (NAC) did inhibit collagen-induced aggregation in 
an identical manner to reducing GSH/GSSG and Cys/CySS redox potentials. 
Subsequent work carried out in our laboratory has shown that NAC may be 
substituted for Cys in the Cys/CySS redox couple and affects platelet function in 
exactly the same manner as Cys/CySS (personal communication from Therese 
Boland, RCSI). These results suggest that reducing redox potentials are affecting the 
collagen-platelet interaction by a mechanism other than simply scavenging external 
ROS.
As metal chelators, both GSH and Cys and the cysteine derivative NAC are known
to bind metal ions to counteract their potentially toxic effects (Flora & Pachauri
2010). The roles o f the divalent cations calcium and magnesium in platelet activation
are well known particularly during integrin activation and ligand binding. Integrin a-
subunits contain up to five divalent cation binding sites, four o f which lie in the P-
propeller o f the N-terminal extracellular region (Xiong et al. 2003). Integrin 0 4 ^ 3
has a Ca2+ binding site at the “genu” between the calf-1 and thigh regions while the
Mg2+ binding site in the al-dom ain is essential for collagen binding to (X2P1 (Emsley
et al. 1997). Integrin P-subunits also contain up to three metal binding sites in the
ligand-associated metal binding site (LIMBS), metal-ion dependent adhesion site
(MIDAS) and the adjacent to MIDAS (AD MID AS) regions o f the pl-domain
(Shimaoka & Springer 2003). Collagen binds exclusively to the al-dom ain o f (X2P1
but ligand binding is depend'* at on the interaction between the al-dom ain and pi-
domain o f the a -  and P-subunits. Recently it has been reported that cation binding to
MIDAS and LIMBS appear to be essential for this interaction between a l  and pi-
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domains, whereas occupancy o f the ADMIDAS has an allosteric effect on the 
conformation o f pi (Valdramidou et al. 2008). Any reagent capable o f decreasing 
divalent cation binding to any o f these sites within the integrins would impair 
integrin activation, ligand binding and ultimately platelet aggregation. Being thiol 
containing metal chelators, the inhibitory effects o f reducing GSH/GSSG and 
Cys/CySS redox potentials on platelet aggregation following collagen-activation 
may be attributable to this divalent cation chelating mechanism.
Our HEPES platelet buffer contains 0.9mM M gC^ and is calcium free, and platelets
• * • • 24"are supplemented with 1.8mM CaCl2 prior to activation. The necessity for both Mg 
and Ca2+ cations for agonist stimulated platelet aggregation was seen in control 
experiments using EDTA, the calcium and magnesium chelating agent (Flora & 
Pachauri 2010). EDTA (2mM) abolished both collagen and thrombin induced 
platelet aggregation. Lower micromolar concentrations o f EDTA (50jjM) 
comparable to the concentrations o f  redox used in these assays had no effect on 
platelet aggregation response to either o f  these agonists. EDTA chelates divalent 
metal cations in molar ratio o f 1: 1 while GSH chelates metals in a 1: 1 or 2: 1 ratio 
(Delalande et al. 2010, Freedman et al. 1989, Polec-Pawlak et al. 2007). M y data 
also showed that addition o f excess calcium or magnesium ions to platelets 
following treatment with GSH/GSSG or Cys/CySS reducing redox potentials did not 
overcome the inhibitory effects o f reducing redox potentials on collagen induced 
platelet aggregation. This implies that availability o f calcium or magnesium ions is 
not the limiting factor in the redox dependent inhibition o f collagen-induced platelet 
aggregation. This indicates that it is unlikely that divalent cation chelation by either 
the GSH/GSSG or Cys/CySS redox couple is responsible for the inhibitory effects
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on platelet function seen at reducing redox potentials as there is simply not enough 
redox reagent available to chelate all o f the divalent cations present.
Collagen-induced platelet activation results in a large increase in intracellular 
calcium levels that are associated with platelet shape change, granule secretion and 
aggregation (Ardlie et al. 1986). Measurements o f intracellular calcium levels 
following collagen activation show that some 30% o f this calcium is derived from 
intracellular stores such as the dense tubular system, and the remaining 70% enters 
the platelet from the extracellular environment. The mechanism o f collagen-induced 
calcium influx into the platelet has been identified as the membrane bound 
sodium/calcium exchanger (NCX) operating in a reverse mode (Roberts & Bose 
2002, Roberts et al. 2004). The presence o f external calcium is necessary for the 
operation o f the NCX (Juska 2011) and it is possible that the rate o f calcium influx 
into the platelet may be dependent on the extracellular calcium concentration. The 
significant increase in collagen-induced platelet aggregation response to elevated 
calcium levels noted in my assays remains as o f yet unexplained, but may in part 
result from the presence o f the large extracellular calcium concentration gradient 
created by addition o f an extra 2mM CaCl2 to the platelet environment.
A mechanism other than divalent cation chelation may therefore be responsible for 
the inhibition o f collagen-induced aggregation in the presence o f reducing redox 
potentials.
The functionality o f the soluble type I collagen used in these studies was shown to be 
unaffected by pre-treatment o f the collagen with either reducing or oxidising 
GSH/GSSG or Cys/CySS redox potentials. The ability o f collagen to bind to its 
receptors is critically dependent on the triple-helical conformation o f the collagen
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(Famdale 2006). Type I collagen has the triple helical structure a l( I )2a 2 (I) 
comprising an uninterrupted helix of approximately 300nm in length and 1.5nm in 
diameter (Kadler et al. 1996). These helices form spontaneously under physiological 
conditions but can also in turn undergo polymerisation to form collagen micro-fibrils 
which m ay further undergo cross linking to form collagen fibres (Shoulders & 
Raines 2009, Wen & Goh 2006). Extracellular factors affecting collagen fibre 
formation include pH and temperature, with optimal conditions at pH 7 - 9  and 
temperatures ranging from 20 -  37°C (Williams et al. 1978), the conditions under 
which all o f the assays in this study were carried out. I found no adverse effect o f 
pre-treatment o f type I collagen with either reducing or oxidising GSH/GSSG or 
Cys/CySS redox potentials in platelet aggregation studies.
The binding o f type I collagen-FITC to platelets has been shown to be a,2pi mediated 
and divalent cation dependent (Wang et al. 2003). Using a similar protocol to this 
one I studied the extent o f  collagen-FITC binding to gel-filtered platelets under 
varying redox conditions. M y data showed a decrease in collagen binding to gel- 
filtered platelets in the presence o f reducing GSH/GSSG or Cys/CySS redox 
potentials on collagen-FITC binding to platelets. This reduction in binding was 
statistically significant following treatment with the reducing Cys/CySS redox 
potential. In agreement with the findings o f Wang et al I demonstrated divalent 
cation dependent collagen binding to platelets with significantly decreased collagen- 
FITC binding in the presence o f EDTA. This divalent cation dependence, 
particularly Mg2+, is typical o f integrin ot2pi dependent collagen binding (Emsley et 
al. 1997).
I then used the CX2P1 specific antibodies P1E6 (Keely & Parise 1996) and 12F1
(Pischel et al. 1988) both o f which have binding epitopes between residues 173 and
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259 in the a,2-I domain, with the collagen binding region spanning residues 140 to 
349 (Kamata et al. 1994), to assess antibody binding in the presence of varying 
redox potentials. No change in binding o f either antibody to (X2P1 was seen in the 
presence o f varying GSH/GSSG or Cys/CySS redox potentials. These data suggest 
that in a redox environment that inhibits collagen-induced platelet activation and that 
decreases collagen binding to the integrin, antibodies specific for the collagen 
binding site on the integrin ct2-I domain are capable o f binding to (X2P1. This is 
suggestive o f a conformational change within the collagen binding region that is 
sufficient to impair collagen binding but is not capable o f preventing access to their 
binding epitopes o f the much smaller anti-012-I antibodies.
The data preclude extracellular ROS scavenging, divalent cation chelation, or 
impaired collagen functionality as possible mechanisms o f the redox control o f 
collagen-induced platelet activation. The redox mediated decrease in collagen 
binding to 012P1 however points to a possible explanation for the decreased activation 
status o f  gel-filtered platelets in response to collagen stimulation. The effects of 
disulphide bond reducing agents on platelet activation and on ligand binding to 
integrins are well established (Peerschke 1995, Yan & Smith 2001). Given that both 
GSH and Cys are also disulphide bond reducing agents their effects on collagen- 
induced platelet function may be attributable to a disulphide bond mediated 
conformational change in the ligand binding site o f integrin (X2P1.
W hen I treated gel-filtered platelets with three common antioxidants, ascorbic acid, 
a-tocopherol and NAC, there was no effect on platelet aggregation except in the case 
o f NAC. Here, as outlined above, there was complete inhibition o f collagen-induced 
platelet aggregation only. Aggregation responses to either thrombin or convulxin
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were unaffected. Extending this study further to include two known disulphide bond 
reducing agents, I found that low micromolar concentrations o f both DTT and TCEP 
also inhibited collagen-induced aggregation to the same degree as NAC and reducing 
GSH/GSSG or Cys/CySS redox potentials. A concentration-response study with 
DTT showed the collagen activation pathway to be highly sensitive to disulphide 
bond reduction.
GSH, Cys and NAC are all physiological disulphide bond reducing agents, capable 
o f reducing a protein intermolecular or intramolecular disulphide bond (PS - SP) 
where P = protein and S = sulphide group. This is achieved by forming a disulphide 
bond between one o f the sulphur atoms and itself (RS -  SP) where R = the redox 
species glutathione, cysteine or NAC, in the process o f S-glutathionylation or S- 
cysteinylation, while donating a hydrogen ion and an electron to reduce the second 
sulphur to a protein-thiol (P-SH) group (Dalle-Donne et al. 2007, Pischel et al. 
1988). The disulphide bond reducing capabilities o f NAC have been used for almost 
50 years as part o f the treatment o f diseases such as chronic bronchitis and cystic 
fibrosis by reducing disulphide bonds in airway blocking mucin polymers, helping 
their clearance from the lungs (Kelly 1998). Recently, NAC has successfully been 
used as a disulphide bond reductant o f von Willebrand (VWF) multimers in the 
treatment o f thrombotic thrombocytopenic purpura (TTP), also resulting in a 
concentration dependent inhibition o f collagen-induced platelet aggregation and 
concentration dependent reduction in VWF binding to collagen (Chen et al. 2011).
M y study and other work from our laboratory has demonstrated the great sensitivity 
o f  the platelet collagen activation pathway to disulphide bond reducing agents, and 
the capacity o f NAC to interchange for Cys in the Cys/CySS redox couple. I believe 
that my data strongly suggests that disulphide bond reduction by reducing redox
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potentials is involved in the inhibition o f collagen-induced platelet activation. The 
role o f  disulphide bonds and thiol groups in the activation and signal transduction 
process in the fibrinogen receptor integrin anbP3 is well documented (Lahav et al. 
2002, O'Neill et al. 2000, Yan et al. 2000, Yan & Smith 2000, 2001). The collagen 
receptor 0,2Pi like all integrins is believed to undergo ligand induced activation and 
signal transduction in a similar manner to the other integrin receptors (Emsley et al. 
2000) and this too must involve thiol/disulphide exchange within the receptor.
The data presented so far in this study suggest that the disulphide bond reducing 
capacity o f  reducing GSH/GSSG and Cys/CySS redox potentials underlie the 
collagen-specific inhibition o f platelet function. The remainder o f this study is 
concerned with verifying this (X2P1 integrin specific targeting by redox and 
establishing a mechanism whereby reducing redox potentials may interact with 
integrin (X2P1 thus affecting thiol groups/disulphide bonds hence disrupting both 
collagen binding and collagen-induced platelet activation.
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Chapter 5 
Investigation of Redox Mediated 
5'-Glutathionylation of the Platelet 
Integrin a 2Pi
In the previous chapter I demonstrated a reduction in the binding o f collagen-FITC 
to gel-filtered platelets in the presence o f a reducing glutathione or cysteine redox 
environment. The data presented thus far indicates that the altered responses 
observed in platelet reactivity in these changing redox environments point to a direct 
modification o f (X2P1. It was necessary therefore, to explore if  the collagen 
interaction with (X2P1 was being directly modified by the various redox potentials. 
The approach taken, explored the effects o f  these redox potentials on the interaction 
o f platelets with triple helical peptides that contain the collagen binding motifs 
specific for each o f the collagen receptors GPVI and CX2P1. Two triple helical 
peptides have structures based on the binding regions within type I collagen triple 
helix that have high binding affinities for 012P1 and for GPVI. These are 
GPC(GPP)5GFOGER(GPP)5GPC, known simply as GFOGER, and 
(GCO(GPO)ioGCOG)n, known as collagen related peptide (CRP-XL), where n is a 
large integer number o f  peptides cross-linked and where O is hydroxyproline 
(Asselin et al. 1999, Knight et al. 2000). GFOGER binds specifically to the a,2-I 
domain o f the integrin (X2P1 (Knight et a l  2000) and CRP is specific for the N- 
terminal D1 domain o f GPVI (Horii et al. 2006). O f note, collagen and (X2P1 specific 
triple helical peptides bind specifically to (X2P1 on the surface o f resting platelets 
(Morton et al. 1989). These triple helical peptides are routinely used to distinguish 
between (X2P1 and GPVI mediated effects, particularly in platelet adhesion assays 
(Famdale et al. 2008). These particular studies were performed in collaboration with 
Prof. Richard Famdale, Cambridge, U.K.
5.1 Introduction
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The nature o f the redox sensitivity o f the collagen-platelet interaction was shown in 
chapter four to be related to the disulphide bond reducing capacity of reducing 
GSH/GSSG or Cys/CySS redox potentials. This supports previous work 
demonstrating the role for thiol/disulphide exchange during the ligand-induced 
activation o f 012P1 (Lahav et al. 2003). Highly reactive cysteines often have a 
decreased pKa, facilitating dissociation to the thiolate anion (S’). This anion is the 
reactive species in thiol-disulphide exchange reactions (Hondorp & Matthews 2009). 
Reactive cysteines can be identified based on their proximity to the basic amino 
acids histidine (H), arginine (R) or lysine (K). This is based on the previous 
identification o f reactive cysteines in other redox sensitive proteins including Fos 
and Jun DNA binding proteins, protein tyrosine phosphatases, bovine papillomavirus 
E2 protein, bacterial dipetidyl peptidase III and Keapl protein (Abate et al. 1990, 
Denu & Dixon 1998, McBride et al. 1992, Vukelic et al. 2012, Wakabayashi et al. 
2004).
Redox modification o f reactive cysteines within integrin (X2P1 by reducing redox 
potentials could result in the formation o f a reversible covalent disulphide bond 
between the protein and either glutathione or cysteine in processes known as S- 
glutathionylation (Dalle-Donne et al. 2007) or S-cysteinylation (Hochgrafe et al. 
2007) respectively. However, little is known about the precise mechanisms and 
controls o f these cysteinyl modifications (Go & Jones 2011).
Both S-glutathionylation and S-cysteinylation are known to be reversible post- 
translational modifications o f protein thiol groups that occur frequently in response 
to conditions o f oxidative stress. Here, their function is to protec' critical protein 
cysteine residues from irreversible oxidative damage. Generation o f highly oxidising 
free radicals including superoxide, the hydroxyl radical and the non-radical species
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hydrogen peroxide readily target protein thiols. Such oxidative damage may be 
reversible as in the formation of cysteine sulphenic or sulphinic acids, or irreversible 
as with the formation o f cysteine sulphonic acid (Ghezzi 2005a). Cysteine sulphenic 
acid (Cys-OH) may be recycled back to the original thiol (Cys-SH) via disulphide 
bonded intermediates by cellular reductants such as thioredoxin, glutaredoxin, 
cysteine or glutathione itself (Poole et al. 2004). Resultant S-glutathionylation or S- 
cysteinylation o f cysteine thiols can modulate protein function by inhibiting or 
enhancing protein function such as the reversible inactivation o f the enzyme a- 
ketoglutarate dehydrogenase by H2O2 induced S'-glutathionylation in response to 
mitochondrial GSH redox status (Nulton-Persson et al. 2003). A large number of 
cellular proteins have been identified as targets for S-glutathionylation including 
endothelial nitric oxide synthase (eNOS) (Chen et al. 2010), the platelet and 
fibroblast cytoskeletal protein actin (Dalle-Donne et al. 2003, Pastore et al. 2003), 
haemoglobin (Bursell & King 2000) and the mitochondrial enzyme NADH 
oxidoreductase (Taylor et al. 2003). S-cysteinylated proteins include the bacterial 
proteins argininosuccinate synthase and cobalamin-independent methionine synthase 
(Hochgrafe et al. 2007), human signal transducer gpl30 (Moritz et al. 2001) and 
human L-xylulose reductase where S-cysteinylation o f Cysl38 resulted in a 10-fold 
decrease in catalytic efficiency (Zhao et al. 2009).
Additionally, some proteins contain reactive cysteines that can regulate protein 
function or activity by an allosteric mechanism (Jones 2008). These proteins include 
the NMD A receptor (Choi et al. 2001) and NADH oxidoreductase (Taylor et al.
2003). Modification o f  such cysteine residues by S-glutathionylation or S- 
cysteinylation provide a type o f regulation o f protein function known as a “rheostat” 
switch. This involves allosteric conformational changes leading to a range o f protein
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functional states as opposed to a simple “on-off’ state (Kemp et al. 2008). An 
example o f such an allosteric modification occurs in heat shock cognate protein 70 
(Hsp70) where S-glutathionylation o f Hsp70 increases the ability o f the protein to 
prevent protein aggregation in the absence o f ATP (Hoppe et al. 2004). The NH2- 
terminal domain o f Hsp70 binds ATP to drive conformational changes in the 
COOH-terminal peptide domain to alter the affinity for substrates (Bukau & 
Horwich 1998). This implies an allosteric regulation o f the protein function as a 
result o f S-glutathionylation (Hoppe et al. 2004). The redox modification of 
collagen-induced platelet activation described in the preceding chapters o f  this thesis 
could plausibly be attributed to a similar S-glutathionylation or 5-cysteinylation 
event occurring on the platelet surface and impacting directly on the collagen- 
platelet interaction resulting in modifications o f conformational changes in a 2Pi.
In this chapter my aims are threefold: firstly to determine if  the redox sensitive 
collagen-platelet interaction is acting specifically via the collagen- CX2P1 pathway, 
secondly to examine prospective platelet surface proteins for the presence o f reactive 
cysteine thiols, and finally to investigate the possible S-glutathionylation or S- 
cysteinylation o f these platelet proteins.
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5.2 Results
5.2.1 Platelet Adhesion to Collagen was Decreased in a Reducing 
Redox Environment
Adhesion o f gel-filtered platelets to type I acid-soluble collagen (lOjig/ml) was 
significantly decreased in the presence o f  the reducing GSH/GSSG Eh = -264mV (n 
= 4 -  6, p < 0.01). Treatment o f gel-filtered platelets with either the mean plasma 
GSH/GSSG Eh = -130mV or the oxidising Eh = -lOmV showed no significant change 
in platelet adhesion to collagen (Figure 5.1 A). Platelets pre-incubated with the 
function blocking, integrin a,2l-domain specific antibody 6F1 (20^g/ml) or with 
EDTA (2mM) showed levels o f adhesion comparable to those adhered to BSA (5% 
w/v) (Figure 5.1 A).
Similarly, pre-treatment o f gel-filtered platelets with Cys/CySS Eh = -148mV 
resulted in a significant reduction in platelet adhesion to collagen (10|ig/ml) (n = 4 -  
6 , p < 0.05). There was no significant effect on the level o f adhesion when gel- 
filtered platelets were treated with either the mean plasma Cys/CySS Eh = -82mV or 
the oxidising Eh = +4mV (Figure 5 .IB). 6F1 (20|ig/ml) and EDTA (2mM) also 
inhibited platelet adhesion to collagen in these experiments. Platelet adhesion to 
CRP (10(ig/ml) was not altered in the presence o f any o f the GSH/GSSG or 
Cys/CySS redox potentials (Figure 5.1C and D).
5.2.2 Platelet Adhesion to the a2Pi Specific Peptide GFOGER was 
Decreased in a Reducing Redox Environment
Adhesion o f washed platelets to the triple helical collagen peptide GFOGER which 
binds with high affinity and specificity to the a 2Pi integrin was measured in varying
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GSH/GSSG redox environments. Adhesion to GFOGER was significantly reduced 
when platelets were pre-treated with the reducing GSH/GSSG Eh = -264mV in the 
presence o f magnesium chloride (2mM) (n = 4, p < 0.001). Treatment with the mean 
plasma GSH/GSSG Eh = -130mV or the oxidising Eh = -lOmV had no effect on 
platelet adhesion to GFOGER (Figure 5.2A). Platelet adhesion to GFOGER was 
abolished in the presence o f 2mM EDTA (Figure 5.2A). There was no adhesion of 
untreated or redox-treated platelets to the non-binding triple helical peptide GPPio 
(10fig/ml) or to BSA (5% w/v) (Figures 5.2B and C respectively).
5.2.3 Platelet Adhesion to GFOGER and CRP using the Xcelligence
Assay
In order to compare the kinetics o f platelet adhesion to the a 2Pi and GPVI specific 
triple helical collagen peptides GFOGER and CRP, the Xcelligence assay was used. 
This assay measures both the rate and extent o f platelet adhesion to a given substrate 
over a prolonged time period. Platelet adhesion and spreading were recorded as the 
dimensionless quantity called cell index (Cl). Data are expressed graphically as the 
change in cell index over time. The rate o f spreading is measured as the time taken to 
reach half o f  the maximum cell index value (time to half C.I. max). The rate of 
spreading is inversely proportional to this time.
The graphs showing cell index against time are shown in Figure 5.3. Platelets treated 
with the most reducing redox potential (GSH/GSSG Eh = -264mV) showed the 
largest decrease in adhesion to GFOGER (10|ig/ml) (Figure 5.3A), and this decrease 
became less pronounced as the redox potentials became more oxidising (Figure 5.3B 
and C). Platelet adhesion to CRP was unaffected in the presence of any of the redox 
potentials (Figure 5.3D, E and F).
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The rate o f platelet adhesion to GFOGER was significantly greater than to CRP in 
the absence o f redox (Figure 5.4A) (n = 4, p < 0 .001). The rate of adhesion to 
GFOGER was significantly decreased following pre-treatment o f platelets with the 
reducing GSH/GSSG Eh = -264mV (n = 4, p < 0.01). There was no effect on the rate 
o f platelet adhesion to GFOGER in the presence o f either GSH/GSSG Eh = -130mV 
or Eh = -lOmV (Figure 5.4B). Furthermore, there was no effect on the rate of 
adhesion to CRP o f platelets pre-treated with any o f the redox potentials (Figure 
5.4C).
5.2.4 Analysis of Platelet Adhesion to Collagen and Triple Helical 
Peptides by Confocal Microscopy
Images o f adhered platelets to collagen and to triple helical peptides are shown in 
Figure 5.5 and the statistical analysis showing the extent o f this platelet adhesion is 
shown in Figure 5.6. Calculation of the area covered (j-irn2) by adhered platelets to 
each substrate was carried out by image analysis using Image J (version 1.4) 
software.
Adhesion o f washed platelets to acid soluble type I collagen (10|ig/ml) was 
decreased in the presence o f both o f the most reducing redox potentials: GSH/GSSG 
Eh = -264mV and Cys/CySS Eh = -148 mV respectively (Figure 5.5, panels IB and 
2B) when compared to platelet adhesion in the absence o f redox (Figure 5.5, panels 
1A and 2A). Similarly, platelet adhesion to GFOGER (lOjig/ml) was also decreased 
in the presence o f both GSH/GSSG Eh = -264mV and Cys/CySS Eh = -148 mV 
(Figure 5.5, panels 3B and 4B) when compared to platelet adhesion in the absence o f 
redox (Figure 5.5, panels 3A and 4A).
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Platelets treated with mean plasma GSH/GSSG Eh = -130mV or with mean plasma 
Cys/CySS Eh = -82mV showed levels o f adhesion to both collagen (1Ojxg/ml) (Figure 
5.5, panels 1C and 2C) and GFOGER (10p,g/ml) (Figure 5.5, 3C and 4C) that were 
comparable to that seen in the absence o f redox.
Platelets treated with the most oxidising GSH/GSSG Eh = -lOmV or Cys/CySS Eh = 
+4mV also showed levels o f platelet adhesion to collagen (10|xg/ml) (Figure 5.5, 
panels ID and 2D) or to GFOGER (10|xg/ml) (Figure 5.5, panels 3D and 4D) 
comparable to that seen in the absence o f redox.
There was no difference in platelet adhesion to CRP (10^g/ml) in the presence o f 
any of the GSH/GSSG or Cys/CySS redox potentials compared to adhesion levels to 
CRP seen in untreated platelets (Figure 5.5, panels 5 and 6).
Analysis o f the adherent platelet area using Image J (version 1.4) software showed 
that platelet adhesion to collagen (10j^g/ml) was significantly decreased in the 
presence of the reducing GSH/GSSG Eh = -264mV (n = 4, p < 0.05), and reducing 
Cys/CySS Eh = -148 mV (n = 4, p < 0.01) when compared to platelet adhesion to 
collagen in the absence o f redox (Figure 5.6A and D). There was no significant 
difference between platelet adhesion to collagen (10pg/ml) in the absence o f redox 
and adhesion o f platelets treated with mean plasma GSH/GSSG Eh = -130mV or 
mean plasma Cys/CySS Eh = -82mV, or with the oxidising redox potentials 
GSH/GSSG Eh = - lOmV or Cys/CySS Eh = +4mV (Figure 5.6 A and D).
Platelet adhesion to GFOGER (10|ag/ml) was also significantly decreased in the 
presence o f  the reducing GSH/GSSG Eh = -264mV (n = 4, p < 0.05) and the 
reducing Cys/CySS Eh = -148 mV (n = 4, p < 0.05) when compared to platelet 
adhesion to collagen in the absence o f redox (Figure 5.6B and E). Platelet adhesion
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to GFOGER in the presence o f mean plasma GSH/GSSG Eh = -130mV or Cys/CySS 
Eh = -82mV, or the oxidising redox potentials GSH/GSSG Eh = -lOmV or Cys/CySS 
Eh = +4mV was not significantly different from platelet adhesion to GFOGER in the 
absence o f redox (Figure 5.6B and E).
The area o f redox-treated platelets adherent to CRP (10(ig/ml) was the same as that 
seen in the absence o f redox (Figure 5.6C and F).
The area o f platelets adherent to BSA (5% w/v) was significantly less, (n = 4, p < 
0.001) than that to collagen (10|ig/ml), GFOGER (lOjig/ml) or to CRP (10|ig/ml) 
(Figure 5.6A-E). Platelets treated with anti-a2-I domain function blocking antibody 
6F1 (20jag/ml) showed a significant decrease in the area o f platelets adherent to 
collagen (10|ig/ml) (n = 4, p ^  0.05 and p < 0.01) and GFOGER (10ng/ml) (n = 4, p
< 0.01) but not to CRP (10^g/ml) (Figure 5.6A-E).
5.2.5 Measurement of Platelet Surface Thiol Groups
In parallel studies m y laboratory colleague Ms. Emily Reddy measured the number 
o f free thiol (-SH) groups on the platelet surface using the cell impermeable thiol 
detection reagent 5, 5'-dithiobis-(2-nitrobenzoic acid) (DTNB). This assay is known 
as Ellmans assay and is widely used to measure free thiol groups (Ellman 1959). A 
cysteine thiol standard curve was generated from which the number o f free thiols on 
the platelet surface was calculated. The standard curve is shown in Figure 5.7.
Activation o f gel-filtered platelets with collagen (38^g/ml) resulted in a significant 
increase in the number o f  free thiol groups on the surface o f the platelet (n = 6, p < 
0.001) (Figure 5.8) when compared to unactivated platelets. There was no change in 
the free thiol population following platelet activation with thrombin (O.lU/ml) or 
convulxin (50ng/ml) when compared to the free thiol population detected on the
160
surface o f unactivated platelets. The fold increase in the concentration (|iM) of free 
thiols expressed on the platelet surface was calculated by dividing the number o f free 
thiols on unactivated or agonist activated platelets ((J.M o f thiol) by the number of 
free thiols on the surface o f unactivated platelets. This calculation was carried out for 
platelets both in the presence and absence o f GSH/GSSG and Cys/CySS redox 
potentials.
When gel-filtered platelets were treated with either the reducing GSH/GSSG Eh = - 
264mV or the reducing Cys/CySS Eh = -148mY redox potentials the fold increase in 
free thiol number seen with collagen activation was significantly decreased for 
GSH/GSSG Eh = -264mV (n = 6 , p < 0.05) and for Cys/CySS Eh = -148mV (n = 6, p
< 0.01) (Figure 5.9A and B). j
There was a significant reduction in the fold increase o f  free thiols expressed on the 
platelet surface o f platelets treated with either o f  the mean plasma GSH/GSSG Eh = - 
130mY or mean plasma Cys/CySS Eh = -82mV redox potentials, following collagen 
activation when compared to the number o f free thiols expressed on the platelet 
surface o f collagen activated platelets in the absence o f redox (n = 6 , p < 0.05) 
(Figure 5.9A and B).
At the most oxidising redox potentials o f either redox couple, there was a slight 
reduction although not significant, between the fold increases in the number o f  free 
thiols expressed on the platelet surface following collagen activation when compared 
to collagen activated platelets in the absence o f redox (Figure 5.9A and B).
The fold increases in number o f free thiols on the platelet surface following collagen 
activation at the two most oxidising redox potentials: GSH/GSSG Eh = -lOmV and 
Cys/CySS Eh = +4mV were significantly greater than the fold increase in the number
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of free thiols expressed at the mean plasma redox potentials GSH/GSSG Eh = - 
130mV and Cys/CySS Eh = -82mV following collagen activation (n = 6, p < 0.01) 
(Figure 5.9A and B).
There was no effect o f redox on the number o f free thiols detected on the surface of 
convulxin or thrombin activated platelets.
5.2.6 Analysis of Potential Reactive Cysteine Residues in Integrin 0- 
subunits
The protein sequences o f integrin P-subunits (denoted Pi -  Ps) were obtained from 
the Uniprot Protein Database. Potential reactive cysteine residues were identified on 
the basis o f the proximity o f neighbouring basic amino acids histidine (H), lysine (K)
I
and arginine (R) (Vukelic et ah 2012, Wakabayashi et ah 2004). The presence o f 
either one or two basic residues on either side o f  each cysteine residue, denoted as - 
XC- or -XXC-, where X = H, K or R was examined. Additionally the sequences 
were analysed for the presence o f the -XCX- sequence consisting o f a cysteine 
flanked on either side by a basic residue, where X = H, K or R.
There are only two beta-integrin subunits present on human platelets, Pi and p3, 
forming part o f the five platelet integrins: anpP3 which binds fibrinogen, vWF and 
fibronectin; a vP3 which binds osteopontin and vitronectin in vitro (Bennett et ah 
2009); (X2P1, a 5Pi and o^Pi which bind collagen, fibronectin and laminin 
respectively (Nieswandt et al. 2009). The P3 integrin contains fifty-six cysteine 
residues, o f which ten were found to be immediately adjacent to a single basic amino 
acid (-XC-), two cysteines hp 1 the (-XXC-) motif, while none were found to be 
flanked on both sides by a basic residue (-XCX-) (Figure 5.10 and Table 5.1).
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Analysis o f the Pi subunit revealed fifty-eight cysteines of which eighteen were 
adjacent to a single basic amino acid, four cysteines had the (-XXC-) m otif of two 
basic residues to either the right or the left o f the cysteine, and three cysteines were 
found to lie between two basic residues (Figure 5.11 and Table 5.1). A comparison 
between all eight human P-subunits is shown in Table 5.2. While the p8 subunit had 
the greatest number o f potential reactive cysteine residues adjacent to a single basic 
amino acid overall (twenty in all), the P2, P4 and Pi subunits had the highest number 
o f cysteine residues flanked by two adjacent basic amino acids. The P2 and P4 
subunits each had six such potential reactive cysteines each while Pi had seven 
(Table 5.2). This greater number o f potentially reactive cysteine thiols on the pi 
subunit makes it a feasible target for redox modification on the platelet surface.
5.2.7 »S-glutathionylation of Platelet Proteins in Resting Gel-filtered 
Platelets
Gel-filtered platelets were treated with platelet buffer or with GSH/GSSG redox 
potentials (Eh = -264mV, -130mV and -lOmV) for 3 minutes at 37°C and then left 
unactivated in a platelet aggregometer for 10 minutes at 37°C at llOOrpm. Platelet 
lysates were generated and samples were separated on 4 -  20% gradient gel and 
transferred to PVDF membrane as described in section 2.2.14. The membrane was 
probed with the anti-GSH antibody (Figure 5.12). In unactivated platelets, in the 
absence o f redox, there are faint bands observed at approximately 48kDa and 70kDa 
under non-reducing conditions (Figure 5.12, lane 1). These bands were attenuated in 
parallel samples prepared with 2X sample buffer with 50mM DTT as outlined in 
section 2.2.15 (Figure 5.12, lane 2). Pre-treatment o f resting platelets with the 
reducing GSH/GSSG Eh = -264mV resulted in an increase in the number o f bands,
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with a large increase in the intensity o f the bands at approximately 48kDa and 
96kDa. Other bands were seen at approximately 30kDa, 60kDa, 64kDa, 76kDa, 
106kDa and 116kDa and 172kDa all under non-reducing conditions (Figure 5.12, 
lane 3). Bands at approximately 106kDa and 116kDa corresponding to the 
approximate position o f  the integrin Pi subunit under non-reducing conditions are 
marked with arrows (Figure 5.12, lane 3) (Thirkill et al. 2004). Several studies have 
demonstrated two different molecular weight forms o f Pi integrin (109kDa and 
116kDa) that appear to result from differences in glycosylation (Beilis et al. 1999, 
Litynska et al. 2002, Ringeard et al. 1996, Thirkill et al. 2004). In the parallel 
reduced samples all o f these bands were absent except for the band at approximately 
48kDa which was much attenuated (Figure 5.12, lane 4).
I
In the presence o f GSH/GSSG Eh = -130mV there was a reduction in the number o f 
bands on the membrane when compared to those in lane 3 (Figure 5.12). The 48kDa 
band was still present though less intense than it was in the presence of the reducing 
redox potential, as was the band at approximately 96kDa (Figure 5.12, lane 5). The 
band at 96kDa was not present, and the intensity o f the band at 48kDa was much 
diminished in parallel samples under reducing conditions with DTT (Figure 5.12, 
lane 6).
The profile o f platelet proteins pre-treated with GSH/GSSG Eh = -lOmV (Figure
5.12, lane 7), was similar to the band pattern o f platelet proteins pre-treated with the 
reducing redox potential o f  Eh = -264mV (Figure 5.12, lane 3). However, it is 
apparent that the intensities o f these bands are slightly attenuated when compared to 
those in lane 3. Only the band at apr 'oximately 48kDa remained, although much 
attenuated, in parallel samples under reducing conditions with DTT (Figure 5.12, 
lane 8).
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5.2.8 .S-glutathionylation of Platelet Proteins in Collagen-activated 
Gel-filtered Platelets
Gel-filtered platelets were treated with platelet buffer or with GSH/GSSG redox 
potentials (Eh =  -264m V , -130m V  and -lO m V) for 3 minutes at 37°C and were then 
activated with collagen (3 8 jig/ml) in a platelet aggregometer for 10 minutes at 37°C 
at llOOrpm. Som e platelet samples were left unactivated. Platelet lysates were 
generated and samples were separated on 4 -  20% gradient gel and transferred to 
PVDF membrane as described in section 2.2.14. The membrane was probed with the 
anti-GSH antibody (Figure 5.13).
Unactivated platelets in the absence o f  redox showed bands at approximately 48kDa  
and 70kD a under non-reducing conditions (Figure 5.13, lane 1) and similar to the 
profile seen in lane 1 in Figure 5.12. These bands were attenuated under reducing 
conditions (Figure 5.13, lane 2). M ore intense bands were observed from collagen  
activated platelets in the absence o f  redox at approximately 48kD a and at 96kDa  
when compared to unactivated platelets (Figure 5.13, lane 3). These bands were 
greatly attenuated in parallel sam ples under reducing conditions with DTT (Figure
5.13, lane 4).
There w as an increased intensity o f  bands at approximately 30kDa, 48kDa, 60kDa, 
64kDa, 96kDa, 106kD a,116kD a and 172kDa from the collagen activated platelets 
that had been pre-treated with the m ost reducing G SH /G SSG  Eh = -264m V  when  
compared to collagen activated platelets in the absence o f  redox (Figure 5.13, lane 
5). These bands were absent, except for the much attenuated band at approximately 
48kDa, in parallel samples under reducing conditions with DTT (Figure 5.13, lane
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In the presence o f  GSH /G SSG  Eh =  -130m V  there was a reduction in the number o f  
bands on the membrane. The band at approximately 48kD a w as still present though 
less intense than it was in the presence o f  the reducing redox potential, as was the 
band at approximately 96kDa (Figure 5.13, lane 7). The band at 96kDa was not 
present, and the intensity o f  the band at 48kD a was much diminished in parallel 
samples under reducing conditions with DTT (Figure 5.13, lane 8).
The profile o f  the platelet proteins pre-treated with the more oxidising GSH/GSSG  
Eh =  -lO m V (Figure 5.13, lane 9), was similar to the band pattern seen in collagen  
activated platelets pre-treated with the reducing GSH/G SSG  Eh =  -264m V  (Figure
5.13, lane 5), although the intensities o f  these bands are low er when compared to 
those in lane 5. These bands were absent, except the m uch attenuated band at 
approximately 48kDa, in parallel sam ples under reducing conditions with DTT 
(Figure 5.13, lane 10).
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Figure 5.1 Adhesion to collagen is decreased in  a reducing external redox environment. Gel- 
filtered platelets were treated fo r 5 minutes at room temperature w ith  platelet buffer (no redox), (A  
and C) GSH/GSSG redox potentials, (B and D ) Cys/CySS redox potentials. Platelet samples were
also pre-treated w ith ED TA (2mM) or the function blocking anti- a 2Pi antibody 6F1 (20ng/ml). 96-
well plates were coated w ith  the substrates collagen (lO ^g/m l), CRP (lO ^g/m l) or BSA (5% w/v). 
Adhesion after one hour was measured colorimetrically as absorbance o f the /»-nitrophenol product at 
405nm. Data shown are expressed as mean ± SE, * *  p <  0.01, * p < 0.05 when compared to adhesion 
in the absence o f redox, n =  4 -  6 .
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Figure 5.2 Adhesion o f platelets to G FO G ER  is s ignificantly decreased in  a reducing redox 
environment. 96-well plates were coated w ith  (A ) the high a ffin ity  c^Pi-binding peptide GFOGER 
(lO ^g/m l) (B) the non-binding GPP]0 peptide (lO ^g/m l) and (C) BSA (5% w/v). Washed platelets 
were treated w ith the indicated GSH/GSSG redox potentials in the presence or absence o f M gCl2 
(2mM) or ED TA (2mM). Platelet adhesion after one hour was measured colorimetrically as 
absorbance o f the / 7-mtrophenol product at 405nm. Data shown are expressed as the mean ± SE o f n 
= 4 separate experiments, * * *  p < 0.001 when compared to adhesion in the absence o f redox.
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Figure 5.3 The rate and extent o f p latelet adhesion to G FO G ER  are decreased in  a reducing 
GSH/GSSG redox environment. Washed platelets were pre-treated w ith platelet buffer (blue) or 
w ith  the GSH/GSSG redox potentials shown (A  and D =  -264mV; B  and E =  -130mV; C and F = - 
lOmV) fo r 5 minutes at room temperature. (A, B, C) Platelets were then allowed to adhere to 
GFOGER (10ng/ml) or (D, E, F) CRP (lO ^g/m l) coated Xcelligence 96-well E-plates for the times 
indicated. Cell index was measured and is an indication o f  the level o f platelet adhesion to the 
substrates. Data shown are expressed as mean ± SE o f  n =  4 separate experiments.
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Figure 5.4 Reducing GSH/GSSG redox potentials decrease the rate o f adhesion o f washed 
platelets to G FO G ER  peptide. (A) In an Xcelligence assay, washed platelets were allowed to adhere 
to GFOGER (10ng/ml) or CRP (10(xg/ml) fo r 3 hours. The adhesion rate is inversely proportional to 
time taken to reach the h a lf maximum cell index (C.I. max). (B) Shown is the time taken to reach C.I. 
max fo r washed platelets adhering to GFOGER in  the presence o f  GSH/GSSG redox potentials 
indicated. (C) Shown is the time taken to reach C.I. max fo r washed platelets adhering to CRP 
(10|xg/ml each) in  the presence o f  GSH/GSSG redox potentials as indicated. Data shown are 
expressed as mean ± SE o f  n =  4 separate experiments, * * *  p < 0.001 when compared to platelet 
adhesion to GFOGER, * *  p <  0.01 when compared to platelet adhesion to GFOGER in the absence o f 
redox.
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Figure 5.5 Decreased adhesion o f washed platelets to collagen and G FOG ER in  a reducing 
GSH/GSSG or Cys/CySS redox environment. Platelets were treated w ith  platelet buffer or w ith the 
indicated GSH/GSSG and Cys/CySS redox potentials fo r 5 minutes at room temperature as follows: 
Left hand panels'. GSH/GSSG (A ) No redox, (B) -264mV, (C) -130mV, (D) -lOmV. Right hand 
panels'. Cys/CySS (A ) No redox, (B) -148mV, (C) -82mV, (D) +4mV. Glass slides were coated as 
indicated. Panels 1 and 2: collagen (10|a.g/ml), panels 3 and 4: GFOGER (lO ^g/m l) and panels 5 and 
6 : CRP (10ng/ml). Platelets were allowed to adhere fo r 1 hour at room temperature. Adherent 
platelets were stained with Alexa Fluor 488 phalloidin for actin. Slides were viewed using a Zeiss 
Axiovert 200M microscope. Images were produced w ith Zeiss LSM Imaging software and image 
analysis was performed using Image J (version 1.4) software. Shown are representative images o f one 
o f  n = 4 separate experiments. Scale bar = 10|im.
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Figure 5.6 Decreased adhesion o f platelets to collagen and GFO G ER in  a reducing GSH/GSSG 
or Cys/CySS redox environment. A , B, C: Washed platelets were treated with GSH/GSSG Eh = - 
264mV, -130mV -lO m V respectively fo r five minutes at room temperature D, E, F: Washed platelets 
were treated w ith  Cys/CySS redox potentials Eh = -148mV, -82mV, +4mV respectively fo r 5 minutes 
at room temperature. Platelet samples were also treated w ith the anti-a2-I domain antibody 6F1 
(20ng/ml) for 20 minutes at room temperature. A  and D: Glass slides were coated w ith  collagen 
(10|ig/ml); B and C: Glass slides were coated w ith  GFOGER (10|ig/ml); E and F: Glass slides were 
coated w ith CRP (10|xg/ml). The platelets were allowed to adhere for 1 hour at room temperature. 
Adherent platelets were stained with Alexa Fluor 488 phalloidin fo r actin. Slides were viewed using a 
Zeiss Axiovert 200M microscope. Images were produced with Zeiss LSM Imaging software and 
image analysis o f adhered platelet area was performed using Image J (version 1.4) software. Data 
shown are expressed as mean ± SE o f  n = 4 separate experiments. *  p < 0.05, * *  p < 0.01 and * * *  p < 
0.001 when compared to platelet adhesion to substrate in the absence o f redox.
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Figure 5.7 Cysteine th io l standard curve. Cysteine (0 -  15(j.M) was incubated w ith DTNB (lOO^iM) 
fo r 1 minute at room temperature, in  triplicate, in  a clear flat bottomed 96 well plate. The absorbance 
was then measured at 405nm using a Wallac plate reader. A  standard curve was generated using 
GraphPad Prism 5 software. The correlation co-efficient r2 = 0.9893 is shown, implying a strong 
positive correlation between absorbance measured and cysteine thiol concentration. The equation o f 
the line is also shown and was used to calculate the concentration o f  thiols (Communication
from  Ms. E. Reddy, RCSI).
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Figure 5.8 A n  increase in  the population o f free thiols on the surface o f collagen activated 
platelets. Gel-filtered platelets were incubated w ith  5, 5'-dithiobis-(2-nitrobenzoic acid) (DTNB 
lOOpM) and were either le ft unactivated or were activated w ith collagen (38|o,g/ml), convulxin 
(50ng/ml) or thrombin (O.lU /m l) fo r 10 minutes at 37°C. Platelets were centrifuged for 30 seconds at 
13,400 x g and the supernatant collected for analysis. The supernatant was removed and transferred to 
a clear, flat-bottom 96-well plate. Absorbance o f  the TNB product was measured at 405nm using a 
Wallac plate reader. The number o f  moles o f free thiols expressed on the platelet surface was 
calculated from  the absorbance values obtained above fitted to the equation o f  the line from a cysteine 
(Cys) standard curve (Figure 5.7). Data shown are expressed as the mean ± SE o f n = 6 separate 
experiments, * * *  p < 0.001 when compared to unactivated platelets. (Communication from Ms. E. 
Reddy, RCSI).
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Figure 5.9 Reducing GSH/GSSG and Cys/CySS redox potentials abolish free th io l population
I
expression in  activated platelets. (A) Gel filtered platelets were activated w ith  collagen (3 8 jig/m l),
thrombin (O.lU/m l) or convulxin (50ng/ml) in the presence or absence o f  GSH/GSSG Eh = -264mV, - 
130mV, -lO m V redox potentials as indicated. (B) Gel filtered platelets were activated w ith collagen 
(38jig/m l), thrombin (O .lU /m l) or convulxin (50ng/ml) in the presence or absence o f Cys/CySS Eh =  - 
148mV, -82mV +4mV redox potentials as indicated. Samples were activated fo r 10 minutes at 37°C. 
DTNB (lOOfxM) was then added to the samples and incubated for 1 minute at room temperature. 
Samples were centrifuged fo r 30 seconds at 13,400 x g. The supernatant was removed and transferred 
to a clear, flat-bottom 96-well plate. Absorbance o f the TNB product was measured at 405 nm using a 
Wallac plate reader. Concentration o f  free thiols was calculated from the cysteine standard curve as in 
Figure 5.7. Fold increase in number o f free thiols was calculated as the ratio o f number o f free thiols 
for each activating condition or each redox condition and the number o f  free thiols on unactivated 
platelets for each redox condition. Data shown are mean ± SE o f n = 6 separate experiments, * p < 
0.05 and **  p < 0.01 compared to fo ld increase in free thiols in the absence o f redox and ## p < 0.01 
compared to fold increase at GSH/GSSG Eh = -lO mV or Cys/CySS Eh = +4mV. (Communication 
from Ms. E. Reddy, RCSI).
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MRARPRPRPLWATVLALGAL2QAGVGVGGPNICTTRGVSSCQ40QCLAVSPMCAWCSDEALPLG60
SPRCDLKENLLKDNCAPESI80EFPVSEARVLEDRPLSDKGSI0°GDSSQVTQVSPQRIALRLRP’20
DDSKNFSIQVRQVEDYPVDI,40YYLMDLSYSMKDDLWSIQNL'60GTKLATQMRKLTSNLRIGFG,8°
AFVDKPVSPYMYISPPEALE20°NPCYDMKTTCLPMFGYKHVL220TLTDQ\/TRFNEEVKKQSVSR24°
NRDAPEGGFDAIMQATVCDE260KIGWRNDASHLLVFTTDAKT280HIALDGRLAGIVQPNDGQCHP00
VGSDNHYSASTTMDYPSLGL320MTEKLSQKNINLIFAVTENV340VNLYQNYSEUPGTTVGVLS360
MDSSNVLQLIVDAYGKIRSK380VELEVRDLPEELSLSFNATC400LNNEVIPGLKSCMGLKIGDT420
VSFSIEAKVRGCPQEKEKSF440TIKPVGFKDSLIVQVTFDCD460CACQAQAEPNSHRCNNGNGT4BO
FECGVCRCGPGWLGSQCECS500EEDYRPSQQDECSPREGQPV520CSQRGECLCGQCVCHSSD
FGS4°KITGKYCECDDFSC\/RYKGE5eoMCSGHGQCSCGDCLCDSDWT580GYYCNCTTRTD CMSS
NGLL600CSGRGKCECGSCVCIQPGSY620GDTCEKCPTCPDACTFKKEC640VECKKFDRGALHDEN
TCNRY6BOCRDEIESVKELKDTGKDAVN6BOCTYKNEDDCWRFQYYEDSS700GKSILYWEEPECPKG
PDIL720WLLSVMGAILLIGLAALLI740WKLLITIHDRKEFAKFEEER760ARAKV\iDTANNPLYKEATST
F780TNITYRGT
Figure 5.10 Potential reactive cysteine residues in  the in teg rin  p3 subunit. This is the amino acid 
sequence o f integrin f}3 subunit showing the 56 cysteines highlighted in  red. The basic amino acids 
histidine (H), lysine (K ) and arginine (R) w ith their adjacent cysteine residues are highlighted in blue 
and underlined. Protein sequence was obtained from the Uniprot® protein database, accession number 
P05106.
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MNLQPIFWIGLISSVCCVFA 20QTDENRCLKANAKSCGECIQ40AGPNCGWCTNSTFLQEGMPT60 
SARCDDLEALKKKGCPPDDI80ENPRGSKDIKKNKNVTNRSK,MGTAEKLKPEDITQIQPQQLV,2°
LRLRSGEPQTFTLKFKRAED140YPIDLYYLMDLSYSMKDDLE160NVKSLGTDLMNEMRRITSDF180
RIGFGSFVEKTVMPYISTTP2°0AKLRNPCTSEQNCTSPFSYK220NVLSLTNKGEVFNELVGKQR240
ISGNLDSPEGGFDAIMQVAV2e0CGSLIGWRNVTRLLVFSTDA280GFHFAGDGKLGGIVLPNDGQ300
CHLENNMYTMSHYYDYPSIA320HLVQKLSENNIQTIFAVTEE340FQPVYKELKNLIPKSAVGTL360
SANSSNVIQLIIDAYNSLSS^EVILENGKLSEGVTISYKSY^CKNGVNGTGENGRKCSNISI420
GDEVQFEISITSNKCPKKDS440DSFKIRPLGFTEEVE\/I LQY460ICECECQSEGIPESI^KCHE^‘*e°
NGTFECGACRCNEGRVGRHC^ECSTDEVNSEDMDAYCRKEN^SSEICSNNGECVCGQCVCKI^
RDNTNEIYSGKFCECDNFNC^DRSNGLICGGNG^ K C ^ CE^CNPNYTGSACDCSLDTSTCE600
ASNGQICNGRGICECGVCKC620TDPKFQGQTCEMCQTCLGVCe40AEHKECVQCRAFNKGEKKDT660
CTQECSYFNITIWESRDKLP^QPVQPDPV^ H C ^ DVDDCW^FYFTYSVNGNNEVMVHWEN7-”
PECPTGPDIIPIVAGWAGI740\/LIGLALLLIWKLLMIIHDR760REFAKFEKEKMNAKWDTGEN7e0
PIYKSAVTTWNPKYEGK
Figure 5.11 Potential reactive cysteine residues in  the in teg rin  p j subunit. This is the amino acid 
sequence o f  integrin Pi subunit showing 58 cysteine residues highlighted in red. The basic amino 
acids histidine (H), lysine (K ) and arginine (R) w ith their adjacent cysteine residues are highlighted in 
blue and underlined. Cysteine residues w ith  basic amino acids on either side are circled. The protein 
sequence was obtained from the Uniprot® protein database, accession number P05556.
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The number o f motifs consisting o f a cysteine residue (C) w ith  adjacent basic amino acids histidine 
(H), lysine (K ) or arginine (R) (all designated X ) present in both integrin Pi and p3 subunits. The three 
-XC X- motifs in the Pi subunit are KCH, KCR and H C K and the four -XXC - or -CXX- motifs are 
RKC, RHC, CRK and CRK. In the p3 subunit there are two -XXC - motifs present, these are HRC and 
CKK. It is not known whether one m otif is potentially more reactive than another. Protein sequences 
were obtained from  Uniprot®  accession numbers P05556 and P05106 fo r p i and p3 respectively.
Table 5.1 A comparison of the reactive cysteine residue motifs in the integrin Pi and p3 subunits.
Integrin subunit Number of - Number of Number of -XXC-
XC- or -CX- -XCX- or -CXX- motifs
niotifs raodfs
Pi 18 3
KCH, KCR, -  
HCK
4
RKC, RHC, CRK, 
CRK
P3 10 0 2
HRC, CKK
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Table 5.2 A  comparison o f the amino acid sequences surrounding cysteine residues in  the 
in tegrin  Pi to p8 subunits. The number o f motifs consisting o f a cysteine residue (C) with an adjacent 
basic amino acid histidine (H), lysine (K ) or arginine (R) (all designated X ) present in all human 
integrin p subunits. Protein sequences were obtained from Uniprot® accession numbers P05556, 
P05107, P05106, P16144, P18084, P18564, P26010 and P26012 (P, -  p8 respectively).
Integrin  subunit N u m b er o f  
-X C - 
or -C X - 
m otifs
N um ber o f-X C X -  
m otifs
N u m ber o f-X X C -  
or -C X X - m otifs
Pi 18 3 4
P2 16 5 1
Pa 10 0 2
P4 9 4 1
P5 18 1 0
P6 16 2 1
Pt 17 3 1
Ps 20 1 2
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+ E h = -264mV 
+ E h = -130mV 
+ E h = -10mV 
+50 mM DTT
Figure 5.12 5-g lu ta th ionyla tion  o f p late let proteins in  unactivated redox treated gel-filtered 
platelets. Gel-filtered platelets were incubated w ith  platelet buffer (lanes 1 and 2); w ith GSH/GSSG 
Eh =  -264mV (lanes 3 and 4); GSH/GSSG Eh =  -130mV (lanes 5 and 6) and w ith  GSH/GSSG Eh = - 
lOmV (lanes 7 and 8) for 10 minutes at 37°C under stirring conditions at llOOrpm. Platelets were 
lysed in RIPA lysis buffer. Total platelet lysate (7.5|ig/lane) was separated by SDS-PAGE on a 4-20% 
gradient gel under both non-reducing (lanes 1, 3, 5, 7) and reducing conditions (lanes 2, 4, 6 , 8). 
Separated proteins were transferred from the gel to a PVDF membrane and probed w ith a 1:500 
dilution o f  a monoclonal anti-GSH antibody. Molecular weight markers (kDa) are indicated to the left 
o f  the figure and are expressed in kDa. Arrows indicate bands at approximately 106kDa and 116kDa 
corresponding to the estimated position o f the integrin a2Pi p-subunit. Shown is a representative 
western blot o f n = 4 separate experiments.
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Figure 5.13 i'-g lu ta th ionyla tion  o f platelet proteins in collagen activated redox treated gel- 
filtcred platelets. Gel-filtered platelets were left untreated {lanes 1, 2, 3, 4) or treated with 
GSH/GSSG Eh =  -264mV (lanes 5 and 6); GSH/GSSG Eh =  -130mV (lanes 7 and 8) or with 
GSH/GSSG Eh = -lOmV (lanes 9 and 10) for 3 minutes at 37°C with constant stirring at llOOrpm. 
The platelets then either remained unactivated (lanes I and 2) or were activated with collagen 
(38ng/ml) (lanes 3 -  10) for 10 minutes at 37°C under stirring conditions at 1 lOOrpm. Platelets were 
lysed in RIPA lysis buffer. Total platelet lysate (7.5ng/lane) was separated by SDS-PAGE on a 4-20% 
gradient gel under both non-reducing (lanes 1, 3, 5, 7, 9) and reducing conditions (lanes 2, 4. 6, 8,10). 
Separated proteins were transferred to a PVDF membrane and probed with a 1:500 dilution o f a 
monoclonal anti-GSH antibody. Molecular weight markers are indicated to the left o f the figure and 
'■re expressed in kDa. Shown is a representative western blot o f  n = 4 separate experiments.
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In chapter three o f  this thesis m y results show ed an inhibition o f  platelet activation in 
the presence o f  reducing glutathione or cysteine redox potentials that was specific to 
the collagen activation pathway. Subsequent data from chapter four demonstrated 
that disulphide bond reduction played a part in this inhibitory process. I set out in 
chapter five to verify that integrin a,2pi w as the target o f  reducing GSH/GSSG and 
C ys/CySS redox potentials and hence to determine the nature o f  the interaction 
between these redox conditions and this integrin. The redox-platelet interaction was 
confirmed to be specific to the collagen binding integrin 0,2(31 by platelet adhesion 
studies using collagen triple helical peptides. The peptide containing the GFOGER 
m otif binds with high affinity to 012P1. This is the m inimum binding m otif within 
type I collagen required for binding to the integrin a i-I  and a.2-1 collagen binding 
domains (Knight et al. 2000). E m sley et al. verified its specific interaction by co­
crystallisation o f  GFOGER with the ot2-I domain (Em sley et al. 1997). M y data show  
significant reduction in  adhesion o f  both gel-filtered and washed platelets to 
GFOGER in the presence o f  the reducing redox potentials. This reduced adhesion 
was seen in several different static adhesion assays using substrate coated plastic 
plates, glass slides and in the electrically measured X celligence assay. Redox 
treatment o f  platelets had no effect on platelet adhesions to the GPVI specific triple 
helical peptide CRP in any o f  these assays, confirming the specific action o f  redox 
on the interaction o f  (X2P1 with its ligands. Both the extent and the rate o f  platelet 
adhesion to GFOGER were decreased in the presence o f  the reducing redox 
potentials as shown in the X celligence assay. Integrin 012P1 is capable o f  binding 
GFOGER in the unactivated platelet, and the integrin then adopts a fully activated 
conformation upon engagem ent o f  the ligand (Siljander et al. 2004). The integrin has
5.3 Discussion
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been show n to exist in different affinity states and on the platelet surface it is 
constitutively active (Gofer-Dadosh et al. 1997). Additionally, collagen binding to 
the integrin induces a conformational shift within the a.2-1 domain involving a -  
helices w hich flank the central ß-sheet o f  the I-domain. This conformational change 
is then believed to be transferred to the rest o f  the integrin ectodomain (Amaout et 
al. 2002, Eble & Tuckwell 2003). M y data suggest that this integrin is unable to 
attain a fu lly  activated conformation under reducing redox conditions resulting in a 
decreased ligand binding capacity and/or decreased intracellular signalling as a result 
o f  a redox induced conformational m odification. In chapter four I demonstrated 
decreased binding o f  collagen-FITC to gel-filtered platelets in the presence o f  
reducing redox potentials. The increased rate o f  adhesion to GFOGER in the 
presence o f  both mean plasm a and oxidising redox potentials compared to that seen 
in a reducing redox environment suggests that the effect is regulated by the reducing 
capacity o f  the redox couple. This m ay point to a redox regulation o f  integrin a.2ßi 
function particularly in conditions o f  reductive stress, such conditions being  
generated by the local depletion o f  pro-oxidant ROS/RNS or by the accumulation o f  
extracellular reducing redox capacity (Zhang et al. 2011, Zhang et al. 2010). This 
increased reducing redox capacity m ay be provided here by the reducing redox 
potentials generated b y  the glutathione and cysteine redox couples.
Ligand induced integrin anbß3 activation has been proposed to occur in the follow ing  
sequence (Essex 2009): ligand binding to integrin follow ed by a disulphide bond  
reshuffling or reduction process, which could include thiol/disulphide exchange 
possib ly mediated by  endogenous thiol isom erase activity within the integrin itse lf  
(O'Neill et al. 2000), the integrin associated PDI (Essex & Li 1999) or increased 
expression o f  free thiol groups in the integrin (Yan & Smith 2001), finally resulting
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in attainment o f  the fu lly  activated integrin conformation. The role o f  free thiols and 
disulphide bond reduction in integrin activation is w ell established. Disruption o f  the 
C ys5-C ys435 disulphide bond within the ß-subunit o f  integrin anbß3 b y  introduction 
o f  the mutations C5A and C 435A  in co-transfected CHO cells resulted in an integrin 
conformation capable o f  binding soluble fibrinogen and the fibrinogen mimetic 
antibodies PI-55 and PAC-1 (Sun et al. 2002). B locking o f  free thiols on the platelet 
surface with membrane impermeant N EM  resulted in inhibition o f  adhesion to 
collagen, fibrinogen and fibronectin, show ing a role for free thiol groups in integrin 
m ediated platelet adhesion (Lahav et al. 2000). More recently, the affinity o f  integrin 
a,4ßi for the specific ligand LDV-FITC-containing small m olecule was shown to 
increase dose-dependently when human m onocyte (U 937) cells were treated with 
increasing concentrations o f  the membrane impermeable reducing agents DTT and 2, 
3-dim ercapto-l-propanesulfonic acid (DM PS). This suggests a sequential reduction 
o f  disulphide bonds generating distinctive conformations o f  the integrin (Chigaev et 
al. 2004). Integrin activation by ultra-violet C irradiation was demonstrated to be a 
direct result o f  disulphide bond reduction and increase in free thiol groups in ßi, ß2 
and ßß integrins on washed human platelets and HL-60 cells (Verhaar et al. 2008). 
Thus the conformational changes required to change from an inactive to a fully  
activated integrin are known to be redox sensitive and are strongly dependent on  
thiol/disulphide interactions.
Our group has recently shown an increase in free thiol groups detected on intact 
platelets follow ing activation with soluble type I collagen. This increase was not 
seen in platelets activated with thrombin or convulxin. The increase in free thiols 
w as not seen in collagen activated platelets that had been pre-treated with reducing 
G SH /G SSG  or C ys/CySS redox potentials (personal communication from Ms. E.
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Reddy, RCSI). This data suggests that free thiol groups are generated by either 
thiol/disulphide exchange or disulphide bond reduction during collagen induced 
platelet activation and that reducing redox potentials are directly interacting with 
these thiol groups. This data also supports our hypothesis that the collagen activation 
pathway in the platelet is redox sensitive.
Thus, the data presented here indicates that a population o f  cysteine thiol groups 
present in the integrin a.2pi are particularly susceptible to disulphide bond reduction 
and react with the reducing capacity o f  the GSH or cysteine redox couples. The 
reversible reactions betw een glutathione or cysteine and a protein cysteine thiol 
group forming a disulphide bond are known as S'-glutathionylation or S- 
cysteinylation respectively (Hochgrafe et al. 2007, Klatt & Lamas 2000). Thiol 
groups differ in their reactivity due to the variability o f  the pKa o f  the cysteine thiol, 
depending on the redox environment o f  the thiols or on the electrostatic interactions 
o f  surrounding amino acid residues. The pKa values o f  cysteine thiols m ay be 
decreased sufficiently by charge interactions with positively charged, basic amino 
acids adjacent to the cysteine thiol (V ukelic et al. 2012, W akabayashi el al. 2004). 
Such thiols can exist as thiolate (-S') groups that are highly reactive and are 
considerably better nucleophiles than their protonated forms (Marino & Gladyshev 
2011), giving rise to the term “reactive cysteine”. Proteins with low  pKa cysteine 
residues include the protein tyrosine phosphatases (PTP). A ll PTPs contain a reactive 
cysteine essential to their catalytic function, having a pKa value o f  4.7 to 5.4, 
compared to the typical thiol pKa value o f  8.5 (Rhee et al. 2000). Cysteine pKa 
values for various proteins have been determined by a variety o f  m ethods including 
Raman spectroscopy (Li et al. 1993), the measurement o f  pH dependence o f  240nm  
absorbance, the reactivity with fluorescein iodoacetamide across a range o f  pH
values and the determination o f  functional pKa by pH-dependence o f  competition  
with HRP for hydrogen peroxide (N elson et al. 2008). The reactive cysteine o f  PTP 
is contained within a signature m otif, H is-C ys-X -X -G ly-X -X -A rg-Ser/Thr, where X  
denotes any amino acid and the thiol group exists as thiolate anion at neutral pH 
(Denu & D ixon 1998). The basic residue histidine (His) is believed to stabilise the 
thiolate anion o f  the cysteine through electrostatic interactions. The highly conserved 
reactive C ys340 found in bovine papillomavirus type-I E2 protein has a basic lysine  
(K) residue im m ediately adjacent to it (M cBride et al. 1992), and D N A  binding to 
the Fos-Jun heterodimer was dependent on the redox state o f  a single reactive 
cysteine residue in the D N A  binding domain o f  both proteins. This reactive cysteine 
is located between two basic amino acids in the Lysine-Cysteine-Arginine (K-C-R) 
tri-amino acid sequence that is invariant among the fas  and jun  gene fam ilies (Abate 
etal. 1990).
Comparison o f  the cysteine rich P-integrin subunits found on human platelets 
showed almost tw ice as m any potential reactive cysteine residues on the Pi 
compared to the P3 subunit. There were three cysteine residues in the pi subunit 
having a basic amino acid residue on either side: Cys477 (K-C-H) and C ys576 (K-C- 
R) in the first and third cysteine-rich repeat regions and Cys691 (H-C-K) w hile this 
is not seen at all in  P3. The Pi subunit also has four cysteines with two basic amino 
acids im m ediately preceding or fo llow ing the cysteine: Cys415 (R-K-C), Cys500 (R- 
H-C), C ys516 (C-R-K) and Cys538 (C-R-K). There are only two o f  these motifs 
C ys474 (H-R-C) and Cys643 (C-K-K) seen in the P3 subunit. Eighteen Pi cysteine 
residues are adjacent to at least a single basic amino acid compared to only ten in P3, 
showing a much greater number o f  potentially redox reactive cysteines in this 
integrin.
In this chapter, the direct interaction o f  glutathione with platelet proteins was 
confirmed using the anti-GSH antibody. U sing the sam e antibody, D alle-D onne et 
al. (D alle-D onne et al. 2005) showed that diamide, a thiol specific oxidant was 
shown to induce a concentration dependent increase in the S-glutathionylation o f  
platelet cytoskeletal proteins, with actin proving to be the m ost readily S- 
glutathionylated protein. Actin, the m ost abundant cytoskeletal protein is found in 
close association with the platelet membrane, and m ay be disulphide linked to other 
membrane proteins (Qingqi & Stracher 1998). More recently, the N A C  mediated 
reduction o f  surface exposed (3-actin in human peripheral blood mononuclear cells  
detected by the cell impermeable thiol detection reagent N  - (biotinoyl) - N - 
(iodoacetyl) ethylendiam ine (BIAM ) has been reported (Laragione et al. 2003). 
Human p-actin possesses a single reactive cysteine (Cys374) that is immediately  
preceded by three basic amino acid residues (H-R-K-C-F) (Uniprot Protein Data 
Bank, A ccession  number P60709).
The m echanism underlying the S-glutathionylation o f  actin was attributed to an 
oxidative m odification o f  the actin thiol group, with loss o f  an electron, and 
subsequent reaction with GSH to form the S-glutathionylated protein (Dalle-Donne  
et al. 2005). Actin has been shown to be S-glutathionylated in human epidermal cells 
and human fibroblasts even under resting conditions (Pastore et al. 2003, W ang et al. 
2001). The appearance o f  S-glutathionylated proteins in unactivated platelets in the 
presence o f  varying external redox potentials suggests the existence o f  redox 
sensitive extracellular protein thiols on the platelet surface. These thiols are more 
sensitive to »S'-glutathionylation in the presence o f  the more reducing and oxidising  
redox potentials than at mean plasma redox potentials. Exofacial membrane protein 
thiols m ay be responding to local conditions o f  reductive stress or oxidative stress
created by the presence o f  either the reducing or oxidising redox potentials. 
Oxidative stress is associated with the more oxidising GSH/GSSH redox potential 
and reductive stress w ith a more reducing GSH/GSSG redox potential (Rajasekaran 
et al. 2007).
The 48kD a S-glutathionylated protein detected in m y study is possib ly platelet actin, 
w hich has previously been shown to be redox sensitive (D alle-D onne et al. 2005). P- 
actin has been identified as a 47kD a band in western blot analysis o f  murine 
fibroblast lysates (Fiaschi et al. 2006). M y data show  that in an external reducing 
redox environment the 48kDa protein is strongly S-glutathionylated possib ly due to 
the formation o f  a disulphide bond betw een the active thiol o f  actin and GSH. As 
GSH is cell impermeable, this could be accounted for i f  the protein is at least in 
som e part exterior to the membrane as discussed above. This level o f  S'- 
glutathionylation is not seen at mean plasm a redox potential, but even at this mean 
plasma redox potential the level o f  S'-glutathionylation o f  the 48kDa band is still 
greater than that seen in the absence o f  redox. O f note is the level o f  S- 
glutathionylation seen in the oxidising redox environment. Here, the level o f  S- 
glutathionylation is comparable to that seen in the presence o f  the reducing redox 
potential. In parallel sam ples at all redox potentials treated with the reducing agent 
DTT, S-glutathionylation was greatly diminished as would be expected follow ing  
reduction o f  the protein-glutathione disulphide bond.
The S-glutathionylation reaction m ay be similar to that o f  the reaction between  
diamide and the actin thiol, with the oxidising redox environment resulting in an 
oxidative reaction betw een the redox reagents and the actin thiol, resulting in a 
thiol/disulphide exchange reaction between G SSG  and the thiol group yielding GSH  
with the resulting S-glutathionylation o f  the protein. Indeed, the exact m echanisms
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b y which S-glutathionylation reactions occur are not yet com pletely understood. 
There are many possib le reactions possible all resulting in protein S- 
glutathionylation that m ay occur intracellularly or extracellularly including: (1) 
thiol/disulphide exchange reactions betw een protein thiols and GSSG, (2) direct 
interaction between partially oxidised protein thiols such as thiyl radical (-S'), 
sulfenic acid or protein S-nitrosothiol and GSH, (3) the reaction between protein 
thiols and S'-nitrosothiols such as S-nitrosoglutathione (G SNO) and (4) direct 
reaction between GSH and a free thiol group triggered by oxidants (G hezzi 2005b, 
Martinez-Ruiz & Lamas 2007). Demonstration o f  the S-glutathionylation o f  platelet 
proteins in unactivated platelets in a reducing extracellular redox environment shows 
that redox m odification o f  the platelet occurs independently o f  platelet activation. 
Platelets activated with collagen showed the sam e pattern o f  S-glutathionylation as 
described in unactivated platelets in response to varying external redox potentials. In 
both activated and unactivated platelets treated with the reducing redox potential (Eh 
= -264m V ) there w as a strongly S-glutathionylated protein at approximately 96kDa. 
S-glutathionylation o f  this protein w as strongest in this reducing environment, 
intermediate with oxidising redox potentials and weakest at mean plasm a redox 
potential. The identity o f  this protein is not known. The integrin-Pi subunit has an 
apparent m olecular w eight o f  88kDa (Uniprot Protein Data Bank, A ccession number 
P05556), and under non-reducing conditions appears at 110 -  1 16kDa in SDS-PAG E  
(Anderson et al. 1990, Shang et al. 2001, Thirkill et al. 2004). The Pi subunit is 
reported often to appear as two bands, possib ly due to differing amounts o f  
glycosylation o f  the protein (Thirkill et al. 2004). The presence o f  S-glutathionylated 
platelet proteins at 106kDa and 116kDa in platelets treated with the reducing reciox 
potential indicate possib le glutathionylation o f  the platelet integrin-pi subunit.
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In summary, this work has established that the collagen activation pathway in 
platelets acting specifically  through the integrin CX2P1 receptor is particularly 
sensitive to redox m odulation by reducing G SH /G SSG  or Cys/CySS redox 
potentials. Platelet activation by  other agonists w as unaffected by redox. Direct 
redox m odification o f  platelet proteins was shown to occur via a thiol/disulphide 
reaction, by demonstration o f  S-glutathionylation o f  platelet proteins in both 
unactivated and activated platelets particularly in the presence o f  the reducing 
GSH/GSSG redox potential. The integrin (X2P1 has been shown to contain eighteen  
potentially reactive cysteine residues. The identity o f  the platelet proteins undergoing 
S-g\ utathionylation in the presence o f  varying redox potentials remains to be 
elucidated. The precise nature o f  the m echanism o f  S-glutathionylation between the 
GSH/GSSG redox couple and platelet surface thiols is another area to be resolved, as 
is the question o f  possib le S'-cysteinylation o f  platelet proteins by the Cys/CySS  
redox couple. These questions form the basis o f  future work to be considered in this 
area. This study has opened up a novel area o f  platelet research and has added new  
insights into the redox control o f  platelet function.
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C h a p t e r  6  
G e n e r a l  D i s c u s s i o n
Platelets exist within the dynamic m ilieu o f  the blood in a quiescent, unactivated 
state for a significant majority, i f  not all o f  their short life span o f  approximately ten 
days. The factors responsible for maintaining this status include the continued  
integrity o f  the vascular endothelial lining and the basal secretion o f  endothelial 
derived nitric oxide (NO ) and prostacyclin (Radomski et al. 1987a). The activation 
o f  the platelet follow ing exposure to sub-endothelial matrix proteins, such as 
collagen, results in a well-established cascade o f  events including platelet shape 
change and adhesion, platelet granule secretion, generation o f  platelet derived 
reactive oxygen species and formation o f  platelet-platelet aggregates via  fibrinogen 
binding to the platelet specific integrin anbPî (Rendu & Brohard-Bohn 2001, Roberts 
et al. 2004, Zucker & N achm ias 1985).
Little is known how ever, about the regulation o f  platelet function by local 
environmental factors, in particular the extracellular thiol/disulphide redox state. 
Platelets and all o f  the other blood com ponents are continuously exposed to the 
redox buffering system s o f  the plasma. These redox buffers comprise chiefly  the 
glutathione and cysteine redox couples (Jones et al. 2002). These thiol/disulphide 
couples are m ainly thought o f  as the first line defence against excess reactive oxygen  
or reactive nitrogen free radical production during tim es o f  oxidative stress (Hayes & 
M cLellan 1999). In this role both glutathione and cysteine are believed to act as 
either potent antioxidants or sim ply ROS scavengers neutralising the pro-oxidant 
effects o f  RONS directly. Such a role could influence platelet activation which is 
known to be more pro-aggregatory under oxidising conditions. However, I found 
that these redox couples exert a modulatory effect on platelet function by directly  
targeting the integrin (X2P1 collagen receptor on the platelet surface, thus impacting 
on the collagen activation pathway o f  platelets.
Platelet thiol/disulphide interactions have been shown to play a crucial role in the 
activation o f  the integrin (XnbP3- The studies that demonstrated this used non- 
physiological disulphide bond reducing agents such as DTT (Yan & Smith 2001), 
the free-thiol blocking agents DTNB and N -ethylm aleim ide (NEM ) (Essex et al. 
2001), or employed the generation o f  specific mutations o f  cysteine residues within 
the integrin ^-subunit itse lf (M or-Cohen et al. 2008). The requirement for free thiols 
and disulphide bond formation/disruption within aubfc during its transitions from the 
inactive to the active ligand-binding receptor conformation is clear. The underlying 
m echanism  behind this thiol/di sulphide exchange process remains unexplained, but 
there is m uch evidence supporting a role for the intrinsic thiol isom erase activity o f  
the integrin itse lf (O 'N eill et al. 2000, W alsh et al. 2004) or for platelet protein 
disulphide isomerase (PDI) (E ssex & Li 1999) in these conformational changes. This 
thiol/disulphide exchange m echanism  o f  integrin activation has also been established 
for a,2Pi (Lahav et al. 2003).
In this thesis I have show n that the redox modulation o f  collagen induced platelet 
activation occurs as a result o f  disulphide bond reduction with a concomitant S- 
glutathionylation o f  platelet proteins by reducing external redox potentials.
The evidence for this com es firstly from platelet function assays carried out under
differing redox and activating conditions. There was decreased platelet reactivity, in
all assays, to soluble type I collagen only, in the presence o f  reducing redox
potentials. A s soluble type I collagen binds with high affinity to CX2P1 (Savage et al.
1999, X u et al. 2000) these data suggested that the effects o f  redox were not directed
at other platelet receptors. Subsequent experiments showed that there was no redox
m odification o f  the ligand itself, as the aggregating ability o f  type I collagen was
unaffected by redox pre-treatment o f  the collagen. It is evident that the redox
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mediated effects on platelet activation demonstrated in this thesis are due to the 
disulphide bond reducing capacity o f  the reducing glutathione and cysteine redox 
potentials. The Pi-subunit o f  (X2P1 like all [3-subunits is cysteine rich with fifty-eight 
cysteine residues in total. A nalysis o f  the cysteine residues and their neighbouring 
amino acids within the Pi subunit revealed a far greater number o f  potential reactive 
cysteine residues than were present in the other platelet integrin anbP3. M y finding 
that there are eighteen cysteine residues within (X2P1 adjacent to at least one basic 
amino acid compared to only ten in anbp3 increases the possib ility  o f  these cysteines 
being reactive cysteines with lowered pKa values, rendering them more susceptible 
to redox modification. This could explain w hy platelet activation via (X2P1 shows 
m uch greater redox sensitivity when compared to activation via the GPVI, PAR-1, 
PAR-4 or am,p3 receptors.
Our laboratory has also recently demonstrated the expression o f  an increased number 
o f  free thiols on the surface o f  collagen activated platelets only (personal 
communication from M s. Em ily Reddy, RCSI). Platelets pre-treated with external 
reducing GSH/G SSG  or C ys/C ySS redox potentials did not show the same surface 
expression o f  free thiols in response to collagen activation. These data im ply that 
thiol/disulphide exchange is not only essential in the collagen induced activation o f  
the integrin but that this thiol/disulphide process is extrem ely redox sensitive. These 
findings could also explain the preferential redox targeting o f  (X2P1. Platelet 
activation with either thrombin or convulxin did not result in any increase in platelet 
surface free thiol expression. The (X2P1 specific nature o f  the interaction with redox 
was demonstrated using a /ariety o f  platelet adhesion assays with the collagen triple 
helical peptides GFOGER, CRP and collagen itself, again ruling out any redox 
mediated effects on GPVI.
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In the presence o f  reducing redox potentials there m ay be a GSH or Cys mediated 
disulphide bond reduction within the Pi subunit, follow ed by an S-glutathionylation  
event on one or more o f  the free thiols generated. This ‘locking’ o f  the free thiols by  
redox m ight stabilise the integrin in a conformation that is not fully activated, a so- 
called intermediate activation state, able to partially bind collagen, GFOGER and 
fully bind anti a.2-1 domain antibodies, but w hich is unable to becom e fully activated 
or to activate the platelet v ia  the ‘out-side in’ signalling process com m on to all 
integrins. This could explain our observation that the number o f  free thiol groups on 
the platelet surface follow ing collagen-induced activation is decreased as the redox 
potentials becom e more reducing. Interestingly, the presence on the platelet 
membrane o f  both PDI and endoplasm ic reticulum protein 5 (ERP5) in addition to 
glutathione reductase could provide an enzym atic m echanism  for the local 
reversibility o f  protein S'-glutathionylation under these redox conditions. These 
enzym es, interacting with integrin receptors, are crucial for the rearrangement o f  the 
membrane disulphide bonds needed for platelet aggregation, secretion and post­
aggregation events (Essex et al. 2004, Jordan et al. 2005, Lahav et al. 2003).
It is o f  note that even in the presence o f  a mean plasm a redox potential for the 
C ys/C ySS redox couple, the major extracellular redox buffer, there is a significantly  
dim inished platelet aggregation response to collagen activation in comparison to that 
seen in an oxidising C ys/C ySS redox environment. This decreased aggregation 
response w as noted with the mean plasm a GSH/G SSG  redox potential too, but was 
less pronounced. This raises the intriguing possibility that the physiological external 
platelet redox environment is som ehow  holding the collagen activation pathway in 
check, perhaps acting as a local regulator o f  collagen induced platelet activation, 
preventing an “all or nothing” platelet response to minor endothelial surface
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disruptions. A t mean plasma redox potentials, the platelet activation status in m ost o f  
the assays used in this thesis was intermediate betw een that seen at either reducing or 
oxidising redox potentials. In gel-filtered platelets devoid o f  any plasm a redox 
components, collagen-induced platelet activation levels were almost always 
equivalent to those levels seen in the presence o f  the m ost oxidising redox potentials. 
This is further indicative o f  a plasma redox mediated restraint on collagen-induced  
activation o f  the integrin.
A n imbalance betw een pro-oxidant species and physiological redox buffers whereby 
pro-oxidant species levels are dim inished w hile reducing redox buffering levels are 
increased is defined as reductive stress. This is the opposite scenario to the more 
w ell-know n phenom enon o f  oxidative stress. This physiological phenom enon o f  
reductive stress w as first reported b y  Rajasekaran et al. In this study, m ice  
expressing the human mutant aB -crystallin  protein developed higher levels o f  GSH, 
increased expression o f  heat shock proteins and glutathione peroxidase with  
decreased myocardial levels o f  ROS. Clinical symptoms were reported as increased 
protein aggregation and cardiomyopathy (Rajasekaran et al. 2007). More recently the 
specific role o f  heat shock protein 27 (Hsp27) in this reductive stress induced 
cardiomyopathy w as demonstrated. Over expression o f  the antioxidant Hsp27 in 
transgenic m ice resulted in elevated G SH /G SSG  ratio and decreased levels o f  ROS, 
with cardiac hypertrophy, dysfunction and reduced lifespan (Zhang et al. 2010). The 
exposure o f  platelets to reducing redox potentials replicates these conditions o f  
physiological reductive stress: the reducing redox potentials are generated using  
increased concentrations o f  the reducing redox species GSH and Cys thus elevating  
G SH /G SSG  and Cys/CySS ratios and under these reducing redox conditions 
intraplatelet ROS generation was decreased. Platelets are known to generate free
radicals and m y work confirmed the generation o f  intra-platelet ROS upon activation 
with various platelet agonists. This ROS generation however, w as not uniform across 
the range o f  platelet agonists tested. Collagen induced platelet activation resulted in 
greater levels o f  intraplatelet ROS than either thrombin or convulxin. These agonist- 
dependent variations in ROS generation were som ewhat surprising, given that 
concentrations o f  each agonist were chosen to give comparable levels o f  platelet 
aggregation. Both thrombin and convulxin derived intraplatelet ROS are believed to 
be generated via both N A D (P)H  oxidase and the cyclooxygenase (COX) pathway. 
N A D (P)H  oxidase inhibition reduces the platelet aggregation response, integrin 
(*iibP3 activation and thrombus formation (Begonja et al. 2005). O nly collagen- 
induced intraplatelet ROS generation was decreased under reducing redox 
conditions. Here, the reducing external redox environment had a direct impact on the 
platelet intracellular signalling pathways follow ing collagen activation.
The level o f  ROS generation through 0,2Pi indicates a greater role for platelet 
integrin generated ROS than has previously been thought. There must be a functional 
role for agonist-induced intraplatelet ROS, that could possib ly be acting as an 
intracellular second m essenger follow ing agonist activation o f  the platelet. From m y  
data, the ROS generation via thrombin activation, although significantly greater than 
the basal level in unactivated platelets, w as significantly less than that generated 
follow ing collagen or convulxin activation. A  lesser role for ROS as a second  
m essenger in thrombin-induced platelet activation is implied. GPVI mediated ROS 
generation follow ing convulxin activation was intermediate betw een that generated 
by thrombin and collagen. However, this greater magnitude o f  ROS generation via  
GPVI suggests a greater role for ROS in the signalling pathways resulting 
specifically from ligation o f  GPVI. The greatest ROS generation occurred follow ing
collagen binding to a 2(3i. It is still unclear to what extent this large integrin-derived 
intraplatelet ROS generation affects the regulation o f  platelet activation but it is 
evidently an integral part o f  this collagen activation pathway in the platelet. Its exact 
role is still an open question. There is no clearly defined role for ROS in platelet 
activation at present, but m y data indicates that the level o f  intraplatelet ROS 
generated is agonist specific and that its generation is dependent on the extracellular 
redox status o f  the platelet. Collagen-induced platelet ROS and hence platelet 
activation is thus extrem ely sensitive to reducing redox conditions. W hile platelets 
are apparently more pro-aggregatory under oxidative stress conditions (Amer & 
Fibach 2004, Freedman 2008), m y work show s that the converse is also true: 
collagen activated platelets neither aggregated nor adhered to collagen under such 
reductive stress conditions through redox m ediated targeting o f  (X2P1.
A  m echanism  for the redox-mediated allosteric regulation o f  protein function is 
already established. The increased reactivity o f  H sp70 protein b y  S-glutathionylation  
that is reversed by  glutaredoxin represents a redox regulated allosteric effector that 
can be turned on or o f f  by thiol/disulphide exchange (Hoppe et al. 2004). I have 
demonstrated S-glutathionylation o f  platelet proteins using an anti-GSH monoclonal 
antibody by western blot. The detection o f  the presence o f  S-glutathionylated platelet 
proteins potentially corresponding to the Pi subunit, coupled with the decrease in 
platelet-collagen binding and platelet adhesion to both collagen and GFOGER in the 
presence o f  reducing redox potentials clearly indicates a possible redox regulated 
allosteric effect within integrin CX2P1. M echanistically, it is unclear still how  this 
particular S-glutathionylation reaction occurs, but m y analysis o f  the cysteine 
residues within the Pi subunit revealing eighteen potential S-glutathionylation sites 
provides a clue. Recent analysis o f  potential reactive cysteine residues within a broad
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spectrum o f  proteins has indicated that in addition to the linear amino acid sequence 
and the proximity o f  basic amino acids to a particular cysteine residue, other factors 
also contribute to the reactivity o f  cysteine thiols. The three dimensional tertiary 
structure o f  the protein may bring basic amino acids into close contact with 
otherwise distant cysteine residues, bringing electrostatic stabilising influences to 
bear on the cysteine thiolate. Additionally, the solvent accessibility o f  the cysteine  
residues is important, as deeply buried cysteine residues are inaccessible to solvent 
and thus unlikely to play a role in redox regulated thiol m odifications. Isolated, 
surface exposed cysteines have been calculated to be more reactive with oxidants 
and thiol containing reagents due to their low er pKa values: approximately 7.5 for 
isolated exposed cysteines compared to approximately 9.5 for isolated, buried 
cysteines (Marino & Gladyshev 2010). Surface exposed cysteine thiols m ay have 
lowered pKa values due to interactions with H-bond partners such as water 
m olecules and other titratable groups o f  polar residues, w hich are abundant on the 
protein surface (Marino & Gladyshev 2012). Another determinant o f  cysteine 
reactivity is the proxim ity to another cysteine residue. A  strong predictor o f  cysteine 
susceptibility to oxidation occurs when the cysteine-cysteine distance is < 6.2 Á. The 
oxidation product m ost likely here w ould be cysteine disulphide (Sanchez et al. 
2008). The Pi subunit contains several such c losely  spaced (vicinal) cysteines which  
are also adjacent to basic amino acids. Reactive cysteine thiols m ay w ell be exposed  
on the surface o f  a,2pi in the unactivated platelet. They m ay also becom e exposed  
during the large conformational changes occurring during integrin activation. That S- 
glutathionylation o f  platelet proteins o f  comparable size to the Pi subunit occurs in 
the unactivated platelet, suggests that redox sensitive thiols are readily solvent 
accessible in this integrin.
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It was interesting to note that the w ell-know n antioxidant and disulphide bond 
reducing agent N -acetyl cysteine (NAC) could be substituted into the Cys/CySS  
redox couple to replace cysteine, with identical effects on collagen-induced platelet 
activation (personal communication from Therese Boland, RCSI). Additionally, I 
found that treatment o f  platelets with N A C  alone, like GSH, also resulted in reduced 
collagen-induced platelet activation. This im plied that a disulphide bond reducing 
reaction was occurring in conjunction with collagen activation. The greater 
sensitivity o f  the platelet-collagen activation pathway to disulphide bond reduction 
was demonstrated using DTT in platelet aggregation studies. Combined with the 
N A C  data, this reinforces the v iew  that reducing redox potentials were acting on 
disulphide bonds within the collagen receptor 012P1. In fact, the therapeutic use o f  
N A C  is largely based on its disulphide bond reducing capacity and not on its 
antioxidant properties (Balsam o et al. 2010, Chen et al. 2011).
The reducing redox couples were not acting as divalent metal cation chelators either, 
as EDTA could inhibit both platelet aggregation and platelet adhesion but only at 
concentration levels in excess o f  thirty tim es that o f  the concentrations o f  the 
reducing G SH /G SSG  or C ys/CySS redox couples used. This means that the 
chelating capacity o f  the redox reagents used in this study was not sufficient to 
chelate the levels o f  divalent cations present in the platelet environment, and thus 
excluded chelation as a m echanism for the redox modulation o f  platelet activation 
demonstrated here.
Several questions still remain unanswered. The identities o f  the S-glutathionylated 
platelet proteins remain unknown. The m olecule' mechanism behind both the 
disulphide bond reduction and the S-glutathionylation o f  platelet proteins is still 
unexplained. This w ould be an important area for future research. In addition, future
2 0 0
work in this area could also include an examination o f  the effects o f  varying plasma 
redox potentials in vivo. A  m ouse m odel whereby m ice are administered N A C  over a 
period o f  tim e and the response o f  their platelets to collagen activation monitored is 
one possibility, or alternatively, m ouse blood sam ples could be treated with 
GSH/G SSG  or C ys/C ySS redox potentials in vitro and replaced back into the m ouse 
for subsequent platelet function testing. A  human m odel with oral administration o f  
N A C  would also be an attractive possibility.
In conclusion, the therapeutic value o f  endogenous redox reagents such as 
glutathione and cysteine has previously concentrated on the antioxidant and RONS 
scavenging ability o f  these compounds. This thesis has shown that in relation to 
platelet activation, this not the case. N A C , which is routinely safely administered 
orally and has been shown to increase plasm a levels o f  both GSH and Cys 
(Bridgeman et al. 1991), has very recently been demonstrated to play a major role in 
cardiovascular b io logy  for its disulphide bond reducing capacity (Chen et al. 2011). 
Platelets are know n to be pro-aggregatory under conditions o f  oxidative stress. This 
thesis has demonstrated that under G SH /G SSG  or C ys/C ySS induced reductive 
stress conditions, collagen-induced platelet activation is significantly decreased. The 
sensitivity o f  the platelet collagen-activation pathway outlined in this thesis provides 
a novel avenue for therapeutic intervention using these physiological redox reagents 
or their precursors.
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